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Introduction 

Introduction 
H eart failure is one of the most common cardiovascular disorders in westem countries (1, 2). Because (congestive) heart failure is a chronic, incapacitating 
disease with a poor prognosis and a substantial public health impact, the attention 
paid to this disorder in research and both scientific as well as popular publications 
is fully justified. In addition, the incidence and prevalence of heart failure tend to 
increase, in particular because of ageing of the population and increased survival 
after acute myocardial infarction. 
Heart failure is characterized by periods of exacerbating signs and symptoms. Iden-
tifying precipitating factors for relapsing heart failure may contribute to optimal 
heart failure management. Only few studies have addressed the issue of precipi-
tating factors for relapsing heart failure (9, 10). Relapses of heart failure are asso-
ciated with substantial morbidity and health care expenditures due to hospital 
readmissions. In chapter 2.1, potentially preCipitating factors of relapsing heart fail-
ure are discussed. 
Several classes of drugs have been associated with drug-induced heart failure. 
Drugs may either induce the first occurrence of heart failure or may precipitate 
relapsing heart failure. Chapter 2.2 discusses several classes of drugs that may 
playa role in drug-induced heart failure. 
Awareness of precipitating factors for a first occurrence or a relapse of heart failure 
may contribute to optimal treatment and care of heart failure patients. In chapter 
2.3, we reviewed hospital discharge letters for the presence of a description of 
potentially precipitating factors. Moreover, we studied medication compliance in 
patients who were readmitted to hospital because of relapsing heart failure. 
NSAIDs have been associated with the occurrence of heart failure in a number of 
reports (11-15). Chapter 3.1 presents a review of the adverse cardiovascular effects 
of non-steroidal anti-inflammatory drugs in patients with heart failure. 
Over the years, the Drug Safety Unit of the Inspectorate for Health Care in The 
Netherlands has received a number of case reports on NSAID-associated heart fail-
ure and fluid retention(16). This case-series is described in chapter 3.2. 
In Chapter 3.3, we studied the association between left ventricular fractional short-
ening and current use of NSAIDs in participants of the Rotterdam Study who under-
went echocardiography at study baseline. The aim of this study was to assess a 
potential effect of current use of NSAIDs on left ventricular systolic function. 
We separately studied the association between use of NSAIDs and the occurrence 
of heart failure in patients with either incident or prevalent heart failure. These 
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studies are described in chapter 3.4 and 3.5, respectively. To study the effect on 
incident heart failure, data were used from the Rotterdam Study, a prospective 
population·based cohort study (17). To study the effect of NSAlDs in patients with 
prevalent heart failure, defined as patients with a history of one hospital admission 
for heart failure, we used data from the PHARMO record linkage database (18). 
Because of the significance of heart failure in terms of morbidity and mortality, 
several cardiovascular drugs have been developed and introduced on the market 
for its treatment, with varying success. Particularly, positive inotropiC agents have 
shown to be associated with increased mortality risk (3·5). Unfortunately, this also 
applied to ibopamine, an oral dopaminergic agent registered in The Netherlands 
in 1991 for the treatment of mild, moderate, and severe heart failure. The PRIME· II 
trial, carried out in patients with NYHA III and IV heart failure and published in 
August 1995, demonstrated an increased mortality risk in patients treated with ibo-
pamine compared to placebo (6). Patients with mild heart failure were not included 
in this trial. To assess the effects of ibopamine in heart failure patients under every-
day circumstances for all registered indications, including mild heart failure (NYHA 
II), we initiated a nationwide cohort-study among heart failure patients who had 
been prescribed ibopamine (7) (chapter 4.1). In addition, the sudden change of an 
indication of a drug to a strict contraindication offered a unique opportunity to 
study quantitatively the impact of "confounding by contraindication" in an epide-
miological study. This study is described in chapter 4.2. 
Apart from its effect on morbidity and health care expenditures, relapsing heart fail-
ure may have a significant impact on quality of life. Chapter 4.3 discusses quality of 
life in heart failure, focussing on the problem of heart failure treatments which may 
improve quality of life but which also have shown to be associated with shortened 
survival (8). 
Chapter 5 evaluates the various aspects of heart failure treatment and how treat-
ment may further be improved in the near future. Finally, the general discussion in 
chapter 6 discusses the results from the perspective of drug safety and recent and 
future developments in heart failure treatment. 
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Chapter 2 
Precipitating factors 
for heart failure 

Prevention of relapses in patients with 
congestive heart failure: the role of 
precipitating factors 
ABSTRACT 
2.1 
Relapse of congestive heart failure (CHF) frequently occurs and has serious conse-
quences in terms of morbidity, mortality and health care expenditure. Many stud-
ies have investigated the aetiologic and prognostic factors of CHF, but there are 
only limited data on the role of precipitating factors that trigger relapse of CHF. 
Knowledge of potential precipitating factors may help to optimise treatment and 
provide guidance for patients with CHF. The literature was reviewed to identify fac-
tors that may influence haemodynamic homeostasis in CHF. Precipitating factors 
that may offer opportunities for preventing relapse of CHF were selected. Potential 
precipitating factors are discussed in relation to the pathophysiology of CHF: alco-
hol, smoking, psychological stress, uncontrolled hypertension, cardiac arrhythmias, 
myocardial ischemia, poor treatment compliance, and inappropriate medical treat-
ment. 
Poor treatment compliance in particular is frequently encountered in patients with 
CHF. Furthermore, studies on medical treatment under everyday circumstances 
indicate that some aspects of the management of CHF can be improved. 
In conclusion, the identification of precipitating factors for relapses of CHF may 
strongly contribute to optimal treatment. Improvement of treatment compliance 
and optimalisation of medical treatment may offer important possibilities to clinici-
ans to reduce the number of relapses in patients with CHF. 
9 
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INTRODUCTION 
There is increasing interest in congestive heart failure (CHF) from both clinicians 
and researchers. The prevalence of CHF continues to increase despite advances 
in the treatment of various risk factors for this disease, such as hypertension and 
coronary artery disease (1, 2). According to a recently published simulation model, 
a further shift from acute to more chronic cardiovascular disease, including CHF, 
is expected in the near future (3). This increase in the prevalence of CHF is the 
result of several medical and demographic developments: an aging population, 
decreasing mortality of patients with acute myocardial infarction, and improved 
treatment of patients with angina pectoris and hypertension (4, 5). In addition, 
survival in patients with CHF has improved since the introduction of angiotensin-
converting-enzyme-inhibitors (ACE-inhibitors) (6, 7). Epidemiological studies also 
indicate a substantial age-adjusted increase in hospitalisation rates for CHF over 
the last twenty years in western countries (1, 8). 
CHF is clinically characterised by periods of remission and exacerbation. Readmis-
sion rates of up to 25 % within six months after a previous hospital discharge for 
CHF have been reported in patients older than 65 years (9, 10). Relapse of CHF 
in patients with previously stable compensated heart failure may be caused by 
unpreventable deterioration of ventricular function, but several precipitating fac-
tors have been suggested (11, 12). 
Some precipitating factors can be regarded as potentially preventable. Many stu-
dies have been performed on prognostic factors for mortality due to CHF, such 
as left ventricular ejection fraction, but research on precipitating factors leading 
to relapses of CHF, however, is scarce (11, 13, 14). Nevertheless, timely identifica-
tion of potential precipitating factors may offer an important advantage in efforts 
to reduce morbidity and the number of hospital admissions attributed to the syn-
drome of CHF. 
We conducted a search of the Medline database from 1966 to December 1997 
and used lateral references to review the literature on potential precipitating fac-
tors. In this article, we focus on the role of preCipitating factors that are relatively 
common in clinical practice and potentially modifiable: the effects of alcohol, smo-
king, psychological stress, uncontrolled hypertension, cardiac arrhytlmlias, myo-
cardial ischaemia, lack of compliance, and inappropriate medical treatment. 
10 
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PRECIPITATING FACTORS FOR RELAPSE OF CONGESTIVE HEART 
FAILURE 
Knowledge of potential precipitating factors for relapse of CHF is crucial to pre-
vent or postpone relapses. As indicated, only a few studies have addressed this 
issue and identified factors which may he related to the onset or exacerbation of 
symptoms of CHF in patients with previously compensated heart failure (11-15). 
In a descriptive study, Ghali et a1. examined potential precipitating factors in 
101 hospital readmissions for CHF (11). Precipitating factors were identified in 
93% of patients. The most common factor was lack of adherence to the prescri-
bed medical regimen with respect to hoth medication and diet (64 % of patients). 
Other frequently identified precipitating factors were uncontrolled hypertension 
(44%), cardiac arrhythmias (29%), iatrogenic factors (21 %), and pulmonary infecti-
ons (17%) (table I). In a more recent study, Opasich et a1. identified precipitating 
factors in 91 % of 328 instances of non-fatal decompensation in 304 patients. All 
patients had a history of at least one previous episode of severe decompensation. 
Common precipitating factors were cardiac arrhythmias (24% of patients), poor 
compliance (15%), infections (23%), angina pectoris (14%), and iatrogenic factors 
(10%). Frequency differences in specific precipitating factors reflect the different 
study populations and designs of the two studies. In addition, the absence of a 
control group in these studies excludes assessment of the relative risk of these 
potential precipitating factors. 
Table I 
Factors that may precipitate relapses in patients with pre-existing CHF 
lack of treatment compliance 
myocardial infarction 
angina pectoris or painless myocardial ischaemia 
alcohol consumption 
cardiac arrhythmias 
inappropriate medical treatment 
infections 
anaemia 
pulmonary embolism 
thyroid disease 
pregnancy 
physical, dietary, fluid, and environmental excesses 
emotional stress 
systemic hypertension 
smoking 
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Table II 
Aetiology of congestive heart failure 
Common causes: 
Uncommon causes: 
coronary artery disease 
hypertension 
idiopathic dilated cardiomyopathy 
valvular disease 
hypertrophic cardiomyopathy 
restrictive cardiomyopathy 
alcoholic cardiomyopathy 
connective tissue diseases 
medication 
inherited diseases 
infectious diseases 
metabolic diseases 
metals 
neurological diseases 
volume overload 
anaemia 
shunts 
Several diseases may induce the syndrome of CHF (Table II). Patients in whom 
CHF is diagnosed should be given optimal medical care to prevent clinical worsen-
ing while maintaining quality of life. An accurate evaluation of potential precipita-
ting factors should also be routinely performed in patients with relapse of CHF. 
This evaluation may reveal important factors which may have contributed to the 
relapse of CHF. For instance, adequate treatment of anaemia or arrhythmias may 
strongly contribute to relief of symptoms of CHF and may prevent future relapses 
ofCHF. 
Although the haemodynamic effects of the above-mentioned potential precipita-
ting factors have been well investigated in healthy subjects and in patients with 
coronary artery disease, only limited data are available on their specific haemo-
dynamic effects in patients with CHF. Therefore, the haemodynamic effects of 
these precipitating factors are discussed within the framework of current views 
on the pathophysiology of CHF. Apart from the precipitating factors discussed 
here, CHF may also be precipitated by infection, anaemia, pulmonary embolism, 
thyroid disease, pregnancy, and physical, dietary, fluid, and environmental exces-
ses (11-15). As most of these factors have either lmown causes, such as excessive 
salt intake and excessive intravenous fluid administration, or relatively uncommon 
causes, they are not discussed in further detail. 
12 
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Alcohol 
CHF resulting from alcoholic cardiomyopathy is a relatively common cause of non-
ischaemic cardiomyopathy (16). The amount and duration of alcohol consumption 
required to induce alcoholic cardiomyopathy is not well defined, but has been esti-
mated at 5 to 6 ounces. (1 ounce~28 mI) of ethanol daily for at least 10 years. 
Abstention from alcohol is crucial in patients with alcohol-induced cardiomyopathy 
(17). Echocardiographic studies show that major clinical improvement and normali-
sation of left ventricular function can be achieved after abstention from alcohol 
in patients with alcoholic cardiomyopathy (18, 19). Resumed alcohol intake may 
act as a precipitating factor for a relapse of CHF in these patients. There is no 
convincing evidence for absolute abstention from alcohol in patients with CHF not 
induced by alcohol. In a study in which the acute effects of moderate alcohol con-
sumption (0,9 g/kg) in patients with New York Heart association (NYHA) class 
III-IV heart failure were assessed, small but significant reductions in arterial pres-
sure, pulmonary artery pressure, pulmonary artery wedge pressure, and systemic 
vascular resistance were seen after a single dose of alcohol, but CHF did not 
deteriorate (20). It was suggested that reduction in afterload counterbalanced 
the negative inotropic effects of alcohol, leaving cardiac performance essentially 
unchanged. Chronic heavy alcohol consumption should be strongly discouraged 
in all patients with CHF, but there are no convincing reasons to warn all patients 
with CHF against incidental moderate consumption of alcohol (21). Clinical prac-
tice shows, however, that some patients with apparently non-alcohol induced CHF 
may have significant improvement after complete abstention from even incidental 
moderate alcohol-consumption. Therefore, evaluation of a period of complete alco-
hol abstention in patients with severe CHF may be worthwhile. 
Smoking 
Several studies have been performed on the acute haemodynamic effects of smo-
king, both in healthy subjects and in patients with cardiovascular disease. Ciga-
rette smoking increases heart rate and blood pressure, both principal determinants 
of myocardial oxygen consumption (22). Increased heart rate as well as increased 
blood pressure are both associated with the intake of nicotine (23). Goldbarg et 
al. showed in healthy subjects that the left ventricular stroke index (mllbeat/m2) 
decreased significantly at several levels of exercise after smalling, although there 
was no significant change of stroke index after smalling at rest (24). Aronow et al. 
investigated the effects of cigarette smoking and breathing carbon monoxide on 
cardiovascular haemodynamics in patients with angina pectoris (23). This study 
showed that an increased level of carboxyhaemoglobin had a negative inotropic 
effect and increased left ventricular end-diastolic pressure. There was a signifi-
13 
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cant decrease in the stroke index after smoking in these patients. Results from a 
study of Pentecost et al. indicated that cigarette smoking tends to decrease cardiac 
output especially in older patients with a history of myocardial infarction (25). Nico-
lozakes et al. investigated the effects of smoking in patients with NYHA class III 
CHF (26). Cardiac output remained unchanged after smoking, but other haemody-
namic changes were seen. As expected, heart rate and systemic blood pressure 
(double product) increased substantially after smoking. In addition, there were 
mild increases in pulmonary artery pressure, ventricular filling pressures, and total 
systemic and pulmonary vascular resistance. The increased ventricular afterload 
probably accounts for the observed mild decrease in stroke volume. Thus, smoking 
increases oxygen demand but decreases myocardial oxygen supply because of 
reduced diastolic filling time and increased carboxyhaemoglobin level. This finding 
has important negative consequences for the myocardial oxygen supply. Patients 
with CHF should be strongly advised to stop smoking and should be informed that 
continued smoking may unfavourably affect CHF. It remains unclear, however, to 
what extent smoking may act as a precipitating factor for relapse of CHF. 
Psychological stress 
Several effects of psychological stress on cardiac function in patients with cardio-
vascular disease have been described in the medical literature. Mental stress in 
patients with ischaemic heart disease can induce transient myocardial ischaemia 
and transient wall motion abnormalities (27). Myocardial ischaemia in response 
to psychological stress is frequently painless (28). Rozanski et al. reported that 
wall-motion abnormalities occurred in 59% of patients with coronary artery disease 
during mental stress. A drop in ejection fraction of more than 5% was seen in 
36% of patients. Wall motion abnormalities were seen in only 8% of normal con-
trols during mental stress, and no clear effect on ejection fraction was observed 
in the controls (29). Mental stress may also induce transient changes of the 
electro physiological properties of the myocardium, which may sensitise the heart 
to life-tlueatening ventricular arrhythmias (30). Emotional factors preceding hos-
pitalisation for CHF have been reported in 49% of patients (15). Some cases of 
stress-induced heart failure have been described (31). Giannuzzi et al. reported 
that psychological stress induced changes in left ventricular diastolic function in 
patients with idiopathic cardiomyopathy (27). The effects of mental arithmetic 
on these patients were compared to those on controls. The ratio of trans mitral 
peak flow velocity in early versus late diastole (EI A) significantly increased during 
mental arithmetic, while transmitral deceleration time markedly decreased. These 
findings suggest that left ventricular function is impaired during psychological 
stress. Neuroendocrine activation and a significant increase in arterial blood pres-
sure, espeCially in hypertensive patients, may also contribute to the haemody-
14 
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namic effects of psychological stress. The full effects of psychological stress on 
cardiovascular function in patients with CHF are not known, but many of the dis-
cussed effects can be considered unfavourable. 
Uncontrolled hypertension 
Hypertension is an important and well-known risk factor for the development of 
cardiovascular disease, including CHF. Recent data from the Framingham Heart 
Study underscore its importance as a major risk factor for CHF (32). Hypertension 
may impair ventricular function by increasing afterload and impairing both systo-
lic contraction and diastolic relaxation (33). Approximately 50% of patients with 
hypertension and a normal coronary angiogram have transient ST -segment depres-
sion during 24 hour Holter monitoring, usually without angina pectoris (34). As 
there was no relation with left ventricular hypertrophy, these findings seem to 
reflect a disturbed coronary microvasculature. This may also explain the increased 
coronary resistance and decreased maximal coronary blood flow after dipyrida-
mole in these patients (34). Intervention trials have provided convincing evidence 
of the efficacy of hypertension treatment in reducing the incidence of CHF (35). 
Obviously, persistent hypertension in patients with CHF will have a detrimental 
effect on ventricular performance. Blood pressure in patients with end-stage CHF 
usually decreases because of low cardiac output. Uncontrolled hypertension des-
pite antihypertensive therapy, defined as diastolic blood pressure of 105 mm Hg 
or more, was identified in 44% of patients readmitted to hospital for CHF (11). 
Adequate blood pressure control in patients with CHF is crucial because of the 
numerous haemodynamic effects of hypertension, although there are few data on 
the extent to which uncontrolled hypertension may account for relapse of CHF. 
Cardiac arrhythmias 
Cardiac arrhythmias are frequently present in patients with CHF and are regarded 
as a sign of impaired left ventricular function. Atrial fibrillation is the most preva-
lent cardiac arrhythmia in patients with CHF. Nevertheless, its prognostic signifi-
cance is controversial. There have been studies in which atrial fibrillation did not 
increase morbidity and mortality as well as studies in which atrial fibrillation was 
a marker for an increased mortality risl( (36, 37). Ghali et al. reported that cardiac 
arrhythmias, particularly atrial fibrillation, were present in 29 % of patients readmit-
ted for CHF and were considered to be directly responsible for relapse of CHF in 
78% of these patients (11). Loss of atrioventricular synchrony and impaired rate 
control because of atrial fibrillation are usually regarded to be an unfavourable 
clinical characteristic in patients with CHF. Cardioversion of chronic atrial fibril-
15 
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lation to sinus rhythm in patients with NYHA functional class I or II significantly 
increased cardiac output during exercise, maximum oxygen uptake, and maximal 
tolerated workload (36). Successful cardioversion in patients with chronic atrial 
fibrillation and idiopathic dilated cardiomyopathy significantly improved left ven-
tricular ejection fraction from 32% to 53% (38). Several studies have reported on 
patients with severe left ventricular dysfunction and atrial fibrillation with rapid 
ventricular response (39, 40). Left ventricular dysfunction in these patients may 
be completely reversed by controlling ventricular rate or restoring sinus rhythm. 
Supraventricular tachycardias are usually the underlying arrhythmia in this so-cal-
led tachycardia-induced cardiomyopathy. The unfavourable haemodynamic conse-
quences of atrial fibrillation compared with those of sinus rhythm suggest that 
development of this arrhythmia may be a trigger for relapse of CHF. 
Myocardial ischaemia 
The detrimental effects of myocardial ischaemia on ventricular function have been 
well documented (41). The main cause of progressive myocardial failure is pos-
tulated as subendocardial ischaemia, even in patients with non-ischaemic CHF 
(42). Silent or symptomatic myocardial ischaemia can also be identified as part of 
the pathway relating other potential precipitating factors, such as psychological 
stress, smoking, cardiac arrhythmias, and hypertension, to relapses of CHF (28, 
34). Impairment of systolic and diastolic ventricular function persists from hours 
to days after transient myocardial ischaemia (43). Hibernating myocardium is a 
widely accepted concept in modern cardiology, defined as a state of persistently 
impaired myocardial and left ventricular function at rest because of reduced coro-
nary blood flow (41). Hibernating myocardium can be considered as a myocardial 
adaptation to reduced coronary blood flow, to prevent irreversible myocardial 
damage. The Significant improvement of left ventricular function after coronary 
revascularisation which can be observed in patients with coronary artery disease 
and left ventricular dysfunction is mainly based on this principle. Although the 
exact frequency of hibernating myocardium is not known, Carlson et al. reported 
hibernating myocardium in 75% of patients with unstable angina pectoris and in 
25% of patients with stable angina pectoriS (44). Abolition of myocardial hiberna-
tion can improve left ventricular function (41). Although only limited information is 
available on the frequency of myocardial ischaemia in patients with CHF, it seems 
reasonable to assume that myocardial ischaemia may deteriorate ventricular func-
tion and may act as a precipitating factor for relapse of CHF. Therefore, preven-
tion of myocardial ischaemia may contribute to the maintenance of haemodynamic 
homeostasis in patients with CHF. 
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Lack of treatment compliance 
Ghali et aL identified lack of compliance to medication and diet as a major preci-
pitating cause in 64 % of the 101 patients presenting with decompensated heart 
failure (11). In this study, 97% of the patients were black and described as a predo-
minantly working-class minority population. As both educational level and ethnic 
background are major predictors of compliance, it has been suggested that non-
compliance in these patients may be attributed to differences in culture, language 
and health education (45). In contrast, in the study of Opasich et al. poor compli-
ance as a precipitating factor for relapse of CHF was encountered in only 15 % of all 
328 instances of decompensation (12). These discrepensies seem to be attributable 
to difficulties in measuring compliance, differences in study population and study 
design. Non-compliance with long-term medication regimens has been found to be 
approximately 50% in several studies (46). This may represent an important impe-
diment to effective treatment of CHF. Dietary intervention, particularly aimed at 
reducing sodium chloride intake to 3 g/day or less in combination with other non-
pharmacologic treatment such as graduated exercise training and psychological 
therapy have shown to improve functional and emotional status in patients with 
CHF (47). Intensive medication counselling may improve compliance significantly 
(48). Interestingly, physicians' personal characteristics and characteristics of their 
practices also influence patients' adherence to medical treatment (49). Physicians' 
global job satisfaction positively influences patient compliance. 
Non-compliance to medication and diet has repeatedly been identified as a fre-
quent precipitating factor for admission to hospital for decompensated heart fai-
lure. Therefore, non-compliance deserves major attention from health professionals, 
as it may offer an opportunity to make a significant contribution to preventing 
relapse in patients with CHF. 
Inappropriate medical treatment 
Iatrogenic factors considered to be responsible for relapses of CHF were identified 
by Ghali et al in 21 % of relapses and by Opaschi et al in 10% of relapses (11, 12). 
The most important causes of iatrogenic CHF are usually inappropriate medication 
and excessive intravenous fluid administration. Although not discussed in detail 
here, several categories of drugs, such as non-steroidal anti-inflammatory drugs, 
P-blockers, and anti-arrhythmics, may affect cardiovascular homeostasis, especi-
ally in patients with pre-existing left ventricular impairment. Rich et al. prospecti-
vely studied the occurrence of iatrogenic CHF in 401 patients hospitalised for CHF 
(50). CHF was considered to be iatrogenic in 28 (7%) patients. As a result of the 
inability of the researchers to reliably assess causality between suspected inade-
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quate medication and the onset of CHF, most instances of iatrogenic CHF were 
attributed to excessive intravenous fluid administration. Therefore, the importance 
of inappropriate medication, such as withdrawal of ACE-inhibitors, seems to have 
been underestimated in this study. 
Patients with CHF deserve optimal treatment and investigation. Intervention trials 
have provided clear evidence for the beneficial effects of ACE-inhibitors on sur-
vival in patients with CHF (6, 7). However, some studies have reported flaws in 
the management of patients with CHF. Clarke et aL carried out a retrospective 
study in six general practices among 505 patients receiving loop diuretics (51). Alt-
hough 74 % of 281 patients who fulfilled diagnostic criteria for CHF were referred to 
hospital, only one third had echocardiogram. Furthermore, 234 patients of the 281 
patients who fulfilled the diagnostic criteria for CHF were not treated with ACE-
inhibitors. Among them were 26 patients with documented evidence of left ventri-
cular impairment. These findings strongly suggest shortcomings in the diagnosis 
and treatment of CHF, but lack of information on the severity of CHF in this study 
makes it difficult to draw definite conclusions. Hilles et aL reported in a review of 
the case notes of 343 patients discharged from hospital with a diagnosis of CHF 
that only 40% of patients received ACE-inhibitors (52). Of patients with NYHA 
class III and IV CHF, only 50% were treated with ACE-inhibitors at the time of 
discharge from hospitaL Although retrospective studies may have methodological 
limitations, they clearly point out some aspects of the management of CHF that 
need to be improved. 
Striving for optimal medical treatment deserves major interest from all who are 
involved in the care of patients with CHF. Prevention of iatrogenic CHF should be 
a major issue in optimising medical treatment in these patients. 
CONCLUSIONS 
Relapse in patients with CHF may result from deterioration of underlying cardiac 
disease. Clinical practice and observational studies, however, have shown that 
precipitating factors can be identified in many patients with increased symptoms 
of CHF. These precipitating factors may have contributed to or even induced 
symptoms of CHF. Few stndies have investigated these precipitating factors des-
pite their presence in relapse of CHF. Suboptimal medical treatment and poor 
patient compliance in particular deserve more attention, as these factors can be 
considered as potentially preventable determinants of relapse of CHF. 
Most of the discussed factors are common in daily practice, but little is known 
18 
Precipitating factors of relapsing heart failure 
about their influence on cardiac performance in patients with CHF under every-
day circumstances. Most studies on the haemodynamic effects of smoking, alco-
hol, or psychological stress have been laboratory experiments. Such findings do 
not always reflect the effects in clinical practice. Despite these limitations, the 
negative haemodynamic effects of most precipitating factors discussed here are 
sufficient for them to be considered as unfavourable. Therefore, the presence of 
potential precipitating factors as listed in table I should be routinely evaluated in 
patients presenting with CHF. Elimination of these precipitating factors, if possi-
ble, may contribute to prevention of relapse in patients with CHF. 
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2.2 
Drug-induced heart failure 
ABSTRACT 
Heart failure is a clinical syndrome that is predominantly caused by cardiovascular 
disorders such as coronary heart disease and hypertension. However, several 
classes of drugs may induce heart failure in patients without concurrent cardiovas-
cular disease or may precipitate the occurrence of heart failure in patients with pre-
existing left ventricular impairment. 
We reviewed the literature on drug-induced heart failure, using the MEDLINE-data-
base and lateral references. Successively, we discuss the potential role in the occur-
rence of heart failure of cytostatics, immunomodulating drugs, antidepressants, 
calcium channel blockers, non-steroidal anti-inflammatory drugs, anti-arrhythmics, 
beta-adrenoceptor blocking agents, anaesthetics and some miscellaneous agents. 
Drug-induced heart failure may playa role in only a minority of the patients present-
ing with heart failure. Nevertheless, drug-induced heart failure should be regarded 
as a potentially preventable cause of heart failure, although sometimes other 
priorities do not offer therapeutic alternatives (e.g., anthracycline-induced cardio-
myopathy). The awareness of clinicians of potential adverse effects on cardiac 
performance by several classes of drugs, particularly in patients with pre-existing 
ventricular dysfunction, may contribute to timely diagnosis and prevention of drug-
induced heart failure. 
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INTRODUCTION 
Congestive heart failure (CHF) is a complex clinical syndrome that results from 
cardiac dysfunction (1). Signs and symptoms that are frequently encountered in 
patients suffering from CHF are dyspnea, fatigue, pulmonary crepitations, and 
peripheral edema. Its clinical course is often characterised by periods of exacerbat-
ing symptoms, alternated with periods in which the patient experiences fewer or 
no symptoms. Epidemiological studies indicate that both the prevalence and the 
incidence of CHF increase (2-4). CHF is predominantly caused by cardiovascular 
diseases, such as coronary artery disease, hypertension and valvular heart disease 
(3, 5). However, in some patients the occurrence of CHF can be attributed to the 
cardiotoxic effect of a particular drug. Furthermore, as several categories of drugs 
may exert unfavourable haemodynamic effects, these drugs may act as a precipitat-
ing factor for relapse in patients with previously compensated CHF. 
Pathophysiologically, CHF may result from drug-mediated effects on cardiac 
preload, cardiac afterload or myocardial contractility. Drugs that increase cardiac 
preload or cardiac afterload may have unfavourable effects on ventricular function, 
because increased cardiac preload or afterload intensifies the demand on ventricu-
lar performance. The ability of the heart to comply with this increased demand 
will depend on pre-existing ventricular function. Drugs may also have a negative 
inotropic effect as a result of their direct cardiotoxic properties. Similarly, the likeli-
hood of the occurrence of heart failure induced by cardiotoxic drugs may depend 
on pre-existing ventricular function, although some drugs may have detrimental 
effects in patients with previously normal cardiac function. We will discuss the 
potential ability of several categories of drugs to induce or exacerbate heart fail-
ure. 
CYTOSTATICS 
Anthracyclines 
The anthracyclines are effective antineoplastic agents that are used in the treat-
ment of many types of malignancy. Daunorubicin and doxorubicin are among the 
most frequently used anthracyclines included in chemotherapeutic regimens (6). 
The anthracyclines are antibiotic agents which antineoplastic action results from 
the inhibition of the nucleic acid synthesis by binding to both strands of the 
desoxyribonucleic acid (DNA) helix. This binding prevents normal function of 
the ribonucleic acid (RNA) polymerase and DNA-polymerase. The introduction of 
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the anthracyclines has contributed considerably to the improvement of survival 
in patients with cancer, However, anthracycline-induced cardiotoxicity is a well-
known adverse effect of this category of drugs and a major limitation to the total 
dose that can safely be administered (6), Cardiotoxicity is considered to be an 
adverse effect of all anthracyclines, although epirubicine may cause less cardio-
toxicity as compared with doxorubicine (7), Formation of free oxygen radicals, 
disturbance of the mitochondrial energy metabolism and intracellular calcium over-
loading are considered mechanisms in the pathogenesis of anthracycline-induced 
cardiotoxicity (8), Based on the dose-dependency of the anthracycline-induced 
impairment of left ventricular function, an upper limit of the cumulative dose of 550 
mg/m2 is generally recommended, When this upper limit of the cumulative dose 
is exceeded, early heart failure may develop in approximately 30 % of the patients 
receiving these high dosages (6), Anthracyclines as part of a combined chemo-
therapeutic regimen, however, may induce heart failure at a cumulative dosage 
below 550 mg/m2 (9), In particular, combined chemotherapeutic treatment with 
cyclophosphamide seems to be associated with an increased risk of cardiotoxicity, 
even when the cumulative dose of the anthracycline remains below 400 mg/m2, 
The addition of cytoprotective agents to chemotherapeutic schemes, such as the 
bispiperazinedione compound ICRF187, seems to reduce cardiotoxicity signifi-
cantly without reducing antineoplastic action (10,11), 
Cardiotoxicity may develop at any moment during or after treatment with anthra-
cyclines. Although anthracycline-induced cardiotoxicity is usually characterised by 
heart failure, cardiac arrhythmias might be the first manifestation in some patients, 
Early cardiac toxicity, which occurs during or soon after treatment with anthracy-
clines, is mainly dependent on the cumulative anthracycline dose (6), However, 
the development of heart failure several years after the last administration of 
anthracyclines is increasingly recognised, In a study among 201 children who 
had completed chemotherapy with anthracyclines, decreased fractional shorten-
ing on echocardiography was present in more than 60% of the patients who had 
received >500 mg/m2 and were followed up for at least 10 years (12), Although 
an adequate control group was lacking, these findings indicate that anthracycline-
induced heart failure may develop several years after completing treatment with 
anthracyclines, Interestingly, in those patients of whom an end-therapy echocar-
diogram was available, it could be demonstrated that decreased fractional shorten-
ing at the end of the therapy was strongly associated with decreased fractional 
shortening at long-term follow-up, Although numbers were small, more than 70% 
(10/14) of the patients with decreased fractional shortening at the end of the ther-
apy still had decreased systolic function at long-tem1 follow-up, In contrast, of 
patients with a normal echocardiogram at the end of therapy, only 12% (8/64) 
had decreased fractional shortening at long-term follow-up (p<O,OOl), Patients suf-
fering from anthracycline-induced cardiotoxicity may finally develop signs and 
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symptoms of heart failure when impaired systolic function is unable to maintain 
haemodynamic homeostasis. Although anthracycline-induced heart failure is gen-
erally considered to be irreversible, some reports on complete recovery of cardiac 
dysfunction have been published (13). 
The severity of anthracycline-induced cardiomyopathy can be quantified with the 
help of a morphological grading system (14). In an endomyocardial biopsy, anthra-
cycline toxicity is characterised by sarcotubular dilatation and myofibrillar loss 
of actin and myosin. Long-tenn myocardial damage has also been identified in 
patients who had received doses of only 45 mg/m2 (15). Therefore, all patients 
exposed to anthracyclines should be considered at risk for the development of 
heart failure as a result of the cardiotoxic properties of these agents. To evaluate 
cardiotoxicity, guidelines for monitoring cardiac function have been implemented 
in most anthracycline-containing chemotherapeutic regimens (16). 
The treatment of anthracycline-induced heart failure does not differ from the 
general pharmacotherapeutical approach to heart failure patients. Diuretics, angi-
otensin-converting-enzyme-inhibitors and digoxin are the mainstays of treatment. 
In some patients with severe anthracycline-induced CHF, heart transplantation 
may finally remain the only therapeutical option. 
Cyclophosphamide 
Cyclophosphamide is an a1kylating agent that causes cytotoxicity by its biologi-
cally active metabolites. Reports have been published on both completely revers-
ible cases as well as on fatal cases of CHF attributed to cyclophosphamide-induced 
cardiomyopathy (17, 18). Cardiotoxicity of cyclophosphamide is thought to be due 
to toxic endothelial damage followed by extravasation of toxic metabolites with 
resultant myocyte damage and interstitial haemorrhage and edema (19). Symp-
toms of CHF usually appear within two weeks after administration of the drug. In 
patients who develop severe progressive CHF, this complication may lead to death 
within a few weeks. Based on analyses of the plasma-concentration time curves 
(area under the curve, AUC) in 19 women with metastatic breast cancer, treated 
with a continuous 96-hour infusion of cyclophosphamide, it has been shown that 
a low AUC and a low peak plasma level of cyclophosphamide were predictive for 
both an increased duration of response as well as for an increased risk of develop-
ing CHF. These findings suggest that patients with a more extensive metabolism 
of cyclophosphamide are more prone to develop cyclophosphamide-induced cardia-
toxicity. Thus, measurement of the AUC may draw attention to patients who are 
most susceptible to develop heart failure. The numerous reports on both revers-
ible and irreversible heart failure indicate a wide spectrum of cyclophosphamide-
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induced cardiotoxicity, which can be influenced by pre-existing cardiovascular 
condition, other chemotherapeutic regimens received before treatment with cyclo-
phosphamide, and the dose and method of administration of cyclophosphamide 
(20). 
PaclitaKel 
Paclitaxel belongs to an important new class of anti-cancer agents, the taxanes. 
Paclitaxel promotes the polymerisation of tubulin. Microtubules formed in the pres-
ence of paclitaxel are extraordinarily stable and dysfunctional. These dysfunctional 
microtubules interfere with normal cell division and interphase processes and may 
eventually lead to cellular death. Paclitaxel is increasingly used in the treatment of 
patients with advanced ovarian and breast cancer. Transient asymptomatic brady-
cardia appears to be the most frequent cardiovascular adverse effect, reported in 
up to 29% of the patients treated with paclitaxel (21). Clinically important cardiac 
bradyarrhythmias appear to have an incidence of only 0.1 %. 
In a case report, the onset of heart failure has been associated with the administra-
tion of paclitaxel (22). Furthermore, heart failure has been reported with a remark-
able frequency in an uncontrolled study of Gianni et al. in which women with 
metastatic breast cancer who had never received chemotherapy were treated with 
the combination of paclitaxel by 3-hour infusion and doxorubicin (23). Six out of 33 
patients (18%) developed symptomatic heart failure within 12 months after start-
ing this treatment. The median received dose of doxorubicin in these patients was 
480 mg/m'. Based on previous studies, an incidence of symptomatic heart failure 
in the range of 1 % to 10% should be expected within one year after treatment 
with doxorubicin at the commonly used total-dose limit of 550 mg/m'. Therefore, 
an incidence of 18% has raised the question whether the combined treatment of 
paclitaxel and doxorubicin may account for this apparently increased risk. Other 
studies, however, in which different schedules of the combined administration of 
paclitaxel and doxorubicin were used did not indicate an increased risk of heart 
failure (23). This finding may suggest that the schedule used for the administration 
of paclitaxel and doxorubicin may influence the risk of CHF. On the other hand, as 
all patients who developed CHF in the study of Gianni et al. had cardiovascular 
risk factors or a history of radiotherapy of the cardiac region, baseline differences 
among the patients included in these studies may also account for differences in 
the risk of paclitaxel-induced CHF. In summary, unequivocal evidence of paclitaxel-
induced CHF is lacking. However, due to the efficacy of paclitaxel as an antine-
oplastic agent, paclitaxel will undoubtedly be prescribed to an expanding group 
of patients outside the setting of clinical trials in the near future. As the risk of 
cardiotoxicity in patients with concomitant cardiovascular disease is unknown, 
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there is a need for additional information on the risk of CHF after administration of 
paclitaxel in patients with cardiovascular comorbidity. 
Mitoxantrone 
Mitoxantrone is structurally related to doxorubicin and has also been associated 
with the development of left ventricular impairment. In a study in 801 patients 
treated with mitoxantrone, a clinical diagnosis of CHF was made in 1,5% of the 
patients, whereas in another 1,5% of the patients reduced left ventricular ejection 
fraction developed without clinically overt CHF (24). Furthermore, cumulative mitox-
antrone dose was associated with an increasing risk of cardiotoxicity. Conclusions 
should be drawn with caution, as a control group was not included in this study. 
Decreased left ventricular ejection fraction has also been observed in a study in 
which patients were treated with mitoxantrone and in which patients with pre-exist-
ing cardiac disease or previous exposure to anthracyclines were excluded (25). The 
findings from these studies and the strucural relationship with doxorubicin support 
the hypothesis that mitoxantrone should be regarded as a potentially cardiotoxic 
agent that may be associated with drug-induced CHF. 
Other chemotherapeutic agents 
Heart failure has been associated with several other chemotherapeutic agents such 
as 5-fluorouracil (5-FU) and cytarabin. Cardiac toxicity induced by 5-FU is usually 
characterised by chest pain and signs of ischaemia, which resemble angina pectoris 
and is generally accepted to be caused by 5-FU-induced coronary spasm (26). There 
have also been reports in which the occurrence of severe but reversible left ventricu-
lar dysfunction was attributed to use of 5-FU (27-29), although the extent to which 
5-FU may have accounted for the occurrence of CHF is not always obvious. As a 
result of 5-FU-induced coronary spasm, decreased ventricular function may also be 
caused by myocardial ischaemia instead of by a direct toxic effect on the myocar-
dium (30). In a retrospective study on cardiotoxic effects of 5-FU and folinic acid in 
390 patients treated for gastrointestinal cancer, heart failure occurred in only one 
patient (31). Therefore, the association between heart failure and 5-FU should be 
evaluated in future studies. Cytarabine-induced reversible CHF seems to be very 
rare and has only been described in a case report (32). 
Recently, Herceptin (recombinant humanised anti-HER2 antibody) has been 
approved for the treatment of breast cancer in the United States. Herceptin inhibits 
the growth of cancer cells overexpressing HER2. The HER2 gene encodes a trans-
membrane tyrosine-kinase receptor, designated p185HERZ • Antibodies directed at 
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p185HER2 have shown to inhibit growth of tumors that express high levels of this 
receptor (33). As overexpression of HER2 appears to be present in a considerable 
number of patients suffering from breast, ovarian and gastric cancer, Herceptin 
may be of value in the treatment of several different cancers. A recent study has 
shown that patients whose tumor cells have increased levels of p185HER2 do signifi-
cantly better when Herceptin is added to standard chemotherapy. However, con-
cern has been raised on cardiac toxicity, which occurred in a number of patients 
participating in a trial on breast cancer treatment. Approximately 27% of the 
patients using doxorubicine, paclitaxel and Herceptin experienced signs of cardiac 
dysfunction, compared with 6% of those using only doxorubicine and paclitaxel 
(34). Although Herceptin may be considered as a potential improvement in the 
treatment of cancer, its cardiac toxicity might restrict its applicability in clinical 
practice. Therefore, cardiac toxicity should be a major point of concern in ongoing 
and future trials. 
ANTI-ARRHYTHMICS 
The cardiodepressant adverse effects of anti-arrhythmic drugs can mainly be attrib-
uted to their negative inotropic properties. Particularly, in patients with pre-exist-
ent left ventricular impairment, anti-arrhythmics can induce or exacerbate CHF. 
Proarrhythmic effects that may occur during treatment with anti-arrhythmics may 
further contribute to the induction or worsening of CHF. The degree of negative 
inotropy may vary from drug to drug. Class III anti-arrhythmics, however, are 
usually considered as lacking these negative inotropic properties. Pathophysiolog-
ically, the negative inotropic effects of anti-arrhythmic drugs are mediated by alter-
ations of the intracellular calcium content (35). The ultimate effect on myocardial 
contractility of anti-arrhythmics does not only depend on their true negative ino-
tropic effect, but also on additional effects on the peripheral circulation, pre-exist-
ing myocardial function and their effect on the prevailing arrhythmia. 
Patients with decreased left ventricular function are at increased risk of supraven-
tricular and ventricular arrhythmias. Sudden death, attributed to the occurrence of 
an acute ventricular arrhythmia, is frequently encountered in patients with CHF. 
Not only are patients with impaired left ventricular function more prone to develop 
cardiac arrhythmias, but the cardiac arrhythmia itself may have a deleterious effect 
on left ventricular performance. Therefore, despite their potential negative ino-
tropic effects and proarrhythmogenic effects, anti-arrhythmic drugs are frequently 
needed in patients with CHF (36). 
Randomised double-blinded placebo-controlled trials have indicated an increased 
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risk of CHF for those patients assigned to treatment with an anti-arrhythmic drug 
(37, 38). Although most anti-arrhythmic drugs have intrinsic negative inotropic 
effects and have been associated with the occurrence of CHF (39-45), there seem to 
be differences among the various anti-arrhythmic agents (39-45). In a randomised 
crossover study in 21 patients with severe left ventricular impairment (mean left 
ventricular ejection fraction 21 %), tocainide and encainide were significantly more 
likely to cause haemodynamic and clinical deterioration as compared with procain-
amide (46). Conclusions should be drawn with caution, however, as the results 
may have been influenced by dose and route of administration of the anti-arrhyth-
mic drug and the evaluation of only the short-term effect of a single dose. Despite 
some differences among the various anti-arrhythmic agents, nearly all anti-arrhyth-
mic drugs should be considered as potentially disadvantageous with respect to left 
ventricular contractility. 
BETA-ADRENOCEPTOR ANTAGONISTS 
CHF is a well-known adverse effect of beta-adrenoceptor antagonists (beta-block-
ers). The negative chronotropic and negative inotropic properties of these drugs 
can easily induce or exacerbate CHF in patients with a propensity to this condition. 
Interestingly, also the topical administration of beta-blocllers in patients with glau-
coma has been associated with the occurrence of CHF in some case reports (47-49). 
Convincing evidence of systemic effects after topical administration of beta-block-
ers has been provided (50-54). In a pharmaco-epidemiological study using auto-
mated databases, however, no relation between the use of topical beta-blockers 
and the occurrence of CHF could be revealed (55). Apart from methodologicallimi-
tations, this finding only indicates that on a population level, the topical admin-
istration of beta-blockers does not appear to be associated with a significantly 
increased risk of hospitalisation for CHF. In susceptible individuals, however, the 
systemic effects of topical beta-blockers may suffice to induce or exacerbate CHF. 
Interestingly, a relatively new approach to the management of CHF includes the 
use of beta-adrenergic antagonists. As activation of the sympathetic nervous 
system is considered to be an important pathophysiological mechanism in the 
progression of CHF, interference with the activated sympathetic nervous system 
appears to have beneficial effects in animal models of CHF (56, 57). Until recently, 
long-term trials on the effects of metoprolol and bisoprolol did not provide convinc-
ing evidence with respect to reduction of mortality in patients with CHF (58, 59), 
However, a clinical trial with carvedilol demonstrated a reduced risk of death and 
hospitalisation for cardiovascular causes (60). Carvedilol is one of the new beta-
adrenergic agents with alpha-i-blocking and antioxidant properties. As a result 
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of these additional properties of carvedilol, it remains unclear whether its favour-
able effects should be attributed to its beta-adrenergic antagonistic effect or to 
these additional properties of this agent. Other recently published clinical trials 
have also reported improved survival when beta-blockers were added to optimum 
standard therapy (61, 62). To prevent acute beta-adrenergic antagonistic effects in 
patients with CHF, starting dosages should be low and can be gradually increased 
if tolerated. 
NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) 
NSAIDs have been associated with fluid retention and the onset of CHF in several 
publications (63-68). CHF that is induced or exacerbated by NSAIDs is not medi-
ated by a direct myocardial depressant effect of NSAIDs. The major mechanism of 
action of NSAIDs is the interference with prostaglandin biosynthesis by inhibiting 
the function of the enzyme cyclo-oxygenase (COX) (69). Furthermore, NSAIDs also 
interfere with the effects of diuretics and ACE-inhibitors (70-72). In healthy indi-
viduals, prostaglandins playa negligible role in maintaining renal blood flow and 
consequently, NSAIDs usually exert no significant effects on renal haemodynamics 
(73,74). In patients with an impaired left ventricular function, however, prostaglan-
dins play an important role in the maintenance of cardiovascular and renal home-
ostasis. Prostaglandins have a vasodilatory effect on the afferent arteriole, oppose 
the effects of angiotensin II on the systemic circulation, and decrease total body 
sodium and water. These effects of prostaglandins are considered to contribute 
significantly to the maintenance of compensated heart failure in patients with 
impaired left ventricular function. In these patients, NSAIDs may interfere with 
cardiovascular homeostasis and may induce or exacerbate CHF (75). 
Two isoforms of COX have been identified, COX-1 and COX-2. COX-2 is predom-
inantly involved in all stages of the inflammatory response, whereas COX-1 is 
mainly responsible for the synthesis of prostaglandin E, (PGE,) and PGI, in Iddney 
and stomach (69). To prevent the potentially adverse effects on renal function, so-
called renal-sparing NSAIDs have been introduced, such as sulindac, nabumetone 
and meloxicam. These agents have been reported to exert less adverse effects on 
renal function (76-80). However, comprehensive data on the effects of these agents 
on renal function and cardiovascular homeostasis in patients with decreased left 
ventricular function are not yet available. 
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CALCIUM CHANNEL BLOCKING AGENTS 
For many years, there has been concern about the extent to which calcium chan-
nel blocking drugs may contribute to exacerbation of CHF in patients with pre-
existing left ventricular dysfunction. As calcium channel blocking drugs are widely 
prescribed for the treatment of angina pectoris in patients with pre-existing left 
ventricular impairnlent, this concern should be regarded as fully legitimated. Most 
calcium channel blockers currently approved for clinical use belong to three dis-
tinct chemical classes: the phenylalkylamines (e.g., verapamil), the dihydropyrid-
ines (e.g., nifedipine) and the benzothiazepines (e.g., diltiazem).ln the SOLVD trial, 
calcium antagonists were prescribed to 30% of patients with CHF (81). Several 
pathophysiological mechanisms that contribute to the potential effects of calcium 
channel blocldng on left ventricular function have been described (82). These mech-
anisms can be characterised by a negative inotropic effect on the heart, caused 
by impeding the transmembrane cellular calcium transport, and the activation of 
endogenous neurohormonal systems such as the renin-angiotensin system and the 
sympathetic nervous system. Marked haemodynamic and clinical deterioration can 
occur in patients with CHF when the negative inotropic effects of calcium channel 
blockers are not counterbalanced by their vasodilatory effects (83, 84). It has been 
postulated that the ability to improve the vascular compliance of the arterial tree 
may be a crucial determinant with respect to the effect of a particular calcium chan-
nel blocker on the natural course of CHF (85). This may also be an explanation 
for the observed effects of calcium channel blockers on the occurrence of CHF in 
some trials. In the Multicenter Diltiazem Postinfarction Trial (MDPIT), postinfarc-
tion patient with a baseline ejection fraction of less than 40% who were treated 
with diltiazem had a statistically significantly increased risk of subsequent CHF 
(86). The risk of CHF rose progressively with increasing impairment of left ventricu-
lar ejection fraction at baseline. Life table analysis excluded the possibility that 
the observed effect could be attributed to improved survival of those patients 
who were treated with diltiazem. However, some caution with respect to these 
findings is warranted, as the hypothesis was formulated after completion of the 
study. Furthermore, the diagnosis of CHF was not required to satisfy specific 
predefined criteria. Although the double-blind design of the study prevents any 
differential misclassification, a complex clinical syndrome such as CHF should 
preferably comply with well-defined diagnostic criteria. Although calcium chan-
nel blockers intrinsically depress myocardial contractility, increased left ventricular 
ejection fraction can be observed after the administration of dihydropyridines such 
as nefidipine. This can be explained by the reflex stimulation of the sympathetic 
nervous system that counterbalances the intrinsic negative inotropic effect of the 
dihydropyridines (87). However, it has been shown that chronic administration of 
nefidipine in patients with CHF may have deleterious effects (88). Recently, results 
from the PRAISE-trial (Prospective Randomized Amlodipine Survival Evaluation 
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Trial) indicated that amlodipine 5 to 10 mg/day in patients with CHF had no signifi-
cant effect on cardiovascular events and mortality (89). Subgroup-analyses in this 
trial pointed out that the benefit of amlodipine was only seen in patients with non-
ischaemic cardiomyopathy. In a similar trial (V-HeFT Ill), felodipine showed nei-
ther beneficial nor unfavourable effects as compared with placebo (90). Although 
the vasodilatory effects of calcium channel blocl{ers should be regarded as benefi-
cial for patients with CHF, the negative inotropic effect and activation of neuro-
hormonal systems by calcium channel blockers have unfavourable effects in these 
patients. Amlodipine, one of the newer dihydropyridines, may be of benefit in 
patients with non-ischaemic cardiomyopathy. 
ANAESTHETICS 
During general anaesthesia, cardiovascular homeostasis will be subject to several 
influences. Patient characteristics, such as age and comorbidity, intravenous fluid 
administration, surgical procedures, and medication used during general anaes-
thesia may all affect cardiovascular homeostasis. Therefore, the occurrence or 
exacerbation of signs and symptoms of CHF in close relationship with general 
anaesthesia can not always easily be attributed to a specific agent used during 
general anaesthesia. Nevertheless, a number of agents which are used during 
general anaesthesia may have negative effects on myocardial contractility. The 
halogenated volatile anaesthetics halothane and enflurane have mild negative ino-
tropic effects (91). Particularly, halothane has been associated with cardiodepres-
sant effects (92). Negative inotropic effects, however, have been found to be more 
pronounced in patients with pre-existing left ventricular impairment (93). Cardio-
depressant effects seem to be less frequent when using newer agents such as iso-
flurane and desflurane, although it has been suggested that these differences may 
apply only to young patients (94). 
The intravenous barbiturate anaesthetics thiopental and methohexital may also 
depress myocardial contractility. In general, the haemodynamic consequences of 
usual plasma levels of these agents are limited (95). In patients who are more 
susceptible to the potential cardiodepressant effect of these agents, such as the 
elderly and patients with impaired left ventricular function, cautious dosages and 
proper fluid administration may prevent undesirable haemodynamic effects. 
Propofol is an intravenous induction anaesthetic that is also used for sedation in 
intensive Care units. Bradycardia and hypotension are the most frequently reported 
adverse effects. The hypotensive effect of propofol is considered to be brought 
about by peripheral vasodilatation, inhibition of the sympathetic nervous system, 
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and rednced myocardial contractility (96). Long-term sedation with propofol in chil-
dren has been associated with fatal myocardial failure, whereas the use in adults 
appears to be safe with respect to this effect (97). It has been suggested that 
the relatively high dosages in children might be responsible for these deleterious 
effects. 
IMMUNO-MODULATING DRUGS 
Interferons 
Three types of interferons, interferon alpha, interferon beta and interferon gamma, 
are used for clinical indications. Interferon alpha and -beta exert antiviral and anti-
proliferative activities, whereas interferon gamma acts primarily as an immunoregu-
latory cytokine. Interferon-alpha has been associated with cardiovascular adverse 
effects, such as hypotension and tachycardia during the first days of treatment in 
5% to 15% of the patients (98). Cardiac adverse effects of the interferons are cardiac 
arrhythmias, cardiomyopathy and symptoms of ischaemic heart disease (99). There 
have been case reports on both reversible and irreversible severe CHF after treat-
ment with interferon-alpha (100-102). A clear pathophysiological understanding of 
interferon-alpha-induced cardiomyopathy is lacking. Both impairment of myocyte 
metabolism as well as increased oxygen demand as a result of fever and tachycar-
dia may be involved in the onset of CHF (100, 103). Until now, interferon-beta has 
not been associated with the onset of CHF (99). Cardiovascular effects attributed to 
treatment with interferon-gamma, such as hypotension and arrhythmia, have been 
observed in patients treated with high dose interferon-ganuna. In most instances, 
these patients had a history of pre-existent cardiovascular disease. Although cardio-
vascular adverse effects seem to be infrequent, CHF has been reported as a possible 
adverse effect of interferon-ganuna (104). 
Interleukin-2 
Interleukin-2 (IL-2), which has been approved for the treatment of metastatic renal 
cell carcinoma, may have serious cardiovascular adverse effects. Hypotension and 
tachycardia are almost invariably encountered in patients treated with IL-2. Revers-
ible left ventricular dysfunction has also been reported in patients treated with IL-2, 
using echocardiography or radionuclide ventriculography (105, 106). It has been 
suggested that the production of cytokines may have a central role in the develop-
ment of IL-2-induced cardiac dysfunction. Cytokines inhibit the accumulation of cel-
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lular cyclic adenosine monophosphate, which may blunt myocardial contractility. 
Histological findings of eosinophiliC and mixed lymphocytic-eosinophilic myocardi-
tis attributed to IL-2 indicate a possible drug hypersensitivity syndrome (107). 
ANTIDEPRESSANT DRUGS 
Antidepressant drugs are usually divided into three main categories: classical 
antidepressants (mainly consisting of the tricyclic compounds), second genera-
tion antidepressants (including the selective serotonine re-uptake inhibitors), and 
monoamine-oxidase inhibitors. The cardiovascular effects of the tricyclic antide-
pressants (TCAs) have always been a source of concern, in particular when the 
prescription of a TCA is indicated in patients with cardiovascular comorbidity. 
Sinus tachycardia occurs in the majority of patients treated with TCAs and approxi-
mately 20% of the patients have postural hypotension (108). TCA-induced postural 
hypotension is attributed to the combined effect of its peripheral anti-adrenergic 
action, its myocardial depressant effect and its alpha-adrenergic blocking effect 
in the central nervous system. Compared with other TCAs, nortriptyline is only 
rarely associated with the occurrence of orthostatic hypotension (109). TCAs also 
affect atrioventricular conduction by prolongation of the conduction time in the 
His bundle and the bundle branches, and prolongation of the duration of both the 
ORS-interval and the corrected OT-interval (110). Second - and third-degree atriov-
entricular block may occur and may lead to asystole and sudden death. TCAs are 
highly concentrated in myocardial tissue, which partly explains their interference 
with heart rate, cardiac rhythm, and myocardial contractility. The effects of TCAs 
on myocardial function are mediated by several mechanisms, such as their anti-
cholinergic and quinidine-like action, interference with the re-uptake of adrenergic 
amines, alternations of membrane permeability and direct myocardial depression 
(42). Several studies have been performed on the effects of TCAs on left ventricular 
function. There have been case reports of CHF attributed to the use of TCAs (111, 
112). Experiments in animals indicate that TCAs may have a negative inotropic 
effect (113), particularly in higher doses, although the findings from these experi-
mental animal studies are difficult to extrapolate to human subjects. Results from 
non-invasive studies in which systolic time interval measurements are used as a 
parameter of left ventricular function suggest that TCAs impair cardiac function 
(114, 115). However, the systolic time interval depends on cardiac conduction, 
which may have been influenced by TCAs. Therefore, these indirect measure-
ments of left ventricular function do not provide convincing evidence of a direct 
TCA-induced cardiodepressant effect at the level of myocardial cells. More recent 
studies in which left ventricular contractility was assessed by radionuclide ven-
triculography failed to demontrate TCA-induced left ventricular impairment. In 
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20 non·depressed patients with moderate to severe baseline ventricular impair· 
ment who were treated with imipramine (mean daily dose 210 mg) or nortriptyline 
(mean daily dose 100 mg) for ventricular premature depolarisations, no significant 
changes in mean ejection fraction could be observed (116). Studies of Glassman et 
al. and Veith et al. also indicate that in patients with decreased baseline ejection 
fraction TCAs have no significant effects on left ventricular ejection fraction (117, 
118). These studies, however, are characterised by a small sample size, selection 
of patients and a short period of follow·up. Despite these limitations, most studies 
indicate that the effects of TCAs on left ventricular function seem to have no major 
consequences for their applicability in everyday clinical practice. Even in patients 
with pre·existent left ventricular impairment, there is no convincing evidence indio 
cating that TCAs are likely to have deleterious effects on left ventricular function. 
However, as CHF is frequently accompanied by disturbances of cardiac conduc· 
tion or low arterial blood pressure, and long·term information on the effect on ven· 
tricular performance of TCAs in heart failure patients is scarce, clinicians should 
be aware of possible adverse cardiovascular effects when prescribing TCAs to 
patients with severe CHF. 
Selective serotonin reuptake inhibitors (SSRI) have a very low rate of adverse 
cardiovascular effects. It has been estimated that the incidence of adverse cardio· 
vascular events is less than 0,0003% (119). This estimate, however, is based on 
reported cases of cardiovascular events to pharmaceutical companies. Estimates of 
the incidence of adverse reactions that are based on the number of reported cases 
should be regarded with caution, but the overall impression is that SSRI have a 
very low incidence of adverse cardiovascular effects. Probably the most important 
effect of SSRI in patients with cardiovascular comorbidity is their potential to inter· 
act with drugs which these patients are taking for cardiac arrhythmias, CHF, or 
hypertension. The interaction between SSRI and several drugs is mediated by 
the inhibition of cytochrome P450 enzymes. The SSRI·induced inhibition of cyto· 
chrome P450 affects the metabolism of several classes of drugs, such as anti· 
arrhythmics, beta·blockers, antihistamines, and calcium channel blockers. It has 
been suggested that this might have been the cause of some unexpected deaths in 
patients who had recently begun fluoxetine therapy (120). As SSRI are a relatively 
new class of drugs, no studies have been performed on their effects on ventricular 
function in patients with CHF. Currently available data on the cardiac effects of 
SSRI suggest that these agents do not have direct effects on myocardial function, 
but attention should be paid to potential interactions with several classes of drugs 
(119, 121). 
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Table I 
Drugs associated with the onset or worsening of congestive heart failure. 
Agents associated with the induction of CHF 
anthracyelines 
paelitaxel 
mitoxantrone 
interferons 
interleukin-2 
Agents associated with the precipitation of CHF in patients with pre-existing 
ventricular dysfunction 
calcium channel blockers 
NSAIDs 
anti-arrhythmics 
beta~receptor antagonists 
anaesthetics 
steroidal hormones with mineralocorticoid effects 
drugs which may increase afterload: 
sympathicomimetic drugs; e.g. adrenaline, dobutamine, dopamine 
cyelosporine (122) 
ketoconazol (123) 
Agents which are only incidenticaiiy associated with the onset of CHF in case 
reports 
tricyclic antidepressants 
5-fluouracil 
cytarabine 
polyethylene glycol-electrolyte lavage solution (124) 
aminocaproic acid (125) 
antidigoxine antibody fragments (126) 
sodium-containing antacids (42) 
amantadine (127) 
bromocriptine (42) 
foscamet (128) 
megestrol (129) 
mannitol (130) 
hydralazine (42) 
edetic acid (42) 
deferiprone (131) 
dapsone (132) 
carbamazepine (42) 
cibenzoline (133) 
prostaglandin E, (134) 
methyl-sergide (42) 
ifosfamide (135) 
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MISCELLANEOUS AGENTS 
Apart from the categories of drugs discussed in the previous sections, various other 
agents have been associated with the occurrence or worsening of CHF (see table I). 
Although the pathophysiological mechanism is rather straightforward with respect 
to some agents, for example, mineralocorticoid effects of steroidal hormones, in 
other instances their causal role remains more obscure. In particular, when a patho-
physiological mechanism appears to be absent, the possibility of coincidence can 
hardly be ruled out. Nevertheless, detailed documentation of all clinical features 
of patients with suspected drug-induced CHF, eVen in the absence of a straightfor-
ward pathophysiological explanation, may finally contribute to an objective risl<-
benefit profile of the agents involved. 
CONCLUSION 
Several categories of drugs may potentially induce or exacerbate CHF. Pathophysi-
ologically, drugs that increase cardiac preload, cardiac afterload, or have negative 
inotropic properties may be able to cause this adverse reaction. In table I, a distinc-
tion has been made between agents which are commonly regarded as being able 
to induce CHF in patients with previously normal ventricular function and agents 
which may precipitate CHF in patients with previously compensated CHF. Obvi-
ously, agents which may induce CHF can also precipitate CHF. Agents reported 
to induce CHF only very rarely are mentioned in this table as a third category. Par-
ticularly patients with pre-existing left ventricular dysfunction who already have 
the propensity to develop CHF appear to be at risk for drug-induced heart failure. 
Although the cardiotoxic effects of drugs such as the anthracyclines and cyclophos-
phamide are obvious and well-known, this is not always the case in all categories 
of drugs we discussed. Moreover, drug-induced cardiac rhythm disorders may also 
induce signs and symptoms of CHF in susceptible patients. Therefore, detailed 
documentation of the medication involved together with all clinical features of 
patients suspected from drug-induced CHF may contribute substantially to a reli-
able assessment of both the pathophysiological mechanism and the lil{8lihood of 
causality. This may contribute to an appropriate risk-benefit profile of the drugs 
involved. 
REFERENCES 
1. Guidelines for the diagnosis of heart failure. The Task Force on Heart Failure of the 
European Society of Cardiology. Eur. Heart J. 1995;16:741-751. 
38 
Drug-induced heart failure 
2. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991;121:951-7. 
3. Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br 
Heart J 1994;72(2 SuppI):S3-9. 
4. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC, et al. The 
epidemiology of heart failure. Eur Heart J 1997; 18(2):208-25. 
5. Teerlink JR, Goldbaber SZ, Pfeffer MA. An overview of contemporary etiologies of con-
gestive heart failure. Am Heart J 1991; 121 :1852-3. 
6. Rhoden W, Hasleton P, Brooks N. Anthracyclines and the heart. Br Heart J 1993;70(6): 
499-502. 
7. Camaggi CM, Comparsi R, Strocchi E, Testoni F, Angelelli B, Pannuti F. Epirubicin and 
doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. Cancer 
Chemother PharmacoI1988;21(3):221-8. 
8. Fu LX, Waagstein F, Hjalrnarson A. A new insight into adriamycin-induced cardiotoxic-
ity. Int J CardioI1990;29(1): 15-20. 
9. Watts RO. Severe and fatal anthracycline cardiotoxicity at cumulative doses below 400 
mg/m2: evidence for enhanced toxicity with multiagent chemotherapy. Am J Hematol 
1991 ;36(3):217-8. 
10. Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, et al. Protective effect of the 
bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women 
with advanced breast cancer. N Engl J Med 1988;319(12):745-52. 
11. Bu'Lock FA, Gabriel HM, Oakhill A, Mott MG, Martin RP. Cardioprotection by ICRF187 
against high dose anthracycline toxicity in children with malignant disease. Br Heart J 
1993;70(2): 185-8. 
12. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years 
after completing anthracycline therapy. JAMA 1991;266(12):1672-7. 
13. Saini J, Rich MW, Lyss AP. Reversibility of severe left ventricular dysfunction due to 
doxorubicin cardiotoxicity. Report of three cases. Ann Intern Med 1987;106(6):814-6. 
14. Billingham ME, Bristow MR. Evaluation of anthracycline cardiotoxicity: predictive ability 
and functional correlation of endomyocardial biopsy. Cancer Treat Symp 1984 ;3: 71-76. 
15. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac 
effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J 
Med 1991;324(12):808-15. 
16. Carrio I, Estorch M, Lopez-Pousa A. Assessing anthracycline cardiotoxicity in the 1990s. 
Eur J Nucl Med 1996;23(4):359-64. 
17. Ayash LJ, Wright JE, Tretyakov 0, Gonin R, Elias A, Wheeler C, et aI. Cyclophosphamide 
pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 
1992; 10(6) :995-1 000. 
18. Manthorpe R, Svensson O. Cardiomyopathy following intravenous cyclophosphamide ther-
apy in a patient with Wegener's granulomatosis. Clin Exp RheumatoI1996;14(6) :702-3. 
19. Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT. Cyclophosphamide cardiotoxic-
ity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J 
Clin Oncol1991 ;9(7): 1215-23. 
20. Goldberg MA, Antin JH, Guinan EC, Rappeport JM. Cyclophosphamide cardiotoxicity: 
an analysis of dosing as a risk factor. Blood 1986;68(5): 1114-8. 
21. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995;332(15): 1004-14. 
22. Jekunen A, Heikkila P, Maiche A, Pyrhonen S. Paclitaxel-induced myocardial damage 
detected by electron microscopy. Lancet 1994;343(8899):727-8. 
23. Gianni L, Munzone E, Capri G, FuUaro F, Tarenzi E, Villani F, et al. Paclitaxel by 
3-hour infusion in combination with bolus doxorubicin in women with untreated meta-
static breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and 
sequence-finding study. J Clin OncoI1995;13(11):2688-99. 
24. Mather FJ, Simon RM, Clark GM, Von Hoff DD. Cardiotoxicity in patients treated with 
mitoxantrone: Southwest Oncology Group phase II studies. Cancer Treat Rep 1987; 
71(6): 609-13. 
39 
CHAPTER 2.2 
25. Cassidy J, Merrick MV, Smyth JF, Leonard RC. Cardiotoxicity of mitozantrone assessed by 
stress and resting nuclear ventriculography. Eur J Cancer Clin OncoI1988;24(5):935·8. 
26. Keefe DL, Roistacher N, Pierri MK. Clinical cardiotoxicity of 5·fluorouracil. J Clin Pharma· 
col 1993;33(11):1060·70. 
27. Akhtar SS, Wani BA, Bano ZA, Salim KP, Handoo FA. 5·FluorouraciJ.induced severe but 
reversible cardiogenic shock: a case report. Tumori 1996;82(5):505·7. 
28. Chaudary S, Song SY, Jaski BE. Profound, yet reversible, heart failure secondary to 5·flu· 
orouracil. Am J Med 1988;85(3):454·6. 
29. Coronel B, Madonna 0, Mercateilo A, Caillette A, Moskovtchenko JF. Myocardiotoxicity 
of 5 fluorouracil. Intensive Care Med 1988;14(4):429·30. 
30. Rahimtoola SH. The hibernating myocardium in ischaemia and congestive heart failure. 
Eur Heart J 1993;14:22·6. 
31. Schober C, Papageorgiou E, Harstrick A, Bokemeyer C, Mugge A, Stahl M, et al. Cardio· 
toxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointesti-
nal cancer. Cancer 1993;72(7):2242·7. 
32. Conrad ME. Cytarabine and cardiac failure. Am J Hematol 1992 ;41(2): 143·4. 
33. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti· 
HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxont-
bicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 
1998; 58(13) :2825·31. 
34. McNeil C. Herceptin raises its Sights beyond advanced breast cancer. J NatI Cancer Inst 
1998 ;90(12):882·3. 
35. SchlepperM. Cardiodepressive effects of antiarrhythmic drugs. EurHeartJ 1989; 10(Suppl 
E):73-80. 
36. Hammenneister KE. Adverse hemodynamic effects of antiarrhythmic drugs in conges-
tive heart failure. Circulation 1990;81(3):1151·3. 
37. Pharand C, Kluger J, E OR, Ujhelyi M, Fisher J, Chow M. Lidocaine prophylaxis for fatal 
ventricular arrhythmias after acute myocardial infarction. Clin Pharmacol Ther 1995; 
57(4):471·8. 
38. Greene HL, Richardson DW, Hallstrom AP, McBride R, Capone RJ, Barker AH, et al. Con· 
gestive heart failure after acute myocardial infarction in patients receiving antiarrhyth-
mic agents for ventricular premature complexf?s (Cardiac Arrhythmia Pilot Study), Am J 
CardioI1989;63(7):393·8. 
39, Gottlieb SS, Packer M. Deleterious hemodynamic effects of lidocaine in severe conges-
tive heart failure. Am Heart J 1989;118(3):611·2. 
40. Hallstrom AP, Cobb LA, Yu BH, Weaver WD, Fahrenbruch CE. An antiarrhythmic drug 
experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 
1985. Am J Cardiol1991 ;68(10):1025·31. 
41. Pratt CM, Podrid PJ, Seals AA, Young JB, Hession M, Lampert S, et al. Effects of Eth· 
mozine (moricizine HeI) on ventricular function using echocardiographic, hemodynamic 
and radionuclide assessments. Am J CardioI1987;60(11):73F·78F. 
42. Dukes MNG. In: Meyler's Side Effects of Drugs, 14th Edition. 13 ed: Elsevier Science Bv 
Amsterdam; 1996. 
43. Maloney JD, Nissen RG, McColgan JM. Open clinical studies at a referral center: chronic 
maintenance tocainide therapy in patients with recurrent sustained ventricular tachy-
cardia refractory to conventional antiarrhythmic agents. Am Heart J 1980;100: 1023·30. 
44. Hohnloser SH, Zabel M. Short· and long· term efficacy and safety of flecainide acetate for 
supraventricular arrhythmias. Am J CardioI1992;70(5):3A·9A. 
45. Schulze JJ, Knops J. Effects of flecainide on contractile force and electrophysiological 
parameters in cardiac muscle. Arzneimittelforschung 1982;32(9):1025·9. 
46. Gottlieb SS, Kuldn ML, Medina N, Yushak M, Packer M. Comparative hemodynamic 
effects of procainamide, tocainide, and encainide in severe chronic heart failure. Circula-
tion 1990;81(3):860·4. 
47. Bail S. Congestive heart failure from betaxolol. Case report. Arch Ophthalmol 1987; 
40 
Drug-induced heart failure 
105(3):320. 
48. Linkewich JA, Herling 1M, Bradycardia and congestive heart failure associated with 
ocular timolol maleate. Am J Hosp Pharm 1981 ;38(5):699-701. 
49. Britman NA. Cardiac effects of topical timolol. N Engl J Med 1979;300(10):566. 
50. AUtins JM, Pugh BR, Jr., Timewell RM. Cardiovascular effects of topical beta-blockers 
during exercise. Am J Ophthalmol 1985;99(2):173-5. 
51. Bauer K, Brunner-Ferber F, Distlerath LM, Lippa EA, Binkowitz B, Till P, et al. Assess-
ment of systemic effects of different ophthalmic beta-blockers in healthy volunteers, 
Clin Pharmacol Ther 1991 ;49(6):658-64. 
52. Berlin I, Marcel P, Uzzan B, Millon D, Le Hoang P, Puech AJ. A single dose of three dif-
ferent ophthalmic beta-blockers antagonizes the chronotropic effect of isoproterenol in 
healthy volunteers. Clin Pharmacol Ther 1987;41(6):622-6. 
53. Mekki GA, Penhall R, Edgar DF, Stewart-Jones JH, Turner P. Local and systemic effects 
of pindolol eye drops. Br J Clin Pharmacol 1983; 15(1): 112-3. 
54. MCMahon CD, Shaffer RN, Hoskins HD, Jr., HetheringJon J, Jr. Adverse effects experi-
enced by patients taking timolol. Am J OphthalmoI1979;88(4):736-8. 
55. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Choodnovskiy I, Avorn J. Topical 
glaucoma medications and cardiovascular risk in the elderly, Clin Pharmacol Ther 
1994;55(1):76-83. 
56. Sabbah HN, Shimoyama H, Kana T, Gupta RC, Sharov VG, Scicli G, et al. Effects of long-
term monotherapy with enalapril, metoprolol, and digoxin on the progression of left 
ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation 
1994 ;89(6) :2852-9. 
57. ver Donck L, Wouters L, Olbrich HO, Mutschler E, Borgers M. Nebivolol increases sur-
vival in cardiomyopathic hamsters with congestive heart failure. J Cardiovasc Pharma-
col 1991;18(1):1-3. 
58. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, et al. Ben-
eficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated 
Cardiomyopathy (MDC) Trial Study Group. Lancet 1993;342(8885):1441-6. 
59. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol 
Study (CIBIS). CIBIS Investigators and Committees. Circulation 1994;90(4): 1765-73. 
60. Packer M, Bristow MR, Cohn IN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of 
carvedilol on morbidity and mortality in patients with chronic heart failure. U.S, Carve-
dilol Heart Failure Study Group. N Engl J Med 1996;334(21):1349-55. 
61. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 
353(9146): 9-13. 
62. Effect of metoprolol CR / XL in chronic heart failure: Metoprolol CR / XL Randomised 
Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-2007. 
63. Tashima CK, Rose M. Letter: Pulmonary edema and salicylates. Ann Intem Med 1974; 
81(2):274-5. 
64. Schooley RT, Wagley PF, Lietman PS. Edema associated with ibuprofen therapy. JAMA 
1977;237(16): 1716-7. 
65. Nevins M, Berque S, Corwin N, Lyon L. Phenylbutazone and pulmonary oedema. Lancet 
1969 ;2(634): 1358. 
66. Walshe JJ, Venuto RC. Acute oliguric renal failure induced by indomethacin: possible 
mechanism. Ann Intern Med 1979;91(1):47-9. 
67. Laiwah AC, Mactier RA. Antagonistic effect of non-steroidal anti-inflammatory drugs on 
frusemide-induced diuresis in cardiac failure. Br Med J 1981;283(6293):714. 
68. Ouweland Van den FA, Gribnau FW, Meyboom RH. Congestive heart failure due to non-
steroidal anti-inflammatory drugs in the elderly. Age Ageing 1988;17:8-16. 
69. Simon LS, Mills JA. Drug therapy: nonsteroidal antiinflammatory drugs. N Engl J Med 
1980;302(21): 1179-85. 
70. Sturrock ND, Struthers AD. Non-steroidal anti-inflammatory drugs and angiotensin con-
verting enzyme inhibitors: a commonly prescribed combination with variable effects on 
41 
CHAPTER 2.2 
renal function. Br J Clin PharmacoI1993;35(4):343-8. 
71. Brater DC. Resistance to loop diuretics. Why it happens and what to do about it. Drugs 
1985 ;30(5):427-43. 
72. Koopmans PP. Pathophysiological and clinical aspects of the interaction between non-ste-
roidal anti-inflammatory drugs (NSAID) and diuretics. Neth J Med 1985;28(11):524-9. 
73. Carmichael J, Shankel SW. Effects of nonsteroidal anti-inflammatory drugs on prosta-
glandins and renal function. Am J Med 1985;78:992-1000. 
74. SChlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int 
1993 ;44(3) :643-53. 
75. Feenstra J, Grobbee DE, Mosterd A, Stricker BHC. Adverse cardiovascular effects of 
NSAIDs in patients with congestive heart failure. Drug Safety 1997;17(3):166-180. 
76. Sedor JR, Davidson EW, Dunn MJ. Effects of nonsteroidal anti-inflammatory drugs in 
healthy subjects. Am J Med 1986;81(2B):58-70. 
77. Bunning RD, Barth WF. Sulindac. A potentially renal-sparing nonsteroidal anti-inflamma-
tory drug. JAMA 1982;248(21):2864-7. 
78. Aronoff GR. Therapeutic implications associated with renal studies of nabumetone. J 
Rheumatol 1992; 19(5uppI36):25-31. 
79. Furst DE. Are there differences among nonsteroidal antiinflammatory drugs? Compar-
ing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal 
antiinflammatory drugs. Arthritis Rheum 1994;37(1):1-9. 
80. Skeith KJ, Wright M, Davis P. Differences in NSAID tolerability profiles. Fact or fiction? 
Drug Safety 1994;10(3):183-95. 
81. Effect of enalapril on survival in patients with reduced left ventricular ejection frac-
tions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991 ;325(5): 
293-302. 
82. Packer M. Pathophysiological mechanisms underlying the adverse effects of calcium 
channel-blocking drugs in patients with chronic heart failure. Circulation 1989;80(6 
Suppl):IV59-67. 
83. Chew CY, Hecht HS, Collett JT, McAllister RG, Singh BN. Influence of severity of ventric-
ular dysfunction on hemodynamic responses to intravenously administered verapamil 
in ischemic heart disease. Am J Cardiol 1981 ;47(4):917-22. 
84. Pollak A, Falk RH. Left ventricular systoliC dysfunction precipitated by verapamil in car-
diac amyloidosis. Chest 1993; 104(2):618-20. 
85. Francis as. Calcium channel blockers and congestive heart failure. Circulation 1991; 
83(1):336-8. 
86. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset conges-
tive heart failure in postiniarction patients with early reduction in ejection fraction. The 
Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research 
Group. Circulation 1991 ;83(1):52-60. 
87. Ferrari R Major differences among the three classes of calcium antagonists. Eur Heart 
J 1997;18(Suppl A):A56-70. 
88. Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rabimtoola SH. A prospective, ran-
domized, double-blind, crossover study to compare the efficacy and safety of chronic 
nifedipine therapy with that of isosorbide dinitrate and their combination in the treat-
ment of chrorilc congestive heart failure. Circulation 1990;82(6):1954-61. 
89. Packer M, CM OC, Ghali JK, Pressler ML, Carson PE, Belkin RN, et a1. Effect of amlodip-
ine on morbidity and mortality in severe chronic heart failure. Prospective Randomized 
Amlodipine Survivai Evaluation Study Group. N Engl J Med 1996;335(15):1107-14. 
90. Cohn IN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, et a1. Effect of the calcium 
antagonist felodipine as supplementary vasodilator therapy in patients with chronic 
heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) 
Study Group. Circulation 1997;96(3):856-63. 
91. 8himosato 8, Iwatsuki N, Carter JG. Cardio-circulatory effects of enflurane anesthesia in 
health and disease. Acta Anaesthesial Scand Supp11979;71 :69-70. 
42 
Drug-induced heart failure 
92. Schmidt U, Schwinger RH, Bohm S, Uberfuhr P, Kreuzer E, Reichart B, et al. Evidence 
for an interaction of halothane with the L-type Ca2+ channel in human myocardium. 
Anesthesiology 1993; 79(2) :332-9. 
93. Rifat K. Effets cardiovasculaires de l'enfiurane. Med Hyg 1979;37:3602. 
94. McKinney MS, Fee JP, Clarke RS. Cardiovascular effects of isoflurane and halothane in 
young and elderly adult patients. Br J Anaesth 1993;71(5):696-701. 
95. Becker KE, Jr., Tonnesen AS. Cardiovascular effects of plasma levels of thiopental neces-
sary for anesthesia. Anesthesiology 1978;49(3):197-200. 
96. Searle NR, Sahab P. Propofol in patients with cardiac disease. Can J Anaesth 1993;40(8): 
730-47. 
97. Parke T J, Stevens JE, Rice AS, Greenaway CL, Bray RJ, Smith PJ, et a1. Metabolic acido-
sis and fatal myocardial failure after propofol infusion in children: five case reports. Br 
Med J 1992;305(6854):613-6. 
98. Vial T, Descotes J. Clinical toxicity of the interferons. Drug Safety 1994;10(2):115-50. 
99. Sonnenblick M, Rosin A. Cardiotoxicity of interferon. A review of 44 cases. Chest 1991; 
99(3):557-61. 
100. Sonnenblick M, Rosenmann D, Rosin A. Reversible cardiomyopathy induced by inter-
feron. Br Med J 1990;300(6733):1174-5. 
101. Cohen MC, Huberman MS, Nesto RW. Recombinant alpha 2 interferon-related cardiomy-
opathy. Am J Med 1988;85(4):549-51. 
102. Deyton LR, Walker RE, Kovacs JA, Herpin B, Parker M, Masur H, et a1. Reversible cardiac 
dysfunction associated with interferon alfa therapy in AIDS patients with Kaposi's sar-
coma. N Engl J Med 1989;321(18):1246-9_ 
103. Sartori M, Andomo S, La Terra G, Pozzoli G, Rudoni M, Sacchetti GM, et al. Assessment 
of interferon cardiotoxicity with quantitative radionuclide angiocardiography. Eur J Clin 
Invest 1995;25(1):68-70. 
104. Todd PA, Goa KL. Interferon gamma-lb. A review of its pharmacology and therapeutic 
potential in chronic granulomatous disease. Drugs 1992;43(1): 111-22. 
105. Goel M, Flaherty L, Lavine S, Redman BG. Reversible cardiomyopathy after high-dose 
interleukin-2 therapy. J Immunother 1992; 11(3):225-9. 
106. Fragasso G, Tresoldi M, Benti R, Vidal M, Marcatti M, Boni A, et al. Impaired left ven-
tricular filling rate induced by treatment with recombinant interleukin 2 for advanced 
cancer. Br Heart J 1994;71(2):166-9. 
107. Schuchter LM, Hendricks CB, Holland KH, Shelton BK, Hutchins GM, Baughman KL, et 
al. Eosinophilic myocarditis associated with high-dose interleukin-2 therapy. Am J Med 
1990;88(4):439-40. 
108. Glassman AH, Bigger JT, Jr., Giardina EV, Kantor SJ, Perel JM, Davies M. Clinical char-
acteristics of imipramine-induced orthostatic hypotension. Lancet 1979;1(8114):468-72. 
109. Glassman AH, Bigger JT, Jr. Cardiovascular effects of therapeutic doses of tricyclic anti-
depressants. A review. Arch Gen Psychiatry 1981 ;38(7):815-20. 
110. Roos JC. Cardiac effects of antidepressant drugs. A comparison of the tricyclic antide-
pressants and fluvoxamine. Br J Clin PharmacoI1983;15(SuppI3):439S-445S. 
111. Jefferson JW. Cardiovascular effects and toxicity of anxiolytics and antidepressants. J 
Clin Psychiatry 1989;50(10):368-78. 
112. Dalack GW, Roose SP, Glassman AH. Tricyclics and heart failure. Am J Psychiatry 
1991; 148(11): 1601. 
113. Lucas CM, Cheriex EC, van der Veen FH, Habets J, van der Nagel T, Penn ac, et al. 
Imipramine induced heart failure in the dog: a model to study the effect of cardiac assist 
devices. Cardiovasc Res 1992;26(8):804-9. 
114. Raeder EA, Burckhardt D, Neubauer H, Walter R, Gastpar M. Long-term tri- and tetra-
cyclic antidepressants, myocardial contractility, and cardiac rhythm. Br Med J 1978; 
2(6138):666-7. 
115. Burckhardt D, Raeder E, Muller V, Imhof P, Neubauer H. Cardiovascular effects of tricy-
clic and tetracyclic antidepressants. JAMA 1978;239(3):213-6. 
43 
CHAPTER 2.2 
116. Giardina EG, Johnson LL, Vita J, Bigger JT, Jr., Brem RF. Effect of imipramine and nor-
triptyline on left ventricular function and blood pressure in patients treated for arrhyth-
mias. Am Heart J 1985;109:992-8. 
117. Veith RC, Raskind MA, Caldwell JH, Barnes RF, Gumbrecht G, Ritchie JL. Cardiovascu-
lar effects of tricyclic antidepressants in depressed patients with chronic heart disease, 
N Engl J Med 1982;306(16):954-9. 
118. Glassman AH, Johnson LL, Giardina EG, Walsh BT, Roose SP, Cooper TB, et aI. The use 
of imipramine in depressed patients with congestive heart failure. JAMA 1983;250(15): 
1997-2001. 
119. Sheline YI, Freediand KE, Carney RM. How safe are serotonin reuptake inhibitors for 
depression in patients with coronary heart disease? Am J Med 1997;102(1):54-9. 
120. Spier SA, Frontera MA. Unexpected deaths in depressed medical inpatients treated 
with fluoxetine. J Clin Psychiatry 1991 ;52(9):377-82. 
121. Hale AS. New antidepressants: use in high-risk patients. J Clin Psychiatry 1993;54 
(Suppl):61-70; discussion 71-3. 
122. Weidle PJ, Vlasses PH. Systemic hypertension associated with cyclosporine: a review. 
Drug Intell Clin Pharm 1988;22(6):443-51. 
123. Aabo K, De Coster R. Hypertension during high-dose ketoGonazole treatment: a prob-
able mineralocorticosteroid effect. Lancet 1987;2:637-8. 
124, Granberry MG, White LM, Gardner SF. Exacerbation of congestive heart failure after 
administration of polyethylene glycol-electrolyte lavage solution. Ann Pharmacother 
1995;29(12): 1232-35. 
125. Johansson SA. Acute right heart failure during treatment with epsilon amino caproic 
acid (E-ACA). Acta Med Scand 1967;182(3):331-4. 
126. Kelly RA, Smith TW. Recognition and management of digitalis toxicity. Am J Cardiol 
1992;69(18):108G-118G. 
127. Vale JA, Maclean KS. Amantadine-induced heart-failure. Lancet 1977; 1(8010) :548. 
128. Brown DL, Sather S, Cheitlin MD. Reversible cardiac dysfunction associated with 
foscarnet therapy for cytomegalovirus esophagitis in an AIDS patient. Am Heart J 
1993; 125: 1439-41. 
129. Tchekmedyian NS, Tait N, Aisner J. High-dose megestrol acetate in the treatment of 
postmenopausal women with advanced breast cancer. Semin Oncol 1986;13(4 Suppl 
4):20-5. 
130. Oken DE. Renal and extrarenal considerations in high-dose mannitol therapy. Ren Fail 
1994; 16(1): 147-59. 
131. Berdoukas V, Bentley P, Frost H, Schnebli HP. Toxicity of oral iron chelator L1. Lancet 
1993 ;341(8852): 1088. 
132. Cowan RE, Wright JT. Dapsone and severe hypoalbuminaemia in dermatitis herpetifor-
mis. Br J Dermatol1981; 104(2):201-4. 
133. Miura DS, Keren G, Torres V, Butler B, Aogaichi K, Somberg JC. Antiarrhythmic effects 
of cibenzoline. Am Heart J 1985;109(4):827-33. 
134. White JL, Fleming NW, Burke TA, Katz NM, Moront MG, Kim YD. Pulmonary edema 
after PGEl infusion. J Cardiothorac Anesth 1990;4(6):744-7. 
135. Quezado ZM, Wilson WH, Cunnion RE, Parker MM, Reda D, Bryant G, et aI. High-dose 
ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 
1993; 118(1): 31 -6. 
44 
Precipitating factors in patients 
hospitalised for congestive heart failure 
ABSTRACT 
2.3 
Objective: Knowledge on potential precipitating factors may improve care and 
treatment of patients with CHF. The aim of this study was to determine the pres-
ence of precipitating factors in patients hospitalised for congestive heart failure 
(CHF), particularly with respect to medication compliance. 
Methods and results: We analysed 318 hospital discharge letters of participants 
of the Rotterdam Study admitted to hospital for CHF. Medication compliance was 
assessed in patients with more than one hospitalisation by comparing dispensed 
medication after the first hospitalisation with the dispensed medication in the 
period preceding a readmission for CHF. 
Potential precipitating factors were described in 60% of the first hospitalisations 
for CHF as compared with 43% of the readmissions. Among the most frequently 
encountered precipitating factors were atrial fibrillation/flutter, myocardial infarc-
tion or ischaemia, and pulmonary disease. Lack of medication compliance was noti-
fied in only 3% of the discharge letters of patients rehospitalised for CHF. Based 
on dispensed medication according to computerised pharmacy records, however, 
non-compliance to either digoxin, diuretics or ACE-inhibitors was observed in 46% 
of rehospitalised patients. 
Conclusion: Little attention is paid in hospital discharge letters to potentially pre-
cipitating factors for CHF. In particular, lack of medication compliance appeared to 
be significantly more common as may be expected on the basis of the information 
provided by hospital discharge letters. As lack of medication compliance should be 
considered as a major impediment of optimal CHF treatment, information on this 
aspect should be notified in hospital discharge letters. 
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INTRODUCTION 
Congestive heart failure (CHF) is a major health problem in western countries. 
Both aging of the population and improved survival in patients with cardiovas-
cular disease contribute to the continuous increase in prevalence and incidence 
of CHF. This trend is also reflected in the hospitalisation rates for CHF. In 1993, 
CHF was the primary diagnosis in more than 875,000 hospital admissions in the 
United States, a number which is 5 times greater than it was 25 years earlier 
(1). Studies from Scotland (2), Spain (3) and the Netherlands (4) indicate a similar 
trend towards increasing numbers of hospital admissions for CHF over the last two 
decades in Europe. 
Although many studies have been performed on etiology and prognosis of CHF, 
relatively little is known about factors which may precipitate hospitalisations in 
patients with congestive heart failure (5). However, knowledge on possible precipi-
tating factors for hospitalisations of CHF may contribute to optimal guidance and 
treatment of these patients. This information may particularly be important for the 
general practitioner who has a critical role in the day-to-day treatment of patients 
with CHF. Moreover, the general practitioner will usually be the first physician 
who will be contacted when a patient experiences symptoms which may indicate 
relapsing CHF. Hospital discharge letters are the main source of information to GPs 
on hospital admissions of their patients. In addition, hospital discharge letters pro-
vide important information when patients are readmitted to hospital or attend the 
outpatient clinic. Therefore, all relevant clinical information on hospital admissions 
should be included in the hospital discharge letters. 
The aim of this study was to determine the presence of precipitating factors in 
patients hospitalised for CHF. Therefore, we evaluated the information on precipi-
tating factors for CHF in the discharge letters of participants of the Rotterdam 
Study hospitalised with a diagnosis of CHF. In addition, to evaluate the role of 
medication compliance as a potential precipitating factor in more detail and inde-
pendently from the hospital discharge data, we analysed dispensed medication 
prescriptions in patients with at least one readmission for CHF during the study 
period. 
SUBJECTS AND METHODS 
The Rotterdam Study is a population-based prospective cohort study in 7,983 
inhabitants aged 55 years or older living in the suburb Ommoord in Rotterdam, 
The Netherlands. Main areas of interest in the Rotterdam Study are cardiovascu-
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lar, neurological, ophthalmological and locomotor diseases in the elderly (6). The 
first cross-sectional survey started in 1990 and was completed in 1993. Apart from 
cross-sectional surveys which were carried out periodically, follow-up information 
was gathered on all cardiovascular, neurological, opthalmological and locomotor 
diseases which have occurred since the start of the study. All available informa-
tion on these diseases, such as hospital discharge letters and notes from general 
practitioners, were copied from the records of the general practitioner. Information 
on the events of interest were assessed independently by two research physicians 
with respect to the certainty of the diagnosis, rated as possible, probable or defi-
nite. A definite diagnosis of CHF was assumed if the diagnosis had been made 
by a medical speCialist. If the two research physicians disagreed on the certainty 
of diagnosis, they re-evaluated these events during a consensus meeting. When 
disagreement on the certainty of diagnosis remained, a final decision was made by 
a cardiologist. In addition, the cardiologist re-evaluated all potential cases of CHF 
on which the two research physicians agreed during the first evaluation. 
We analysed 318 hospital discharge letters of participants of the Rotterdam Study 
admitted to hospital with a definite diagnosis of CHF since the start of the Rotter-
dam Study in 1990 until 1997. A total of 249 hospital discharge letters pertained 
to a first hospitalisation for CHF within the study period, whereas 69 discharge 
letters concerned readmissions for CHF. Hospital discharge letters were examined 
with regard to the presence of potential precipitating factors for the onset of CHF. 
All medication prescriptions dispensed to participants of the Rotterdam Study by 
the three automated pharmacies in the suburb of Ommoord are stored in a date-
base as from January 1" 1991. To assess medication compliance independently 
from the hospital discharge letters, we compared in patients with more than one 
hospitalisation during the study period the dispensed medication in a 3-month 
period after the first hospitalisation for CHF with the dispensed medication in the 
period preceding the second hospitalisation for relapsing CHF. The analysis of 
dispensed prescriptions was restricted to digoxin, angiotensin converting enzym-
inhibitors (ACE-inhibitors) and diuretics, and the time interval between first and 
second hospitalisation had to be at least 90 days (n ~35). Patients were considered 
to be non-compliant to these drugs if they were dispensed at least once within 
3-months after discharge from hospital and if the calculated legend duration of the 
last prescription did not overlap the date of the second hospitalisation for CHF. A 
similar analysiS was carried out in patients with 3 or more hospital admissions for 
CHF (n~17). 
47 
CHAPTER 2.3 
RESULTS 
Information on hospital admissions for CHF was obtained from 318 hospital dis-
charge letters on 249 participants of the Rotterdam Study. The general charac-
teristics of the study population are given in table L Factors which may have 
precipitated the onset of CHF were reported in 60% of the hospital discharge let-
ters of patients with a first hospitalisation for CHF (table II). Precipitating factors 
were described in 43% of the hospital discharge letters which pertained to readmis-
sions for CHF (table III). In the remaining hospital discharge letters, no information 
on any potential precipitating factor could be identified. Atrial fibrillation or atrial 
flutter were supposed to precipitate CHF in 20% of the first hospitalisations. Acute 
myocardial infarction was diagnosed in 12% of the patients first hospitalised for 
CHF. Myocardial ischaemia, either symptomatic (angina pectoris) or asymptomatic 
(silent ischaemia), may have precipitated CHF in 11 % of the first hospitalisations. 
Respiratory tract disease, in particular exacerbations of chronic obstructive pulmo-
nary disease and lower respiratory tract infections, could be identified in 10% of 
the first hospitalisations. Anemia and hypertension were recorded as potential pre-
cipitating factors in respectively 4% and 2% of the first hospitalisations for CHF. 
Some rarer precipitating factors such as a total atrioventricular blocl< accounted for 
the remaining number of precipitating factors. 
Table I 
General characteristics of the study population (N=249) 
Age (years) 79.1 SD: 8.8 
Gender: 
females 126 (51%) 
males 123 (49%) 
No. of hospitalisations for CHF: 
1" 249 (78%) 
20d 46 (15%) 
3,d 14 (4%) 
4th 6 (2%) 
5th 2 (0.6%) 
6th 1 (0.4%) 
History of: 
myocardial infarction 72 (29%) 
diabetes mellitus 38 (15%) 
angina pectoris 41 (17%) 
hypertension 57 (23%) 
chronic obstructive pulmonary disease 47 (19%) 
48 
Precipitating factors in patients hospitalised for congestive heart failure 
Precipitating factors for relapsing CHF in patients readmitted to hospital are given 
in table III. Myocardial ischaemia appeared to be the most frequently encountered 
precipitating factor for relapsing CHF. Atrial fibrillation or atrial flutter were identi-
fied as a preCipitating factor in 6 % of the rellospitalisations for relapsing CHF. Lack 
Table" 
Precipitating factors identified in hospital discharge letters of 249 first 
hospitalisations for CHF. 
No precipitating factor identified 99 (39.8 %) 
Atrial fibrillation/flutter 50 (20.2 %) 
Myocardial infarction 29 (11.6 %) 
Angina pectoris 24 ( 9.6 %) 
Respiratory tract disease 24 ( 9.6 %) 
Anaemia 9 ( 3.6%) 
Silent myocardial ischaemia 4 ( 1.6 %) 
Hypertension 4 ( 1.6 %) 
Atrioventricular blocks 3 ( 1.2 %) 
Other precipitating factors 3 ( 1.2 %) 
-chorda-rupture 
-tamponade 
-intravenous fluid administration 
Table III 
Precipitating factors identified in 69 hospital discharge letters of patients with 
at least one previous hospital admission for CHF. 
No precipitating factor identified 39 (56.5 %) 
Atrial fibrillation/flutter 4 ( 5.8 %) 
Myocardial infarction 4 ( 5.8 %) 
Angina pectoris 9 (13.0 %) 
Respiratory tract disease 2 ( 2.9%) 
Anaemia 4 ( 5.8 %) 
Silent myocardial ischaemia 3 ( 4.3 %) 
Hypertension ( 1.4 %) 
Atrioventricular blocks ( 1.4 %) 
Lack of medication compliance 2 ( 2.9 %) 
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Table IV 
Medication dispensed in a 3-month period after a first hospitalisation for CHF 
compared with medication use (according to the calculated legend duration) 
at the time of second hospital admission in 35 patients with at least two 
hospitalisations*. 
ACE-inhibitors 
Digoxin 
Diuretics 
Dispensed drugs in a 3-
months period after a first 
hospitalisation for CHF 
27 
22 
33 
* interval between both hospitalisations " 90 days 
Patients not using the drug 
according to the legend 
duration at the time of the 
second hospitalisation 
10 
6 
7 
(37%) 
(27%) 
(21%) 
of medication compliance was notified in only 2 hospital discharge letters concern-
ing a second hospitalisation for CHF (3%). 
Table IV presents the dispensed medication, based on computerised pharmacy 
records, in a 3-months period after the first hospitalisation compared to the dis-
pensed drugs of which the calculated legend duration overlapped the date of the 
second hospitalisation for CHF. According to the calculated legend duration, 37% 
of the patients who were prescribed an ACE-inhibitor after the first hospitalisation 
were not compliant to this drug at the time of the second hospitalisation for CHF. 
For digoxin and diuretics, these percentages were 27% and 21 %, respectively. A 
total of 15 out of 35 patients (43%) were non-compliant on the basis of the legend 
duration to at least one of these three drugs. Based on a similar approach, non-com-
pliance could be demonstrated prior to 9 out of 17 hospital readmissions in patients 
with more than two hospitalisations for CHF. Hence, non-compliance according to 
our definition was observed in 24 out of 52 hospitalisations for CHF (46 %; 95 % CI: 
32% - 60%). 
During 74% (n~234) of the hospital admissions, patients with CHF were treated 
by cardiologists, whereas in the remaining 26% (n~84) of the hospitalisations for 
CHF, patients were treated by other medical specialists, mainly internists. Over 
the years 1992 until 1996, the percentage of patients hospitalised for CHF who 
were primarily treated by a cardiologist remained stable at approximately 75 %. 
Precipitating factors were described in 59% of the hospital discharge letters of 
patients treated by cardiologists compared to 49 % of the hospital discharge letters 
of patients treated by other specialists (p~O.10). 
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Death attributed to congestive heart failure occurred in 13% of all hospitalisations 
(n~42). 
DISCUSSION 
From just over a half (60%) of the hospital discharge letters of patients with a first 
hospitalisation for CHF, information could be obtained on factors which may have 
precipitated the onset of CHF. In hospital discharge letters of patients readmitted 
to hospital due to relapsing CHF, precipitating factors could be identified in 43 % 
of the hospital discharge letters. Non-compliance to the prescribed drug regimen 
was only rarely noted in the hospital discharge letters as a potential precipitating 
factor. Analysis of dispensed medication prescriptions, however, suggested sub-
stantial non-compliance to medication in patients readmitted to hospital for relaps-
ingCHF. 
Although the evaluation and prevention of factors which may precipitate CHF are 
important objectives in the care and management of CHF patients, few studies 
have addressed this issue (7, 8). Ghali et al. examined 101 hospital readmissions 
for CHF in a large public hospital, and demonstrated that precipitating factors 
could be identified in 93% of these patients. Non-compliance to the medical regi-
men (diet, medication, or both) was by far the most commonly identified respon-
sible factor for readmission (64%). Opasich et aI. followed patients referred to a 
specialised heart failure unit for assessment of indication for cardiac transplanta-
tion. During a mean follow-up period of 310 days, 328 cases of nonfatal decompen-
sation were recorded. Precipitating factors could be identified in 91 % of the cases. 
Most frequently encountered were cardiac arrhythmias (24%) and infections (23%), 
particularly pulmonary infections, whereas poor compliance was recorded in 15 % 
of the cases. 
Both the study of Ghali et aI. and the study of Opasich et al. identified precipitating 
factors in over 90% of the patients with relapsing congestive heart failure, whereas 
in our study preCipitating factors could be identified in only 43% of the hospitalisa-
tions for CHF. This may be due to a number of differences between our study and 
these two previous studies. 
First, as both the study of GhaH et al. and the study of Opasich et al. were carried 
out prospectively and especially aimed at revealing precipitating factors for relaps-
ing CHF, this may have contributed substantially to the disclosure of a very high 
percentage of precipitating factors as compared to our study, in which informa-
tion on precipitating factors was obtained from hospital discharge letters which 
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were already available. Second, in contrast to the studies of Ohali et al. and Opa-
sich et aI., which evaluated only patients with a relapsing CHF, we included both 
patients with a first hospitalisation as well as patients with readmissions to hospi-
tal because of CHF. It may be conceivable that precipitating factors for CHF are 
more easily identified in patients with pre-existing CHF. However, in our study, 
precipitating factors could be found in only 43% of the hospital discharge letters of 
patients with at least one previous hospital admission for CHF. Third, a major point 
of difference between our study and the studies of Ohali et al. and Opasich et 
al. is the source of information on which the results of the study are based. We 
deliberately confined our information on precipitating factors to the hospital dis-
charge letters which are added to the hospital medical record and sent to the gen-
eral practitioner (OP). Hospital discharge letters provide the OP with all relevant 
information on the hospital admission. In addition, they are an important source of 
information in case of subsequent hospital admissions. The presence of precipitat-
ing factors which preceded the onset of CHF should be regarded as particularly 
relevant information. For instance, lack of medication compliance or preceding 
myocardial ischaemia may provide important clues to improve the management 
of patients with CHF. Therefore, such information on precipitating factors should 
be recorded in the hospital discharge letter. However, this information may have 
been notified in the medical record without mentioning it in the hospital discharge 
letter. 
Poor medication compliance was regarded as a precipitating factor for CHF in 
43% of the patients in the study of Ohali et al. and in 15% of the patients in the 
study of Opasich and al. Poor medication compliance will be encountered predomi-
nantly in patients with a previous hospitalisation for CHF. For this reason, we ana-
lysed patients with at least one previous hospital admission for CHF within the 
study period separately (table III). Poor medication compliance was specifically 
mentioned in the hospital discharge letters of only 3 % of the patients readmitted to 
hospital because of a relapse of CHF. However, a considerable number of patients 
(46%) did not use the heart failure medication which had been prescribed follow-
ing a preceding hospitalisation for CHF, according to the calculated legend dura-
tion at the time of rehospitalisation for CHF. ACE-inhibitors appeared not to be 
used in 37% of the patients who had been prescribed an ACE-inhibitor after 
their first hospitalisation. Comparable findings, although less pronounced, were 
observed with respect to the use of digoxin and diuretics. As drugs may have 
been discontinued by the physician because of adverse effects or an altered thera-
peutical regimen, the calculated legend duration has some limitations in exactly 
estimating medication compliance. On the other hand, filled prescriptions do not 
necessarily imply medication compliance. It has been demonstrated that among 
participants of the Rotterdam Study, there is a very high agreement between phar-
macy records and actual use of cardiovascular drugs (9). Therefore, our findings 
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strongly suggest that lack of medication compliance seems to be much more preva-
lent as suggested on the basis of information in hospital discharge letters. In addi-
tion, the abovementioned studies of Ghali et al. and Opaschi et al. indicate that 
lack of medication compliance should be regarded as a relatively common problem 
in the treatment of chronic diseases such as CHF (10). The findings in our study, 
however, demonstrate that poor medication compliance is only rarely recorded in 
the hospital discharge letters. In view of the estimated frequency of poor medica-
tion compliance in the literature (7, 8, 10, 11) and the estimated medication com-
pliance on the basis of the calculated legend duration of prescribed heart failure 
drugs, this may indicate that in our study population poor medication compliance 
is either rarely noted as a potential precipitating factor at the time of hospital 
admission or that poor medication compliance is rarely recorded in the hospital 
discharge letter despite its identification as a precipitating factor at the time of 
hospital admission. If poor medication compliance is rarely recognized at the time 
of hospital admission, it may be interesting to know whether physicians ask explic-
itely for medication compliance when patients are readmitted to hospital for CHF. 
Although this should be regarded as an essential part of the anamnesis of each 
hospital readmission for CHF, it remains unclear whether all patients are asked for 
medication compliance routinely. If poor medication compliance is only recorded in 
the medical records without any notification in the hospital discharge letter, the 
GP may not be able to pay attention to this aspect when the patient has been dis-
charged from hospital. 
Over the last few years, some studies have been published which aimed at 
improvement of care in patients with CHF (12-15). Main objectives of these stud-
ies were to reduce the number of hospital readmissions and to improve quality of 
life. Most of these studies were characterised by a relatively intensive counselling 
programme for patients discharged with CHF. Although the results of these stud-
ies are not consistent, there is a general impression that intensive counselling of 
patients with CHF may contribute to the prevention of hospital readmissions for 
relapsing CHF and may improve their quality of life. However, the opportunity 
to participate in such programmes can be offered to only a minority of patients. 
Under everyday circumstances, the GP has an important role in the counselling 
of CHF patients. Therefore, it is of professional importance for the GP to receive 
all relevant information, including information on precipitating factors, concerning 
patients discharged from hospital with a diagnosis of CHF. Such information may 
help the GP to draw his attention to patient's characteristics (e.g. lack of medica-
tion compliance, atrial fibrillation, myocardial ischaemia) which may have an unfa-
vorable effect on the clinical course of CHF. 
The presence of potential precipitating factors does not necessarily imply a causal 
relationship with the onset or worsening of CHF. In particular, the high percentage 
53 
CHAPTER 2.3 
(;;'90%) of precipitating factors identified in previous studies might give rise to the 
impression that many hospital admissions for CHF may be preventable. However, 
the absence of control groups in our study and the studies of Ghali et al. and Opa-
sich et al. prevents a meaningful estimation of the relative risk for the occurrence 
of CHF associated with the presence of these precipitating factors. Nevertheless, 
convincing evidence for a Significant beneficial effect of pharmacotherapy on the 
prognosis of CHF has been provided by several randomised clinical trials (16-18). 
Hence, especially lack of medication compliance has to be regarded as a major 
impediment to optimal treatment of CHF. 
In conclusion, the findings in our study suggest that information on precipitating 
factors for CHF could be obtained from a small majority (60%) of the hospital dis-
charge letters of first hospitalisations for CHF and from only a minority (43 %) of 
the patients hospitalised for relapsing CHF. In contrast to the results of previous 
studies and to the estimated medication compliance on the basis of computerised 
pharmacy records, lack of medication compliance was identified in only 3% of the 
patients with a previous hospitalisation for CHF. These findings strongly suggest 
that routine hospital discharge letters pay too little attention to undercompliance 
of heart failure medication. 
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Chapter 3 
The role of non-steroidal 
anti-inflammatory drugs 
in heart failure 

Adverse cardiovascular effects of non-
steroidal anti-inflammatory drugs in 
patients with congestive heart failure 
ABSTRACT 
3.1 
Congestive heart failure (CHF) is a complex clinical syndrome, especially in the 
elderly, which results from cardiac dysfunction. Epidemiological studies have shown 
a gradual increase in age-adjusted hospitalization rates for CHF and overall popu-
lation prevalence of CHF during the last two decades in western countries. The 
health-care costs associated with CHF are considerable and are likely to increase 
in the near future. Hence, identification of risk factors which could induce or exac-
erbate CHF is of major importance. 
Non-steroidal antiinflammatory drugs (NSAID) are frequently prescribed in elderly 
patients for several rheumatological- and non-rheumatological indications. Numer-
ous adverse reactions, mainly related to the gastro-intestinal tract and kidney func-
tion, have been described. Some case-reports have suggested a causal relation 
between the use of NSAID and the onset of CHF. The pathophysiology of CHF and 
the pharmacological properties of NSAID support this hypothesis. In particular, the 
inhibition of prostaglandin-synthesis may adversely affect cardiovascular homeosta-
sis in patients with a propensity to develop congestive heart failure. 
Notwithstanding the adverse effects, however, the prescription of NSAID in elderly 
patients is often desirable and justifiable. Therefore, further pharmacoepidemio-
logical research is needed to quantify the risk for CHF attributable to the use of 
NSAID and to identify patients who are particularly susceptible to their adverse 
cardiovascular effects. In these patients, it may be advisable to avoid the use of 
NSAID. 
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INTRODUCTION 
Over the years, several reports have been published in which the onset of conges-
tive heart failure (CHF) was attributed to the use of non-steroidal antHnflamma-
tory drugs (NSAID) (1-3), Recently, a study with a record linkage data base showed 
that concomitant use of NSAID and diuretics doubled the risl{ for hospitalization 
because of congestive heart failure (4), In this review, we will discuss the putative 
relation between the use of non-steroidal anti-inflammatory drugs and congestive 
heart failure, First, we will provide background information on the definition, epi-
demiology and prognosis of congestive heart failure, We will also summarize cur-
rent views on the pathophysiology of congestive heart failure, Second, we will 
discuss aspects of NSAID-utilization and pharmacology, paying special attention 
to their effects on prostaglandin-synthesis and renal function, since both provide 
important information on how NSAID may induce or exacerbate congestive heart 
failure, 
CONGESTIVE HEART FAILURE 
Definition and classification 
Although many definitions of congestive heart failure exist, none is entirely sat-
isfactory, Recently, the Task Force on Heart Failure of the European Society of 
Cardiology proposed that patients should have the following: symptoms of CHF, 
typically breathlessness or fatigue, either at rest or during exertion, or ankle swell-
ing and objective evidence of major cardiac dysfunction at rest (5), Signs and symp-
toms of CHF may be difficult to interpret, especially among elderly and obese 
patients, To measure the severity of CHF, the classification of the New York Heart 
Association (NYHA-classification) is in widespread use, The NYHA-classification 
is based on anamnestic criteria only, But, although often used, the association 
between NYHA-classification and the severity of cardiac dysfunction is poor, There-
fore, in the Framingham study and the Boston score, more detailed diagnostic cri-
teria based on history, physical examination and chest X-ray were formulated (6, 
7), 
No gold standard diagnostic procedure is currently available in the detection of 
CHF, Echocardiography is now the key investigation in patients suspected of CHF 
as it gives direct information on ventricular function, Echocardiography provides 
also information about valve- and pericardial disease, 
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Epidemiology 
Although epidemiological data concerning CHF are still rather sparse, there has 
been a gradually increasing interest during the last decade in the epidemiological 
background of CHF (8). Findings in the Framingham Heart Study showed that the 
prevalence of CHF roughly doubled with each decade in persons aged 50-89 years 
from about 1 % prevalence in persons aged 50-59 years to 10% in persons aged 
80-89 years (9). The incidence of CHF showed a similar pattern, from about 0,2% 
in persons 45-54 years of age, to 4,0% in men 85-94 years of age. The incidence in 
men exceeded that in women in all patient-groups aged under 75 years. Above the 
age of 75 years, the incidence in women showed a steep increase which eventually 
exceeded that in men (9). 
Several sources indicate an important age-adjusted increase in hospitalization 
rates for CHF in western countries over the last twenty years (10, 11). In 1991, 
more than two million patients were discharged from hospital in the United States 
with a primary or secondary diagnosis of CHF (12). Total healthcare expenditure in 
1991 for this group of patients was estimated at nearly 40 billion US-dollars. In the 
Netherlands, annual hospital admissions for CHF increased from 14.441 in 1980 to 
24.368 in 1992 (11). Age-adjusted hospitalization rates showed an increase in the 
period 1980-1992 of 43% for men and 30% for women. Re-admissions due to recur-
rent CHF occur frequently, especially in elderly patients. Re-admission rates up 
to 25 % within 6 months after discharge have been reported in patients over 65 
years of age(13, 14). A recently published simulation model predicted that in the 
near future there will be a further shift from acute to more chronic cardiovascular 
disease, including CHF (15). 
Despite advances in the treatment of various risk factors for CHF, the overall 
population prevalence of CHF increases (10). As shown in the Framingham study, 
hypertension was the major etiologic factor in the development of CHF, followed 
by coronary-artery disease and rheumatic heart disease (7). More recent data, both 
from the Framingham Study as well as from other studies, suggest that the predom-
inant role of hypertension in the development of CHF may have shifted towards 
ischemic heart disease (16-18). 
To explain the increase in the overall population prevalence of CHF, it seems rea-
sonable to concentrate on medical and demographical developments. First of all, 
with increasing average age of the population, the risk of the ageing individual to 
develop overt cardiovascular disease, including CHF will rise. Second, a decrease 
in the fatality rate of acute myocardial infarction will result in more patients who 
are at an increased risk for developing CHF. Recent trends in acute coronary 
heart disease indicate that survival among patients hospitalized for acute myo-
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cardial infarction has increased substantially during 1985-1990 (19). Furthermore, 
improved survival among patients with angina pectoris and hypertension as a 
result of modern medical treatment may have contributed to an increase in the 
prevalence of CHF, especially in those 65 years of age and older (20). 
In conclusion, epidemiological data suggest that CHF will be an increasing cause 
of morbidity among the elderly. This also has important socio-economic implica-
tions, since growing morbidity gives rise to increasing health expenditures. The 
bulk of costs can be attributed to hospitalizations for CHF (first admissions as well 
as readmissions). Therefore, further research on primary and secondary prevention 
is of major importance. A further evaluation of the role of NSAID in CHF may con-
tribute to this, as these drugs are often used in the elderly. 
Prognosis 
The prognosis of CHF remains quite poor. Recent analyses from the Framingham 
Heart Study showed no appreciable change in median survival after the onset of 
CHF from 1948 to 1988 (17). In the Framingham Heart Study, the median survival 
after the onset of CHF in an unselected population was 1,7 years in men and 3,2 
years in women. The one- and five-year survival rates were 57% and 25% in men 
and 64% and 38% in women respectively. No significant improvement in median 
survival was found during the 40 year-period under study. However, the mean age 
at diagnosis of CHF increased from 57,3 years in the 1950s to 76,4 years in the 
1980s. After adjusting for age and aetiology of CHF, survival after the development 
of CHF remains better in women than men. Advancing age was also a predictor 
of reduced survival in patients with CHF. When patients who died within three 
months after the diagnosis of CHF were excluded from the analysis, the results 
closely resembled those from the placebo-group in heart failure intervention trials 
such as the V-HeFT study, in which inclusion and exclusion criteria led to selected 
populations_ 
Several cohort studies of prognostic factors in patients with CHF have been per-
formed (table I). Reduced left ventricular ejection fraction (21), diminished peak 
oxygen consumption during exercise (22), coronary artery disease (23), low plasma 
sodium level and NYHA-classification (24) are among the most important predic-
tors of an unfavourable prognosis. 
Pathophysiological aspects 
It is now well-recognised that the clinical syndrome of CHF cannot always be 
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explained simply by reduction of left ventricular ejection fraction. Besides systolic 
dysfunction, characterised by impaired left ventricular contractility, the importance 
of diastolic heart failure is now widely accepted (25-27). These patients present 
with the syndrome of CHF and have normal, or near normal, resting systolic func-
tion. Fundamental to the diagnosis of isolated diastolic heart failure is the demon-
stration of a raised filling pressure, despite normal ventricular dimensions and 
systolic contractility (27). Impairment of diastolic ventricular filling may have vari-
ous mechanisms (28). Diastolic dysfunction may result from impaired active relax-
ation of the ventricular wall and reduced compliance. Furthermore, mechanical 
resistance to ventricular filling, such as in constrictive pericarditis and mitral steno-
sis, may induce diastolic dysfunction. Hence, the pathophysiology of CHF cannot 
be explained in temlS of impaired left ventricular contractility only. Although most 
investigations on hemodynamic changes in patients with CHF have concerned sys-
tolic dysfunction, parts of what we know may also apply to patients with diastolic 
dysfunction (29). However, we will focus our discussion on the pathophysiology 
primarily on patients with the syndrome of CHF due to systolic dysfunction. 
In response to an initial injury to the heart, resulting in a loss of functioning myo-
cardial cells, hemodynamic and neurohumoral mechanisms are activated to com-
pensate for negative circulatory consequences (30). First, a decrease in the ability 
of the left ventricle to empty during systole increases the tension on non-injured 
parts of the heart during diastole. This increase in diastolic wall tension (preload) 
will enhance ventricular contraction, following the Frank-Starling curve. Second, a 
decreased ability of the left ventricle to eject blood in the aorta activates the sympa-
thetic nervous system. Stimulation of beta-adrenergic receptors in the non-injured 
myocardium will result in increased force and frequency of contraction. These two 
mechanisms also have potential risks. Ventricular dilatation and sustained sym-
pathetic activation will lead to a striking increase in internal wall stress during 
systole. This distorts ventricular architecture and accelerates energy expenditure. 
In response to this potential adverse effect, synthesis of myofibrillar proteins is 
stimulated which leads to an increase in wall thickness and a subsequent reduc-
tion of ventricular wall stress and dilatation (30). In an attempt to achieve balance 
between sympathetic activation and inhibition, increased diastolic wall stress 
in the atria suppresses the activity of the sympathetic nervous system. Atrial 
baroreceptors are stimulated and inhibit sympathetic outllow from the vasomotor 
centre in the central nervous system (31). Atrial stretch also leads to the release 
of atrial natriuretic peptide, which inhibits the release of noradrenaline and its 
actions on peripheral blood vessels (32). It also exerts vasodilator and natriuretic 
effects. These so-called stress-reducing mechanisms are essential in limiting the 
potential adverse consequences of sustained sympathetic activation and ventricu-
lar dilatation. 
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Ref. Year First author Size Months of Endpoints Risk factors / Prognostic factors I~ pub!. follow-up 
1. 1983 Franciosa(103) 182 12 mortality High LV filling pressure, CAD 
2. 1994 Madsen(24) 190 24.5 mortality LVEF, creatinine> 121 ~mol, sodium:;; 137 
mmol, CAD, urea>7.6 mmol 
3. 1992 Parameshwar(21) 127 14.6 mortality plasma sodium concentration, LVEF, trans-
plantation, peak oxygen consumption 
4. 1993 Ho(17) 652 47 mortality male, age, diabetes, cause of CHF, LVH, 
5. 1993 Carson(104) 206 30 mortality atrial fibrillation I hospitalization 
6. 1993 Cohn(22) 1325 60 mortality LVEF, CTR, peak oxygen consumption, ven-
tricular arrythmias, plasma norepinephrine 
7. 1993 Middlekauff(105) 491 12 mortality syncope 
8. 1993 Anguita(106) 130 15 mortality intravenous inotropic requirements, maximal 
tolerated captopril dose, decreased systolic 
blood-pressure. 
9. 1995 Stevenson(107) 737 12 mortality 
10. 1995 Roul(108) 50 21 mortality exercise peak oxygen consumption, invasive 
haemodynamic data 
11. 1989 Gradman(109) 295 16 mortality LVEF, ventricular tachycardia 
12. 1987 Likoff(110) 201 11 mortality LEVF, maximal oxygen uptake, ischemic cardio-
myopathy, 
13. 1989 Romeo(111) 104 45 mortality ventricular arrhythmia 
14. 1990 Kelly(23) 133 29 mortality coronary artery disease, syst. blood pressure 
< 120 mm Hg, congestion on chest-X-ray, age 
over 64 years 
'" tn 
15. 1988 Juilliere(112) 111 56 mortality LVEF 
16. 1988 Hofmann(113) 110 53 mortality LVEF, cardiac index < 2.5 Umin/m 2, ventricular 
arrhythmia, atrial fibrillation 
17. 1991 Middlekauff(114) 390 8 mortality atrial fibrillation 
LV = Left Ventricle; LVEF = Left Ventricular Ejection Fraction; CAD = Coronary Artery Disease; CTR = Cardiothoracic Ratio; Major event = 
heart failure, severe ventricular arrhythmia 
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CHAPTER 3.1 
In established CHF, systemic perfusion is maintained by peripheral vasoconstric-
tion and sodium retention. Whereas the sympathetic nervous system is activated 
early in the disease process, the renin-angiotensin system is usually triggered only 
once symptoms develop (30). Besides circulating vaso-active factors, CHF is accom-
panied by an increased release of locally active vasoconstrictors like endothelin, 
which is produced by vascular endothelium. In patients without CHF, endogenous 
vasoconstrictors are counterbalanced by endogenous vasodilators. Atrial natri-
uretic peptide (ANP) normally inhibits the release of noradrenaline, renin and vaso-
pressin as well as their effects on peripheral vessels. In early CHF, increased levels 
of ANP appear to prevent a rise in plasma renin concentration and plasma aldoste-
rone concentration, because of the inhibitory action of ANP on these two hormones 
(33-36). In long-standing CHF, however, the release and effectiveness of ANP will 
gradually diminish and the actions of vasoconstrictors are left unopposed. This 
will eventually lead to mutual neurohormonal amplification resulting in increased 
plasma concentrations of renin, angiotensin and aldosterone (37). 
Sodium retention, resulting from activation of the renin-angiotensin system, is 
another important feature of neurohormonal activation (30). Angiotensin leads to 
a constriction of the efferent arteriole and an increase in glomerular filtration frac-
tion. The latter will enhance the proximal tubular sodium reabsorption by altering 
the peritubular balance of hydraulic and osmotic forces. In addition, angiotensin 
enhances sodium retention both directly and indirectly by stimulating the release 
of aldosterone. Angiotensin also gives rise to water retention by stimulating the 
cerebral thirst centre and enhancing the release of vasopressin from the pituitary. 
In healthy individuals, these endogenous salt-retaining systems are offset by 
endogenous salt-excreting systems, such as atrial natriuretic peptide and prosta-
glandins. In patients with congestive heart failure, ANP loses its inhibitory effects 
on the release and actions of renin and vasopressin (38). Renal hypoperfusion plays 
a central part in this attenuated natriuretic response. Renal hypoperfusion alters 
intrarenal haemodynamics and triggers the release of vasoconstrictors. It also 
leads to the release of prostaglandins which exert some natriuretic and diuretic 
effects (39). Both peripheral vasoconstriction and sodium retention are central 
mechanisms in the development of the circulatory state of decompensation. 
Long-term haemodynamic stress and neurohormonal activation will progressively 
cause deterioration of ventricular function. It can cause irreversible structural 
remodelling of the heart. Progressive ventricular dilatation may lead to subse-
quent mitral regurgitation. Hypertrophic response to stress will increase energy 
demands while reducing energy supply (wall thickening may impair oxygen diffu-
sion). In experimental models, high concentrations of noradrenaline and angioten-
sin II exert direct toxic effects on myocardial cells (40, 41). Increased production 
of oxygen free radicals may also be involved in progressive heart failure(42). Poten-
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tially cardiotoxic cytoldnes such as tumour necrosis factor are increased in patients 
with CHF, especially in those patients with neurohormonal stimulation (43). Pro-
gression of CHF may thus be the result of a complex hemodynamic and neuro-
hormonal response to an initial cardiac injury that gradually compromises cardiac 
performance (44). 
NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND 
CONGESTIVE HEART FAILURE 
NSAID have numerous effects on renal and cardiovascular homeostasis. In particular 
in patients with CHF, there seems to be an increased susceptibility for the renal and 
cardiovascular effects of NSAID. As shortly mentioned in the introduction, several 
case reports have been published in which the onset of CHF was attributed to the 
use of an NSAID (45-47). In the following paragraphs, various aspects of NSAID and 
their potential effects on cardiovascular homeostasis in patients with CHF will be 
discussed. 
Utilization of NSAIDs 
Non-steroidal anti-inflammatory drugs (NSAIDs) are a heterogeneous group of 
organic acids which exert analgesic, antipyretic, antiinflammatory and platelet-
inhibitory actions. World-wide, over 100 NSAID are marketed or at an advanced 
stage of development (48). Although originally used predominantly for rheumato-
logical conditions, current indications include many non-rheumatological condi-
tions such as dysmenorrhoea, posttraumatic pain, colic pain or patent ductus 
arteriosus in infants. The effective relief of pain provided by NSAID makes this 
category of drugs popular among both users and prescribers. The overall NSAID-
exposure in the Netherlands was valued at 10.8 defined daily dosages (DDD)11000 
persons/day in 1987, over-the-counter products not included (49). More than the 
NSAID utilization is in patients of 60 years and older. In patients older than 75 
years, NSAID utilization increases to 45 DDDI1000 persons/day in women and 20 
DDDI1000 persons/day in men. In the United States of America, 50 million Ameri-
cans were expected to use NSAID intermittently or routinely in 1991 (50). Neverthe-
less, most presently available NSAID have a far from satisfactory risk/benefit 
profile. The adverse reaction profile of several NSAID has proved to be unaccepta-
ble and led to withdrawal from the market. Adverse drug reactions which are 
attributed to the use of NSAID are mostly related to the effects of these drugs on 
the upper gastro-intestinal tract and on kidney function. 
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Pharmacology 
The major mechanism of action of NSAID is the inhibition of prostaglandin biosyn-
thesis (51). 
NSAID inhibit the function of cyclooxygenase, an enzyme essential for the trans-
formation of arachidonic acid into prostaglandins. Arachidonic acid can be oxy-
genated by cyclo-oxygenase to prostaglandin G2• A peroxidase component of 
cyclo-oxygenase reduces prostaglandin G, to prostaglandin H" which is the precur-
sor of several specific prostaglandins. Finally, many different prostaglandins are 
produced in various tissues, such as tromboxane A, in platelets and prostacycline 
in vascular endothelium. Recently, two isoforms of cyclo-oxygenase (COX) have 
been identified, COX-l and COX-2. COX-2 is an inducible isoform of cyclo-oxygen-
ase and predominantly present throughout all stages of the inflammatory response, 
whereas COX-l is mainly responsible for the production of prostaglandin E, and 
prostaglandin I, in kidney and stomach (51). 
A new class of COX-2 selective NSAID such as meloxicam exhibit greater inhibi-
tory action against COX-2 as compared with COX-i. The adverse effects of NSAID 
on renal function seem to be in part attributable to inhibition of COX -1 and sub-
sequently decreased production of renal prostaglandin E,. As renal prostaglandin 
E, is important in maintaining renal perfusion in patients with CHF, more selec-
tive agents may offer benefits for these patients (37). Animal studies in rats have 
shown that meloxicam exerts less inhibitory effects on urine PGE, excretion than 
most other NSAID (52). Furthermore, no effects of meloxicam on blood pressure 
could be observed in experimental studies rats and dogs (53). In 12 healthy human 
volunteers, indomethacine 25 mg 3 times daily for 8 days markedly reduced urinary 
PGE,- excretion, whereas meloxicam 7,5 mg/day for 6 days had no effect (54). From 
a theoretical point of view, the new COX-2 selective agents may be more appropri-
ate when treatment with NSAID is demanded in patients with CHF. However, fur-
ther studies on these selective NSAID are needed in which patients at an increased 
risk of adverse renal effects are included, such as patients with CHF, before the 
evidence for this hypothesis can be provided. 
Prostaglandins playa major part in the inflammatory response in tissues. Prostag-
landins are also involved in the pyretic response by activating the hypothalamus. 
Apart from the inhibition of prostaglandin synthesis, another postulated mecha-
nism explaining the therapeutic effect of NSAID pertains to the interaction with 
the adenylate cyclase system (51). Indomethacin and several other NSAID inhibit 
phosphodiesterase, thereby raising the intracellular concentration of cyclic AMP. 
Cyclic AMP has shown to stabilize membranes, including lysosomal membranes. 
By preventing the release of enzymes, this mechanism may have an important role 
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in modifying the inflammatory response. 
Inhibition of the production of prostaglandins does not only explain to a large 
extent the beneficial antipyretic and antiinflammatory action of NSAID, but also 
many of their adverse reactions. For example, upper gastro-intestinal bleeding 
caused by NSAID results mainly from the inhibition of locally produced prostaglan-
dins, since prostaglandins have a protective effect on the mucosa. In other cases, 
such as hepatoxicity due to diclofenac and other NSAID, the pathophysiological 
mechanism is less clear. 
Role of prostaglandins in congestive heart failure 
In patients with CHF, in particular the advanced stages, renal function is at risk 
because of a decrease in renal blood flow. Nevertheless, until the terminal stage of 
the disease, glomerular filtration rate is usually preserved within acceptable limits. 
This appears to be achieved in part by the synthesis of two vaso-active peptides 
within the kidney, angiotensin II and prostaglandins (39). These two substances 
are rapidly released in response to a fall in renal blood fiow or an increase in renal 
sympathetic nerve stimulation. Although these two hormonal factors exert oppo-
site effects on systemic and renal blood flow and on sodium and water excretion, 
both act to preserve glomerular filtration rate. Prostaglandins exert a vasodilator 
action on the afferent arteriole and angiotensin II leads to a vasoconstrictor effect 
on the efferent arteriole. There is a close correlation between circulating levels of 
prostaglandin metabolites and angiotensin II (37). 
The kidneys release two types of prostaglandins that are important in the regu-
lation of renal function, prostacyclin (PO-I,) and prostaglandin E,. Prostacyclin is 
produced mainly in the cortex, while prostaglandin E, is produced mainly in the 
medulla (55). Under basal conditions they possess minimal vasodilator activity. 
However, in case of prior vasoconstriction they act as potent vasodilators. A signifi-
cant increase in the excretion of metabolites of prostaglandins occurs especially 
in patients with hyponatremia (37). Principal renal sites of prostaglandin synthe-
sis are the vasculature, the glomerulus, the collecting tubule and the medullary 
interstitial cells (56). Besides the beneficial effect on the glomerular filtration rate, 
prostaglandins antagonize many extraglomerular actions of angiotensin II. Pros-
taglandins oppose the action of angiotensin II on the systemic circulation and 
decrease the afterload of the failing heart. Prostaglandins decrease total body 
sodium and water as a result of multiple interactions such as direct inhibition of 
sodium reabsorption in the renal tubules (PO-E,) and counteraction of the stimula-
tion of the thirst centre caused by angiotensin II. They also oppose the actions 
of vasopressin in the collecting duct (PO-E,). To what extent these interactions 
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contribute to the maintenance of a clinical state of compensation in patients with 
left ventricular dysfunction remains unclear. 
Interactions of NSAID with ACE-inhibitors and diuretics 
Both ACE-inhibitors and diuretics are cornerstones of the pharmacotherapeutic 
treatment of patients with CHF. Because many patients suffer from multiple pathol-
ogy, it is not unusual that these drugs are prescribed in combination With an NSAID. 
NSAID and ACE-inhibitors, however, may exert counteractive effects that may affect 
renal function (57). NSAID and ACE-inhibitors inhibit the synthesis of prostaglan-
dins and angiotensin II respectively. Both angiotensin II and prostaglandins act to 
preserve glomerular filtration rate in patients with CHF: angiotensin II by a vaso-
constrictor effect on the efferent arteriole and prostaglandins by a vasodilator effect 
on the afferent arteriole. Four specific factors have been identified that predispose 
patients with CHF to the development of functional renal insufficiency after treat-
ment with ACE-inhibitors or NSAID: marked renal hypoperfusion, vigorous diuretic 
treatment, diabetes mellitus and the intensity of hormonal inhibition within the 
kidney (39). When combined treatment of these two drugs is indicated, these risk 
factors for renal impairment need to be considered. 
In patients with CHF, functional renal insufficiency can easily induce intravascular 
volume overload and exacerbation of signs and symptoms of CHF. Hall et aL demon-
strated that aspirin (dose 350 mg) interacted relevantly with the circulatory effects 
of enalapril in patients with severe heart failure (58). In this randomised double-
blind crossover study in patients with severe CHF, enalapril given before aspirin 
led to a significant decrease in systemic vascular resistance, left ventricular filling 
pressure and total pulmonary resistance and an increase in cardiac output. How-
ever, combined with aspirin, no significant changes in these parameters could 
be observed. The combined effect of NSAID and ACE-inhibitors in patients with 
CHF should be considered as potentially harmful in patients with CHF. Therefore, 
co-prescribing an NSAID with an ACE-inhibitor in these patients should be done 
cautiously. 
NSAID can also antagonize the effects of loop diuretics. Loop diuretics increase 
renal blood flow and block tubular sodium reabsorption, both of which contribute 
to natriuresis (59, 60). Urinary excretion of prostaglandins increases in response to 
loop diuretics. (60, 61). In the setting of administration of loop diuretics, inhibition 
of renal prostaglandins by NSAID can affect the tubular and/or the haemodynamic 
component of natriuresis. Sodium balance can be considered as a major determinant 
in the interaction between loop diuretics and NSAID (62). Sodium depleted patients 
seem to be at an increased risk for this interaction. The interaction between NSAID 
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and diuretics has been shown most clearly in conditions of circulatory volume 
depletion. In these states, NSAID may decrease glomerular filtration rate and blunt 
the action of diuretics, which may lead to severe fluid retention (63). Although the 
attenuation of the natriuretic response to loop diuretics as a result of NSAID is pre-
dominantly mediated by affecting prostaglandin dependent mechanisms, competi-
tion between NSAID and loop diuretics with respect to the active secretion into the 
proximal tubule may also alter the pharmacokinetics of loop diuretics (59, 63). 
The effects of thiazides on renal prostaglandin synthesis and their interaction 
with NSAID are not as well investigated as the effects of loop diuretics on renal 
prostaglandin synthesis. Although some investigators demonstrated an increased 
prostaglandin excretion rate in both human and animal studies, others were unable 
to confiml these effects after administration of thiazides (64, 65). Nevertheless, 
NSAID may attenuate the diuretic response to thiazides. Apart from the effect of 
NSAID on prostaglandin synthesis, a possible mechanism by which NSAID can 
blunt the effects of hydrochlorothiazide may be the decreased chloride delivery to 
the diuretic's prinCipal site of action in the distal tubule. Obviously, underlying dis-
ease, such as CHF, may also affect the potential interaction between thiazides and 
NSAID .. 
An interaction between NSAID and triamterene has been documented in some 
reports (66, 67). Creatinine clearance decreased significantly in two healthy indi-
viduals who received indomethacine and triamterene. In another report, acute 
renal failure developed when indomethacine was added to triamterene. 
NSAID and hypertension 
In the study of Ghali et aI. on precipitating factors for congestive heart failure, uncon-
trolled hypertension was considered to be a causative factor for the re-occurrence of 
heart failure in 44 % of the patients (68). This study was carried among merely blacl< 
citizens where hypertension may have a high prevalence. Even so, the increase of 
cardiac afterload due to systemic hypertension can only be considered as harmful 
in patients with CHF. Several randomized trials have studied the effect of NSAID 
on blood pressure. As many trials were too smail to provide conclusive results, John-
son et al. performed a meta-analysis on this issue (69). Their overail results suggest 
that NSAID elevate mean blood pressure by approximately 5.0 mm Hg. Mean blood 
pressure is defined as 1/3(2.diastolic blood pressure + systolic blood pressure). The 
hypertensive effect of NSAID was most marked in hypertensive patients taking anti-
hypertensive medication. Sulindac and aspirin seem to have no appreciable effect 
on mean blood pressure as compared to placebo, whereas piroxicam was the only 
NSAID that gave rise to a statisticaily significant elevation of blood pressure. No 
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effects of NSAID on weight and creatinine clearance could be observed in this meta-
analysis, but the wide 95 % confidence intervals of the pooled mean changes of these 
parameters suggest different findings in various studies. For most NSAID, further 
studies are required to provide a conclusive assessment with respect to their effects 
on blood pressure. As different statistically non-significant effects are observed 
within various categories of persons (e.g. normotensive volunteers without antihy-
pertensive treatment, normotensive volunteers on antihypertensive treatment), it 
remains unclear which patients are in particular at risk for the effects on blood 
pressure of NSAID. Since hypertension may exert negative effects on the gradually 
increasing group of patients with CHF, the effect on blood pressure of NSAID in heart 
failure patients should be subject to future research. 
NSAID and renal function 
The kidney is extremely active in the synthesis and metabolism of prostaglandins 
(70). Under normal conditions, prostaglandins playa negligible part in maintaining 
renal blood Dow and consequently, NSAID exert no negative effects on renal hae-
modynamics (71, 72). In healthy individuals, NSAID have little effect on glomerular 
filtration rate (73). However, because of altered circulatory dynamics, prostaglan-
din production increases in patients with CHF and acts in a protective autoregula-
tory manner (74). Not only patients with CHF, but also those with an ineffective 
circulatory volume due to hepatic cirrhosis or other conditions are at risk for renal 
insuffiCiency during treatment with NSAID (75).There have been several reports of 
renal impairment and edema, both pulmonary and peripheral, probably induced by 
NSAID (1-3, 45). 
NSAID are associated with a number of renal function abnormalities (table II). 
Among these renal function abnormalities, Duid and electrolyte disturbances 
appear to be the most frequently encountered renal function abnormalities in users 
of NSAID. Although some degree of Duid retention occurs in virtually all patients 
exposed to NSAID, clinically detectable edema can be demonstrated in approxi-
mately 3-5% of patients (50). The interference of NSAID with sodium and water 
excretion is mainly established by inhibition of the synthesis of prostaglandins (50, 
56, 76). PGE, inhibits the reabsorption of sodium chloride in the thicl, ascending 
loop of Henle and in the collecting tubule and also antagonizes the antidiuretic 
effect of vasopressin in the collecting tubule (77). Therefore, inhibiting PGE, syn-
thesis by NSAID increases both sodium and water reabsorption and usually results 
in a net Duid retention of approximately 0.5 - 1.0 liter. Although this fluid retention 
will be of little importance in healthy subjects, it may affect the unstable cardiovas-
cular homeostasis in patients with congestive heart failure. 
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Table II 
Potential renal and cardiovascular effects of NSAIDs 
water and sodium retention 
hyperkalemia 
decreased renal blood flow 
decreased glomerular filtration rate 
interaction with the effects of ACE-inhibitors 
interaction with the effects of diuretics 
increased mean blood pressure 
acute renal failure 
acute tubular necrosis 
interstitial nephritis 
nephrotic syndrome 
papillary necrosis 
acute glomerulonephritis 
Hyperkalemia is also a well known complication of NSAID. Although hyperkalemia 
is not frequently encountered among users of NSAID, patients with pre-existing 
renal impairment or cardiac failure and patients using potassium-sparing diuret-
ics or ACE-inhibitors seem to be at an increased risk (50). Both POI, and PGE, 
stimulate the release of renin in the kidney (71). The inhibition of the synthesis 
of prostaglandins by NSAID lowers renin secretion and will contribute to a state 
of hyporeninemic hypoaldosteronism. Apart from hyporeninemic hypoaldosteron-
ism, inhibited synthesis of prostaglandins gives rise to decreased distal tubular 
now rate, decreased distal sodium delivery and increased action of antidiuretic 
hormone, which may all contribute to the reduced ability of the kidney to secrete 
potassium (71). 
As NSAID do not affect glomerular filtration in healthy subjects (78, 79), NSAID 
induced acute renal failure occurs predominantly in patients with concomitant dis-
eases (80). Several risk factors for NSAID induced renal failure have been identi-
fied (50, 71, 75) (table 1II). NSAID associated acute renal failure accounts for nearly 
40% of all cases of drug induced acute renal failure (81). In patients at risk of 
NSAID induced renal failure, renal function has become prostaglandin dependent. 
When in these patients the balance between vasoconstrictive effects (catechol-
amines and angiotEmsin II) and vasodilatory effects (prostaglandins) is disturbed 
by NSAID, the vasoconstrictive effects are left unopposed and renal failure may 
develop (70). The deterioration of renal function in these patients is usually revers-
ible when treatment with NSAID is discontinued. (82). However, incomplete recov-
ery has been reported in 20% of the cases of NSAID induced acute renal failure 
(83). 
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Table III 
Risk factors for NSAID induced acute renal failure 
Congestive heart failure 
Hepatic cirrhosis 
Renal insufficiency and renal diseases, including nephrotic syndrome 
Diabetes mellitus 
Anaesthesia and surgery 
Advanced age 
States of impending renal hypoperfusion: 
sodium depletion 
serious sepsis 
diuretic use 
hypotension 
As discussed in the paragraph on the pathophysiology of CHF, the balance between 
vasoconstriction and vasodilatation is crucial in the maintenance of cardiovascular 
homeostasis in patients with CHF, The effects of decreased cardiac output and 
sodium depletion on renal blood flow have been studied in several experimental 
animal models, White et aI. demonstrated that reduction of cardiac output by bra-
dycardia in unanesthetized dogs induced marked vasoconstriction in mesenteric 
and iliac vascular beds without inducing renal vasoconstriction (84). Similar find· 
ings were reported by Higgens et aI., who decreased cardiac output in unanesthe· 
tized dogs by reducing venous return to the heart (85). Oliver et aI. performed 
a study in anesthetized dogs where cardiac output was decreased by inflating 
a balloon in the thoracic inferior vena cava (86). Although total peripheral vas-
cular resistance increased significantly, renal blood flow and renal vascular resis-
tance showed no significant changes. Plasma concentration of prostaglandin E, in 
renal venous blood showed a fourfold increase, However, after administration of 
an NSAID (diclofenac or meclofenamate), renal blood flow decreased and renal vas-
cular resistance increased significantly, and plasma prostaglandin levels in renal 
venous blood also fell significantly. Experimental studies in anesthetized dogs 
have also shown that sodium depletion does not affect renal blood flow and renal 
vascular resistance despite a significant increase in total peripheral resistance and 
both arterial as well as venous renin and norepinephrine activity (87), Increased 
renal venous PGE, concentrations in the sodium depleted dogs seemed to be 
responsible for the maintenance of renal blood flow, because administration of 
indomethacin in sodium depleted dogs lowered renal blood flow and renal venous 
PGE, concentrations significantly, whereas no effect of indomethacin on renal 
blood flow could be observed in sodium repleted dogs. Dzau et aI. demonstrated 
that the most explicit adverse hemodynamic effects of the inhibition of prostaglan-
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din synthesis in patients with severe heart failure were observed in those with 
hyponatremia (37). These adverse hemodynamic effects pertained to decreased 
cardiac index and increased left ventricular filling pressure, mean arterial pressure 
and systemic vascular resistance. 
Apart from the prostaglandin mediated renal function disturbances described in 
this paragraph, NSAID are also associated with nephrotic syndrome, acute intersti-
tial nephritis, acute tubular necrosis, papillary necrosis and acute glomerulonephri-
tis. (70, 72, 81, 88, 89) 
Risk of NSAID induced renal function impairment 
Data from interventional studies indicate that various NSAID can affect renal func-
tion in patients with an increased susceptibility to the inhibition of renal prosta-
glandin synthesis (90, 91). As these interventional studies are usually small and do 
not reilect everyday circumstances, reliable risk estimates for specific groups of 
patients at risk are difficult to infer from these stUdies. Therefore, larger pharma-
coepidemiological studies are needed to provide insight with respect to the actual 
risk of renal function impairment under everyday circumstances in the population 
at large (92). However, the design of the epidemiological studies carried out on the 
association between NSAID and renal function impairment do not allow to maim 
reliable estimates regarding the risk of NSAID induced renal impairment in the 
population at large. In most studies, there is a lack of sensitivity with respect to 
the ability to demonstrate impaired renal function. In a population-based study, 
Fox et al. found no hospital admission for renal parenchymal disease in more than 
65,000 patients who received NSAID (93). Although this finding implicates that 
hospitalization for NSAID induced renal function impairment appears to be rare, 
this study does not allow any estimation of NSAID induced renal function impair-
ment, as NSAID may have been discontinued based on increased serum creatinine 
concentrations during follow-up in the outpatient clinic. Apart from the lack of sen-
sitivity in the determination of renal function impairment in pharmacoepidemiolog-
ical studies, the exclusion of populations at risk for NSAID induced renal function 
impairment will also underestimate its incidence. Johnson et al. found no hospital-
ization for renal disease within 3 months after a prescription of ibuprofen in 13,230 
patients (94) However, patients above the age of 65 years were excluded from the 
study. Similarly, Bonney et al. examined renal function in 1468 patients with arthri-
tis on NSAID, but excluded all patients with major pre-existing disease (95). An 
incidence of approximately 5 % of potentially significant elevations of renal func-
tion parameters was observed. 
In conclusion, no reliable estimate of the incidence of NSAID induced renal func-
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tion impairment is available at present. To obtain more insight in the actual risks 
of NSAID induced renal function impairment, epidemiological studies should be 
carried out in which more sensitive measures of renal function are used, such as 
serum creatinine concentration or creatinine clearance in stead of hospitalization 
for renal disease. These studies should also include those patients who are at an 
increased risl( as a result of their prostaglandin dependent renal function. 
Safety of NSAID in patients with congestive heart failure 
In view of the pharmacological properties of NSAID and the important role of pros-
taglandins in the pathophysiology of CHF, it seems reasonable to assume that 
NSAID may exert adverse effects in patients at risk for CHF. Induction or exacerba-
tion of CHF due to treatment with NSAID has been suggested in several publica-
tions (45-47). However, pharmacoepidemiologic studies conceming the association 
between CHF and the use of NSAID are scarce. The mechanisms discussed in the 
previous paragraphs may provide an explanation for the twofold increase in the 
risk of hospitalization in patients with a primary diagnosis of CHF during concomi-
tant use of diuretics and NSAID compared with use of diuretics only (4). Heerdink 
et al. also showed that most hospitalizations for CHF occurred within 30 days of 
initiation of comhined diuretic and NSAID therapy, with the highest risk during 
the first days of combined treatment. Analysis of the NSAID dosages showed no 
clear dose-response relationship. However, detailed information on renal function 
of those patients who developed CHF after using NSAID was not available in this 
study. 
The actual risk of induction or exacerbation of CHF during treatment with NSAID 
is still unknown. (37, 76). Nevertheless, it is obvious that the increased prostaglan-
din synthesis in patients with severe CHF is important for the maintenance of 
cardiovascular and renal homeostasis. In view of the pathofysiology of CHF and 
the pharmacological properties of NSAID, the central mechanism by which NSAID 
influences cardiovascular homeostasis is their effect on renal function. Therefore, 
the potential effects of NSAID on renal function should be considered as the cen-
tral criterium on which their suitability for patients with CHF has to be assessed. 
Efforts have been made to develop NSAID which may spare renal prostaglandin 
synthesis and thereby lack the prostaglandin mediated effects of NSAID on renal 
and cardiovascular homeostasis. Sulindac is an NSAID with potential renal sparing 
properties, despite controversy with respect to the extent of these renal sparing 
effects. 
Several studies have been performed in which various NSAID were compared with 
respect to their effect on renal function. Whelton et al evaluated the renal effects 
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of ibuprofen, piroxicam and sulindac in patients with asymptomatic renal failure 
(90). In this study, only ibuprofen was associated with acute renal failure, which 
occurred within 7 to 10 days of initiating NSAID treatment. However, as both piroxi-
cam and sulindac have a long half-life, the study may have been too short to 
assess the renal effects of these agents reliably. Although sulindac was not asso-
ciated with acute deterioration of renal function in this stUdy, a statistically sig-
nificant increase of serum creatinine and decrease of urinary PGE, excretion was 
observed. Sedor et al. compared the effects of sulindac, indomethacine and placebo 
on renal prostaglandin synthesis in healthy females during a 4 days exposure to 
NSAID or placebo (96). Whereas a significant decrease in urinary prostaglandin 
excretion was observed in patients treated with indomethacine 25 mg 4 times 
a day, no significant decrease in urinary excretion of prostaglandin was demon-
strated in those who were treated with sulindac 200 mg twice daily_ Extrarenal 
cyclooxygenase activity, as assessed by platelet tromboxane p" was inhibited by 
both sulindac and indomethacine. All participants were pretreated with furose-
mide to induce negative sodium balance and enhance renal dependence on prosta-
glandin synthesis. Bunning et al. described three patients who experienced rapidly 
reversible renal failure related to the use of naproxen and ibuprofen (97). When 
NSAID treatment was resumed with full dose sulindac (200 mg twice daily), renal 
function remained stable. On the other hand, others have reported on renal func-
tion impairment attributed to sulindac (71). Apart from sulindac, namubetone 
has also been reported to have renal sparing properties (98). Further studies are 
needed to confirm the potentially greater tolerability of these agents. According to 
current opinion, sulindac and namebutone may induce less haemodynamic impair-
ment as compared to other NSAID (99, 100), although they may still be potential 
causes of renal impairment. Results from studies with the new COX-2 selective 
agent meloxicam indicate that this agent may also exert renal sparing effects, but 
more studies have to be performed to give a meaningful judgement on the renal 
effects of meloxicam (54). 
Aspirin is an NSAID which is frequently prescribed in patients with cardiovascu-
lar disease. Aspirin leads to an irreversible inhibition of cyclooxygenase, whereas 
other NSAID inhibit cyclooxygenase reversibly. Aspirin is usually prescribed in low 
doses (80-100 mg/day) to inhibit platelet aggregation in patients with cardiovascu-
lar disease. Similar to other NSAID, renal function impairment in patients at risk 
has been reported, whereas no effect could be observed in healthy subjects (73, 
101, 102). In all these reports, however, aspirin was prescribed in clinical dosages, 
usually above 2000 mg/day. As platelets lack the possibility to generate cyclooxy-
genase, low dosages of aspirin are sufficient to inhibit platelet aggregation. 
Summarizing the currently available data on NSAID, no clear hierarchy exists with 
respect to the potential adverse effects of NSAID on cardiovascular and renal 
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homeostasis. In particular, data on the safety of NSAID in patients with conges-
tive heart failure are scarce. Interference with renal function seems to be the main 
pathophysiological mechanism by which NSAID may induce or exacerbate CHF. 
Therefore, in patients with CHF, newer agents with renal sparing properties may 
be of benefit, although firm and consistent evidence has still not been provided. 
Monitoring treatment with NSAID in congestive heart failure patients 
In view of the cardiovascular effects of NSAID, prescribing these drugs should 
be done carefully in patients with eHF. The first step in preventing undesirable 
effects on cardiovascular homeostasis in patients with eHF is the awareness of 
the prescriber that he or she prescribes a drug to a patient who is at an increased 
risl! of experiencing such effects. Preconceiving that a prescription of an NSAID is 
indicated, the patient should be carefully monitored and instructed. Determina-
tion of baseline serum creatinine concentrations can be of value in assessing the 
effect on renal function of NSAID. As patients with elevated baseline serum creati-
nine concentration are at an increased risk of renal effects of NSAID, serum cre-
atinine concentration should be monitored regularly. Whelton et al defined that a 
serum creatinine concentration above 180 pmolll can be regarded as a risk factor 
for NSAID induced renal failure (90). However, the assessment of the risk of cardio-
vascular effects of NSAID is primarily based on clinical judgement of the clinician, 
and such criteria should be used cautiously. Acute renal failure can occur within 
one week after initiating treatment, therefore, weekly follow-up of renal function 
in patients at risk seems to be warranted. Furthermore, an increase in body weight 
and the occurrence or exacerbation of signs and symptoms of eHF also clearly indi-
cate undesirable effects of NSAID in these patients. When patients are instructed 
to be attentive to these signs and symptoms, treatment with NSAID can be discon-
tinued at an early stage. As most of the NSAID induced effects on renal function 
are reversible, discontinuation of NSAID at an early stage may prevent further mor-
bidity such as an exacerbation of eHF. In order to lose fluid excess, a short course 
with a diuretic may be considered. 
CONCLUSION 
NSAID are prescribed for a wide range of indications. Despite their undisputed ben-
eficial effects, many of them may also cause important adverse reactions. For both 
beneficial effects and most adverse reactions, inhibition of the synthesis of prosta-
glandins seems to be of major importance. In patients with congestive heart failure, 
in particular in those with severe disease, prostaglandin synthesis is increased 
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to maintain adequate renal perfusion. NSAID interfere with this increased prosta-
glandin synthesis. Therefore, these drugs may be an important risk factor for the 
onset of heart failure and patients with established heart failure are likely to be at 
an increased risk for the adverse circulatory effects of NSAID. However, currently 
available data do not allow a reliable quantitative assessment of the risk of adverse 
cardiovascular effects of NSAID. Pharmaco-epidemiological studies should pro-
vide further information necessary for clinicians to assess the risk of adverse car-
diovascular reactions from NSAID uncler everyday circumstances. 
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Heart failure and fluid retention 
attributed to the use of non-steroidal 
anti-inflammatory drugs: a case series 
ABSTRACT 
3.2 
Background: NSAIDs have been associated with the onset and worsening of heart 
failure in previously published case-reports. 
Objective: identification of NSAIDS as a potential risk factors for the onset or reoc-
currence of signs and symptoms of CHF. 
Methods: description of a case series of patients with symptomatic heart failure or 
fluid retention which was attributed to the use of NSAIDs. The case series consists 
of reports to the Drug Safety Unit of the Inspectorate for Health Care in The Neth-
erlands. 
Results: During the period 1985-1995, the Drug Safety Unit of the Inspectorate 
for Health Care received 4 reports of patients with symptomatic heart failure attrib-
uted to the use of NSAIDs. These 4 patients complied to the Framingham criteria 
of heart failure. In addition, 16 reports were received of fluid retention attributed 
to NSAIDs. All reports in this case series were considered to be at least probably 
associated with the use of NSAIDs. 
Conclusion: There is convincing evidence that NSAIDs may induce fluid retention 
and CHF. These adverse effects seem to occur predominantly in patients with pre-
existing cardiovascular Of renal disease. 
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INTRODUCTION 
Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently prescribed for loco-
motor disorders, especially in elderly people. In The Netherlands, more than half 
of all prescribed NSAIDs are dispensed to patients of 60 years and older (1). There-
fore, NSAIDs are both quantitatively and qualitatively an important class of drugs. 
Over the years, reports have been published in the literature on a possible associa-
tion between the use of NSAIDs and the onset of fluid retention and congestive 
heart failure (CHF) (2). As CHF is an invalidating disease with an increasing inci-
dence and prevalence, the identification of factors which may contribute to the 
onset or reoccurrence of signs and symptoms of CHF is of major importance (3, 4). 
In this study, we present a case series of patients in whom the onset of signs and 
symptoms of fluid retention and CHF was attributed to the use of NSAIDs. 
CASE SERIES 
During the period 1985-1995, the Drug Safety Unit of the Inspectorate for Health 
Care in The Netherlands received a number of reports on CHF which onset was 
attributed to the use of NSAIDs. An outline of these reports is presented in table 
I. In these patients, a clinical diagnosis of CHF could be made, based on the Fram-
ingham criteria. All patients were known with a history of cardiovascular disease, 
such as atrial fibrillation and coronary artery disease. Most reports concerned 
elderly women who were prescribed NSAIDs for locomotor disease. Apart from 
these four reports, the Drug Safety Unit received several reports on fluid retention 
and increase in body weight attributed to the use of NSAIDs. These reports did 
not fulfil the requirements for a clinical diagnosis of CHF according to the Framing-
ham criteria. An outline of these reports is presented in table II. The increase in 
body weight and the occurrence of peripheral edema was attributed to the use of 
NSAIDs prior to the onset of these signs of fluid retention. 
In all patients, a causal relation with the use of NSAIDs was considered to be at 
least probable. Discontinuation of the use of NSAIDs resulted in most patients in 
the disappearance of peripheral edema and a loss of body weight. However, a posi-
tive dechallenge may have been influenced by the prescription of diuretics to coun-
teract fluid retention. As shown in table II, fluid retention may occur within only a 
few days after initiation of treatment with NSAIDs. Although the dosage of NSAIDs 
influences their pharmacological effects, the occurrence of fluid retention or symp-
tomatic heart failure seems to depend predominantly on patient characteristics 
such as concomitant cardiovascular disease. 
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Table I 
Reports of congestive heart failure attributed to the use of NSAIDs. 
concomitant 
patient age gender NSAID use of 
diuretics 
A 90 yrs female indometadne 50 mg yes 
every other day 
B 82 yrs male naproxen 250 mg 2 dd no 
C 63 yrs female ibuprofen 400 mg 3 dd no 
D 89 yrs female ibuprofen 400 mg 3 dd yes 
time interval 
since start of 
treatment 
2 months 
1 month 
6 weeks 
3 months 
signs and symptoms 
dyspnea, peripheral edema, 
pulmonary crepitations 
dyspnea, peripheral edema, 
pulmonary crepitations 
dyspnea, pulmonary crepita-
tions 
dyspnea, peripheral edema, 
pulmonary crepitations 
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co I~ co Table II Reports on edema and fluid retention attributed to the use of NSAIDs. iii 
'" time interval I~ Patient age gender NSAID indication adverse effect since start of 
treatment 
A 65 female naproxen backache edema, dyspnea 1 day 
B 50 female indometacine 25 mg 3 dd left shoulder pain edema 2 weeks 
C 72 male indometacine 25 mg 3 dd right shoulder pain edema 10 days 
D 61 female indometacine rheumatoid arthritis 8 kg weight increase 
E 45 male diclofenac 50 mg 3 dd pain right knee oliguria, edema 3 days 
F 40 female naproxen myalgia 4 kg weight increase, 10 days 
edema 
G 52 female phenylbutazon arthritis left wrist edema 4 days 
H 76 female ibuprofen arthrosis oliguria, edema 
75 female ibuprofen 400 mg 4 dd gonarthrosis fluid retention 5 days 
J 52 female ibuprofen 400 mg 4 dd peri-arthritis 3 kg weight increase, 1 day 
oliguria, edema 
K 47 female indometacine 25 mg 3 dd reumatic disease 2 kg weight increase, 1 day 
edema 
L 42 female ibuprofen joint pain edema 
M 62 female naproxen 250 mg 3 dd edema 1 day 
N 61 male ibuprofen 400 mg 4 dd backache edema 3 days 
0 75 female diclofenac spondylarthrosis edema 2 weeks 
p 41 female ketoprofen 200 mg 1 dd ischialgia edema 2 days 
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DISCUSSION 
During the period 1980-1995, the annual number of hospitalisations for CHF in The 
Netherlands increased from 14.441 to 25.324 (5). This finding corresponds with 
the results of epidemiological studies which indicate an increase in both incidence 
and prevalence of CHF, particularly in patients over 70 years of age. Main reasons 
for the increasing incidence and prevalence of CHF are aging of the population, 
improved survival after acute myocardial infarction and the availability of drugs 
such as the angiotensin converting enzyme inhibitors (ACE-inhibitors) which have 
proven to be effective in the treatment of CHF. Nowadays, ischaemic heart disease 
and hypertension are regarded as the most important causes of CHF. 
In the past, some case reports have been published on the onset of CHF which 
was attributed to the use of NSAIDs (6-8). Both in these published case reports 
as well as in the case series presented here, fluid retention occurred during treat-
ment with commonly prescribed dosages of NSAIDs. Peripheral edema is a well-
known adverse effect of NSAIDs which is mentioned in the product information of 
most NSAIDS, and should be regarded as a direct consequence of NSAIDs induced 
fluid retention (9). Heart failure, however, is explicitely mentioned in the product 
information of only a few NSAIDs. The product infomlation of most NSAIDs include 
only a statement that NSAIDs should be prescribed with caution to patients with 
impaired cardiac function. 
In a retrospective study in 600 patients hospitalised for CHF, the use of NSAIDs 
was considered to be responsible for the onset of CHF in five patients (2)_ How-
ever, medication is not always exactly known at the time of hospitalisation, and 
some physicians tend to notify only those drugs which appear relevant to them. 
Therefore, the retrospective design of this study prevents a valid estimate of the 
incidence of NSAIDs induced CHF. In a study carried out with data from a record 
linkage system, a twofoldly increased risk of hospitalisation for CHF was dem-
onstrated during concomitant use of diuretics and NSAIDs compared to use of 
diuretics without NSAIDs (10). The majority of the hospitalisations for CHF (56.8%) 
occurred within one month after start of concomitant use of diuretics and NSAIDs. 
It may be conceivable, however, that the true effect of NSAIDs on the occurrence 
of CHF may even be stronger if not only hospital admissions but also cases of CHF 
treated by the general practitioner are taken into account. In addition, the patients 
presented in table I indicate that NSAIDs may induce CHF in patients who do not 
concomitantly use diuretics. 
The pathophysiological basis of NSAIDs-induced fluid retention has several aspects. 
The main effect of NSAIDs is characterised by their inhibition of the enzyme cyclo-
oxygenase (COX). This enzyme is essential for the transformation of arachidonic 
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acid into prostaglandins and tromboxanes. The inhibition of the synthesis of pros-
taglandins causes both the therapeutical effects of NSAlDs as well as many of their 
adverse effects. It has been demonstrated that the enzyme COX has two isoforms, 
COX-l and COX-2. The synthesis of prostaglandins in the stomach and kidney 
seems to depend predominantly on the activity of COX-l, whereas COX-2 has an 
important role in inflammatory processes. There are some indications that COX-2 
selective NSAlDs, such as meloxicam, may have less gastro-intestinal and renal 
adverse effects (11). However, additional research has to be carried ont before 
definite conclusions can be drawn on the risl<-benefit profile of COX-2 selective 
NSAlDs. Among the commonly prescribed NSAlDs, indometacine appears to be 
relatively frequently associated with serious adverse effects (11). It is of interest, 
therefore, that indometacine is in vitro a potent inhibitor of the activity of COX-l. 
Renal effects are considered to be very important in the pathophysiology of fluid 
retention due to the use of NSAlDs. Prostaglandin E, and I, are synthesized within 
the kidney and have vasodilatory properties which stimulate renal perfusion (12). 
As adequate renal perfusion may be jeopardised by decreased cardiac output, the 
synthesis of prostaglandins increases substantially in patients with CHF, in par-
ticular in those with hyponatremia (13). Hence, the increased synthesis of pros-
taglandins stimulates renal vasodilation and maintains renal perfusion within an 
acceptable range. In such situations, the use of NSAlDs will inhibit prostaglandin 
synthesis and may have detrimental effects on renal perfusion and cardiovascular 
homeostasis. Apart from the effects on renal perfusion, experimental studies show 
that prostaglandin E2 antagonises the effects of antidiuretic hormone, and prosta-
glandin E2 reduces the reabsorption of natrium and chloride in the proximal and 
distal tubulus and the loop of Henle (14). In most healthy individuals, inhibition 
of COX does not give rise to clinically relevant retention of water and sodium, 
although some asymptomatic sodium retention Can be observed shortly after initia-
tion of treatment with NSAlDs in healthy persons (15). NSAlDs may also interfere 
with the effects of diuretics (16). Organic acids inhibit the secretion of diuretics 
into the tubular lumen. Most diuretics, apart from spironolactone and triamterene, 
are only effective from the tubular lumen. As most NSAlDs are organic acids, the 
inhibition of the secretion of diuretics into the tubular lumen by NSAlDs may coun-
teract the effects of diuretics (17). 
Inhibition of prostaglandin synthesis may also lead to hyperkalemia, another 
adverse effect of NSAlDs. NSAIDs interfere with the stimulating effect of prosta-
glandins on renine release, which may lead to hyporeninic hypoaldosteronism and 
hyperkaliemia, particularly in patients with impaired renal function (18,19). Finally, 
prostaglandins appear to be involved in the regulation of coronary perfusion. It 
has been demonstrated that indomethacine may increase arterial blood pressure 
and vascular resistance in the coronary artery (20). It remains unclear, however, to 
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what extent these effects attribute to the deterioration of cardiovascular homeosta-
sis which may occur during treatment with NSAIDs. 
The pathophysiological basis of NSAIDs-induced fluid retention and CHF suggests 
that these adverse effects of NSAIDs are uncommon in healthy individuals and will 
predominantly occur in patients with pre-existing cardiovascular or renal disease 
(21). 
CONCLUSION 
In view of published case reports and additional studies, and the plausible patho-
physiological mechanism, there is convincing evidence that NSAIDs may induce 
fluid retention and CHF. These adverse effects seem to occur predominantly in 
patients with pre-existing cardiovascular or renal disease. NSAIDs are an impor-
tant class of drugs which are highly effective in the symptomatic treatment of 
chronic locomotor disease. In particular, elderly patients may have a legitimated 
indication for the prescription of NSAIDs. However, the undoubted effectiveness 
of NSAIDs should counterbalance their potential adverse effects. Patients with car-
diac or renal disease are particularly prone to NSAIDs induced fluid retention and 
CHF. NSAIDs should be prescribed only cautiously to these patients or should even 
be avoided if possible. 
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Non-steroidal anti-inflammatory drugs 
and left ventricular systolic function 
ABSTRACT 
3.3 
Background: NSAIDs are associated with the onset of symptomatic congestive 
heart failure (CHF). In particular patients with left ventricular (LV) dysfunction seem 
to be susceptible to this adverse effect of NSAIDs. However, little is known about 
the effect of NSAIDs on LV systolic function. 
Objective: To study the effects of NSAIDs on fractional shortening (FS) of the left 
ventricle. 
Methods: Data were retrieved from the Rotterdam Study, a population-based 
prospective cohort study among 7,893 participants aged 55 years and older. 
Echocardiographic measurements were carried out in a random sample of 1919 
participants. The lower limit of normal LV function was considered to be FS:2 30%. 
Exposure to NSAIDs was determined on the basis of computerised medication his-
tories. Participants were considered to be current use of NSAIDs when the date 
of echocardiography fell within the legend duration of a prescription of an NSAID. 
Past users were defined as participants with a prescription of NSAIDs in the 6 
months preceding the date of echocardiography, but who were not current users. 
Non-use was defined as no prescription in the 6 months preceding echocardiogra-
phy. Multiple linear regression and logistic regression analyses were carried out to 
assess the effect of NSAIDs on FS. 
Results: In an overall analysis, current use of NSAIDs was associated with a small 
and statistically non-significant absolute decrease in FS with 1.6% (95% CI: -4.9%, 
1.7%). In participants with a FS < 30%, current use of NSAIDs was associated with 
an absolute decrease in FS of 11.8% (95% CI:-1.3%, -22.3%), whereas in partici-
pants with FS :2 30% a decrease in FS of 1.7 % (95% CI: -4.4%, 1.1%) was demon-
strated. 
Conclusion: In patients with FS < 30%, current use of NSAIDs had a substantial 
negative effect on FS. In patients with normal LV function, current use of NSAIDs 
was associated with a negligible effect on FS. 
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INTRODUCTION 
The use of non-steroidal anti-inflammatory drugs (NSAlDs) has been associated 
with the onset of symptomatic congestive heart failure in several case reports (1-4). 
In most of these reports, congestive heart failure during treatment with NSAlDs 
occurred in patients with pre-existing cardiovascular disease. This suggests that 
pre-existing cardiovascular diseases may increase the susceptibility to cardiovas-
cular effects of NSAlDs (5). Recently, a twofoldly increased risk of hospitalization 
for congestive heart failure has been found in patients who concomitantly used 
diuretics and NSAlDs (6). 
Inhibition of prostaglandin synthesis is regarded as the main pathophysiological 
mechanism by which NSAlDs adversely affect cardiovascular homeostasis in 
patients with a propensity to congestive heart failure. Prostaglandins have an 
important role in maintaining adequate renal perfusion in patients with decreased 
cardiac output (7). NSAlDs interfere with prostaglandin synthesis by inhibiting 
the enzym cyclo-oxygenase. Fluid retention resulting from the use of NSAlDs is 
probably the main mechanism responsible for the onset of symptomatic congestive 
heart failure in susceptible patients. 
Although an association between the use of NSAlDs and heart failure has repeat-
edly been established, little is known about the effect of NSAlDs on left ventricu-
lar function. More than half of the persons with impaired left ventricular systolic 
function are not found to have signs or symptoms of heart failure on thorough 
clinical evaluation (8, 9). Asymptomatic impaired left ventricular systolic function, 
however, is generally accepted to be a precursor of heart failure. Approximately 
20% of the participants of the placebo-arm of the SOLVD prevention study devel-
oped heart failure or died within one year of follow-up (10). It seems reasonable 
to assume that patients with decreased ventricular function are more susceptible 
to NSAlDs-induced fluid retention, and hence overt heart failure. However, this 
hypothesis is mainly based on pathophysiological plausibility, as echocardiographic 
studies relating use of NSAlDs to left ventricular systolic function have not been 
published. In the present study, we evaluated the effect of current use of NSAlDs 
on fractional shortening of the left ventricle as determined by echocardiography. 
METHODS 
The Rotterdam Study is a prospective population-based cohort study (11). The first 
cross-sectional survey started in 1990 and was completed in 1993. All inhibitants of 
Ommoord, a suburb of Rotterdam, who were 55 years of age or older were invited 
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to participate. Of the 10,275 eligible subjects, 7,983 agreed to participate (78%) and 
signed informed consent. All participants were visited at home for a standardised 
questionnaire and were subsequently examined at the research centre. 
During the first cross sectional survey taking place from 1990 to 1993, echocar-
diography was performed at the research centre in a group of 2,823 partiCipants 
to assess systolic ventricular function. Echocardiography was carried out with 
the participant in the partial left decubitus position (echocardiographic device: 
Toshiba SSH-60A). Echocardiographic measurements were made according to the 
guidelines of the American Society of Echocardiography. Left ventricular internal 
dimension was measured at end diastole (LVIDed), as defined by the onset of the 
QRS complex and at end systole (LVIDes), as determined at the nadir of septal 
motion. The percentage fractional shortening (FS) was calculated as 100 * ((LVIDed-
LVIDes)/LVIDed) and used as an index of systolic ventricular function. In 19.7% 
(n~556), the echocardiographic registrations were deemed inadequate to obtain a 
reliable measurement of left ventricular dimensions. These participants were more 
likely to be older, to have a higher body mass index and to use medication for 
chronic obstructive pulmonary disease. During the interview and at the research 
center, information was gathered on several potential confounders such as pre-
existing cardiovascular disease, renal function, blood pressure, smoking behaviour 
and body mass index. 
Computerised pharmacy data were available for all participants of the Rotterdam 
Study. Prescriptions dispensed to participants of the Rotterdam Study by the three 
automated drug dispensing outlets in the suburb of Ommoord are stored in a data-
base as from January 1" 1991. To be eligible for the present study, at least six 
months medication history before the date of echo cardiography had to be available. 
Therefore, those patients who underwent echocardiography before July 1" 1991 
were excluded from this study (n~348). Hence, 1919 participants of whom both an 
adequate echocardiographic registration and a medication history of at least six 
months were available were included in this study. Patients were considered to 
be current users of every drug of which the date of echocardiography fell within 
the calculated legend duration. The legend duration was calculated by dividing 
the number of filled tablets / capsules of a drug by the prescribed daily number. 
Past users were defined as participants with a prescription in the 6 months preced-
ing the date of echocardiography, but of which the date of echocardiography did 
not fall within the calculated legend duration. Non-users were defined as those 
participants who did not have a prescription in the 6 months preceding the date 
of echocardiography. Although exposure to NSAIDs was the main determinant of 
interest in this study, use of several cardiovascular and pulmonary drugs was also 
taken into account. 
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Statistical analyses were carried out with the statistical software pacimge SPSS. 
Univariate comparisons between proportions were assessed by Chi-square statis-
tics. For comparisons between continuous variables, Student-t-test was used, or 
the Mann-Whitney test when non-normally distributed. Multiple linear regression 
analysis was used to carry out multivariate analyses on the effect of NSAIDs on 
fractional shortening after adjustment for potential confounders. 
RESULTS 
In table I, the general characteristics of the study population are presented. The 
mean age of the 1919 eligible participants was 65 years. There was a slight female 
predominance among the participants (54%). Mean fractional shortening as deter-
mined by echocardiography was 39%. Dyspnea during normal daily activities was 
experienced by 26% (95% CI: 24% - 28%) of the partiCipants, whereas 5% (95% 
CI: 4%-6%) had ankle edema on physical examination. Ankle edema at the end of 
Table I 
General characteristics of 1919 participants eligible to this study. 
Gender: 
female 1034 (54%) 
male 885 (46%) 
Age (years) 65 (7.4) 
Blood pressure: 
systolic (mmHg) 139 (22.4) 
diastolic (mmHg) 75 (11.6) 
Serum creatinine (llmolll) 83 (20.4) 
Fractional shortening (%) 39 (7.4) 
Body mass index (kg/m') 26.0 (4.2) 
Current smoker 404 (21%) 
Alcohol-intake (g/day) 10.3 (14.1 ) 
Ankle edema during physical examination 100 (5%) 
Ankle edema at the end of the day 278 (15%) 
Dyspnea during normal daily activities 498 (26%) 
History of coronary artery bypass surgery 41 (2%) 
History of myocardial infarction 113 (6%) 
Values are means (SO) or numbers (%) 
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the day was reported by 15% (95% CI: 13%-17%) of the participants. A history of 
myocardial infarction was present in 6% (95% CI: 5%-7%) of the participants, and 
2% (95% CI: 1 % - 3%) had undergone coronary artery bypass surgery in the past. 
Current medication on the date of echocardiography is shown in table II. Approx-
imately 4% (95% CI: 3%-5%) (n~68) of the participants were current users of 
NSAIDs according to the calculated legend duration of the prescription. Beta-block-
ers were the most frequently prescribed cardiovascular drugs in this study popula-
tion. 
In a univariate analysis, no differences in fractional shortening were present in 
current users of NSAIDs (n~68) as compared to the combined group of past users 
(n~198) and non-users (n~1653) (38.7% in current users versus 38.8% in past and 
non-users). After adjustment for possible confounders in a multiple linear regres-
sion model (table III), both current and past use of NSAIDs were associated with 
a small non-significant decrease of the absolute value of the fractional shortening 
with 1.6% (95% CI: -4.9%, 1.7%) and 0.9% (95% CI: -2.9%, 1.1 %) respectively as 
compared to non use of NSAIDs. 
In table IV, results are shown of multiple linear regression analyses carried out 
separately in participants with a fractional shortening < 30% (n~207) and in partici-
pants whose fractional shortening was <: 30% (n~1712). In participants with a frac-
Table II 
Current use of NSAIDs and other drugs on the date of echocardiography 
Medication 
Beta blockers 
ACE-inhibitors 
Calcium antagonists 
Potassium sparing diuretics in combination with low ceiling diuretics 
Vasodilators 
NSAIDs 
COPD-medication 
Digoxin 
High ceiling diuretics 
low ceiling diuretics 
Potassium sparing diuretics 
Number of 
patients (%) 
214 (11%) 
106 (6%) 
87 (5%) 
94 (5%) 
102 (5%) 
68 (4%) 
51 (3%) 
40 (2%) 
39(2%) 
26 (1%) 
7 (0,4%) 
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Table III 
Results of multiple linear regression analysis on the association between 
current or past lise of NSAIDs and fractional shortening in 1919 participants. 
Regression coefficient b 9S%CI 
History of myocardial infarction -4.79 -7.74 -1.83 
Female gender 2.0S 0.S7 3.S3 
Current use of diuretics -2.67 -S.20 -0.1S 
Current use of NSAIDs -1.60 -4.91 1.71 
Past Use of NSAIDs -0.93 -2.92 1.07 
The regression coefficient b reflects the effect of the variables on fractional shortening 
after adjustment in the multiple linear regression model. 
Variables which were not statistically significantly associated with fractional shortening in 
the mUltiple linear regression model: age, serum-creatinine (~lmol/l), body mass index, 
current use of digoxin, ACE-inhibitors, beta-blockers or peripheral vasodilators, systolic and 
diastolic blood pressure, alcohol intake (g/day) and current smoking. 
Table IV 
Results of multiple linear regression analysis on the association between cur-
rent Use of NSAIDs and fractional shortening in participants with a fractional 
shortening < 30% and participants with a fractional shortening" 30%. 
Fractional shortening < 30% (n~207) 
Current use of NSAIDs 
Fractional shortening;:, 30% (n~ 1712) 
Current use of NSAIDs 
Coefficient b 
-11.8 
-1.7 
9S%CI 
-22.3, -1.3 
-4.4, 1.1 
Adjusted for age, gender, body mass index, history of myocardial infarction, serum-
creatinine (~mol!l), current use of digoxin, beta-blockers, diuretics, ACE-inhibitors or 
peripheral vasodilators, systolic and diastolic blood pressure, alcohol intake (g/day} and 
current smoking. 
tional shortening < 30 %, current lise of NSAIDs was associated with an absolute 
decrease of fractional shortening of 11.8% (95% CI: -1.3% , - 22.3%) compared to 
non lise, whereas in participants with a fractional shortening;, 30%, a decrease in 
fractional shortening of 1.7% (95 % CI: -4.4 % , 1.1 %) was demonstrated compared 
to non lise. 
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DISCUSSION 
The results of this study indicate that current use of NSAIDs has an overall small 
and statistically non-significant negative effect on fractional shortening in persons 
over 55 years of age. However, in those with a fractional shortening < 30%, which 
is considered to be the lower limit of normal fractional shortening (12), current use 
of NSAIDs appeared to have a clear negative effect on fractional shortening. As the 
results of linear regression analysis reflect an absolute effect, fractional shorten-
ing in current users of NSAIDs with a fractional shortening < 30% appeared to be 
approximately 30% to 40% lower as compared to non-users. 
These findings suggest that NSAIDs may exert a marked negative and clinically rel-
evant effect on fractional shortening in patients with impaired left ventricular func-
tion, whereas the negative effect of NSAIDs on fractional shortening in persons 
with a fractional shortening'" 30 % appears to be only very small. 
These findings are consistent with the presumed pathophysiological mechanisms 
responsible for the association between the occurrence of signs and symptoms of 
congestive heart failure and the use of NSAIDs (5). NSAIDs inhibit the function of 
cyclo-oxygenase, an enzyme essential for the transformation of arachidonic acid 
into prostaglandins. Under normal conditions, prostaglandins playa negligible part 
in maintaining renal blood flow. In patients with decreased ventricular function, 
however, renal function may be compromised because of decreased renal blood 
flow. Under these circumstances, prostaglandins may improve renal haemodynam-
ics and stimulate the excretion of water and sodium. In this way, prostaglandins (in 
particular PG-I, and PG-E,) have an important role in preserving renal function and 
cardiovascular homeostasis in patients with decreased ventricular function. Con-
sequently, inhibiting the production of prostaglandins by NSAIDs may adversely 
affect cardiovascular homeostasis and renal function in patients with decreased 
ventricular function. Retention of sodium and water may lead to increased intravas-
cular - and extravascular volume and may precipitate congestive heart failure. 
Most patients in case-reports in which the occurrence of congestive heart failure 
was attributed to the use of NSAIDs had pre-existing cardiovascular disease. The 
twofolclly increased risk of hospitalization for congestive heart failure during con-
comitant use of diuretics and NSAIDs in a recent record-linkage study was dem-
onstrated in patients who also used diuretics, which again indicates pre-existing 
cardiovascular disease (6). Our finding that current use of NSAIDs has a stronger 
effect on fractional shortening and the risk of dyspnea in persons with a fractional 
shortening < 30% supports the clinical experience that patients with decreased 
ventricular function are more prone to adverse cardiovascular effects of NSAIDs. 
99 
CHAPTER 3.3 
In this study, exposure to NSAIDs on the date of echocardiography was based on 
the calculated legend duration of prescriptions. In the Rotterdam Study, drug expo-
sure based on calculated legend durations accords to a large extent to actual drug 
use as recorded during the interview at home, indicating that dispensed prescrip-
tions reliably reflect actual drug exposure (13). Therefore, significant underestima-
tion of exposure to NSAIDs due to extensive use of over-the-counter NSAIDs as 
well as significant overestimation due to poor medication compliance seem to be 
unlikely. 
The outcome variable in this study was fractional shortening. Fractional shorten-
ing is an outcome parameter which can be measured precisely and objectively 
during echocardiography. As both participants and research assistents were not 
aware of our study hypotheses, any misclassification of outcome may be consid-
ered as non-differential which will only lead to a conservative estimate of the risk 
estimates in our study. 
The potential effects of NSAIDs on cardiovascular homeostasis may be influenced 
by several factors. In our study, we were able to adjust for a number of possible con-
founders, such as smoking, alcohol intake, blood pressure, history of myocardial 
infarction, renal function and concomitant medication. Due to the design of the Rot-
terdam Study, there may have been selection-bias based on the physical condition 
of those participating in the study_ Old and diseased individuals were less likely 
to participate in the study. However, it seems improbable that this may have led 
to an overestimation of the effect of NSAIDs on fractional shortening, as these non-
participating elderly are likely to have a relatively high prevalence of heart failure 
and use of NSAIDs. This might be an explanation for the limited number of current 
users of NSAIDs among the participants with a fractional shortening <; 30% (n~4). 
Consequently, although current use of NSAIDs was associated with a clear and 
statistically significant effect on fractional shortening, confidence intervals were 
wide. 
In conclusion, NSAIDs appear to have only a very small effect on fractional short-
ening in persons with normal left ventricular function. Therefore, congestive 
heart failure as an adverse effect to NSAIDs is likely to be rare in patients with 
normal systolic function. However, in patients with decreased ventricular function, 
NSAIDs may have a clinically significant effect on fractional shortening. NSAIDs 
should be avoided as far as possible in patients with impaired left ventricular sys-
tolic function. 
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3.4 
Non-steroidal anti-inflammatory drugs do 
not cause first occurrence of heart failure 
but are associated with relapsing heart 
failure 
ABSTRACT 
Introduction: NSAIDs have been associated with a first hospitalisation of conges-
tive heart failure (CHF). Based on the pathophysiology of NSAID-induced CHF, 
however, it seems more likely that NSAIDs may precipitate relapsing CHF in 
patients with prevalent heart failure, and that NSAIDs are less likely to induce a first 
occurrence of heart failure (incident heart failure). 
Objective: to estimate the risk of NSAID-induced CHF in patients with incident 
CHF as well as in patients with prevalent CHF. 
Design: prospective population-based cohort study (Rotterdam Study). 
Methods: 7,277 participants of the Rotterdam Study were followed from the inter-
view date until the first of one of the following events: a diagnosis of incident heart 
failure, death, removal from the study area or institutionalisation, or end of the 
follow-up period. Incident heart failure was encountered in 345 participant during 
follow-up. Excluded from the study population were all participants with prevalent 
CHF at baseline or an uncertain diagnosis during follow-up. Exposure to NSAIDs 
and other medication was calculated on the basis of automated data on filled drug 
prescriptions in the pharmacies within the study area. In a second analysis, we fol-
lowed all participants with incident heart failure until the first relapse or the end of 
followup. 
Results: Current use of NSAIDs was associated with a relative risk of incident CHF 
of 1.11 (95% CI; 0.74 - 1.68), after adjustment for age, gender, and concomitant 
medication. In patients with prevalent heart failure who filled at least one NSAID-
prescription since diagnosis of CHF, the univariate and multivariate risk estimates 
of NSAIDs-associated relapsing CHF were respectively 3.79 (95% CI: 1.13 - 12.73) 
and 9.89 (95% CI: 1.72 - 57.01). 
Conclusion: NSAIDs are not associated with an increased risk of incident CHF. In 
patients with prevalent CHF, current use of NSAIDs is associated with a substan-
tially increased risk of relapsing CHF, which is in accordance with the supposed 
pathophysiological mechanism. 
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INTRODUCTION 
Heart failure is a syndrome that results from complex circulatory and neurohor-
mona! responses to cardiac dysfunction (1, 2). The main causes of heart failure 
are ischaemic heart disease and arterial hypertension (3, 4). According to recent 
guidelines of the European Society of Cardiology objective evidence of cardiac dys-
function has to be present in addition to symptoms, such as shortness of breath or 
fatigue at rest or during exercise, and ankle swelling, to establish the presence of 
heart failure (5). 
Non-steroidal anti-inflammatory drugs (NSAIDs) have been associated with the 
occurrence of congestive heart failure in several case reports (6-9). Inhibition of 
the enzyme cyclo-oxygenase may result in a decrease of prostaglandin synthesis. 
Prostaglandins have an important role in renal physiology, and inhibition of their 
synthesis may give rise to fluid retention (10). Fluid retention due to NSAIDs may 
adversely affect cardiovascular homeostasis, and patients with a propensity for 
congestive heart failure seem to be particularly susceptible to the cardiovascular 
effects of NSAIDs. Moreover, NSAIDs may interfere with the cardiovascular effects 
of ACE-inhibitors and diuretics (10). 
Previous studies demonstrated that NSAIDs may precipitate a first hospitalisation 
for CHF (11, 12) which suggests that NSAIDs may not only induce a relapse of pre-
existing heart failure but also be a cause of a first occurrence of heart failure. In 
view of the pathophysiology of NSAID-induced heart failure, however, there can be 
doubt whether NSAIDs may induce heart failure in patients without pre-existing 
left ventricular impairment. We examined the extent to which NSAIDs may induce 
a first occurrence of CHF and a relapse of heart failure in patients with prevalent 
CHF. Hereto, we first studied the association between NSAIDs and a first occur-
rence of heart failure (incident CHF) in a population of elderly. Subsequently, we 
studied the association between NSAIDs and the first relapse of CHF in these 
same patients in order to investigate a potential different effect of NSAIDs on inci-
dent and prevalent heart failure. 
METHODS 
Setting 
The study is a part of the Rotterdam Study, a population-based prospective cohort 
study on the prevalence, incidence, and determinants of cardiovascular, neurolog-
104 
NSAfDs and the risk of incident heart faifure 
ical, ophthalmological and locomotor diseases in the elderly (13). The baseline 
examination started in 1990 and was completed in June 1993. All inhabitants of 
Ommoord, a suburb of the city of Rotterdam, The Netherlands, who were 55 years 
or older were invited to participate in the Rotterdam Study. Of the 10,275 eligible 
subjects, 7,983 (78 %) agreed to participate and signed informed consent. Since the 
start of the Rotterdam Study, reexaminations have been carried out periodically 
by means of home interviews and periodic visits of participants to the research 
centre. In addition, all neurological, ophthalmological, cardiovascular and locomo· 
tor diseases which occurred since start of the follow-up in participants of the Rot-
terdam Study have systematically been gathered. 
Study population 
From the cohort of 7,983 participants of the Rotterdam Study, we excluded partici-
pants who were not registered at the pharmacy or who had an unknown date of 
death (n~48). Participants with prevalent heart failure at study entrance or partici-
pants who developed heart failure after start of the study but who did not fulfil the 
below-mentioned criteria of first occurrence of heart failure (incident CHF) were 
excluded from the analyses (n~453). In acldition, baseline echocardiographic data 
were available of 2246 participants. We excluded from the analyses 205 partici-
pants with a baseline fractional shortening < 30%, defined as I(left ventricular inter-
nal dimension at end diastole -left ventricular internal dimension at end systole) / 
left ventricular internal dimension at end diastole] , 100%. A total number of 7,277 
participants was included in the study population of this present study. The study 
period ran from July 1" 1991 through December 31" 1998. The cohort was followed 
from the date of entry in the study until the end-point of the follow-up which was 
the first of one of the following events: a diagnosis of incident heart failure, death, 
removal from the study area or institutionalisation, and end of the follow-up period. 
In a second analysis, we followed all participants with incident heart failure until 
the first relapse or the end of follow-up as defined. 
Exposure definition 
Computerised pharmacy records were available of all participants of the Rotterdam 
Study as of January 1" 1991. All prescriptions dispensed to participants of the Rot-
terdam Study by the three automated pharmacies in the study area were routinely 
stored in a database. Drugs were coded according to the Anatomical-Therapeuti-
cal·Chemical classification (ATC-classification) (14). Every prescription included a 
filling date, the product name, daily dosage, the number of filled tablets/capsules, 
and the prescribed daily number. For each member of the study population, use of 
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NSAlDs and concomitant cardiovascular and pulmonary medication was assessed 
during the follow-up period. The drug-exposure-window was defined as the legend 
duration (prescription length), calculated on the basis of the total number of filled 
tablets divided by the prescribed daily number, plus a carry-over period of 7 days. 
If the drug-exposure windows of consecutive prescriptions of the same drug over-
lapped, this was considered to be one single period of drug exposure. Hence, the 
follow-up period for each member of the cohort was divided into periods of expo-
sure and non-exposure to the drugs of interest. Patients were considered to be 
current users of each drug of which the exposure window overlapped the date of 
diagnosis of incident heart failure. 
Outcome definition 
The outcome of the first analysis was defined as a diagnosis of incident heart fail-
ure, defined as the first occurrence of heart failure. Heart failure is one of the areas 
of special interest in the Rotterdam Study. The continuous follow-up of all partici-
pants of the Rotterdam Study, in close co-operation with the participating general 
practitioners, is aimed at identifying all events of interest, including heart failure. 
It is part of the routine follow-up procedure that all available data on the events 
of interest, such as hospital discharge letters and notes from general practitioners, 
are copied from the records of the general practitioner. Two research physicians 
independently evaluate all information on cases of heart failure that have occurred 
during follow-up of the Rotterdam Study. Certainty of diagnosis is rated as possi-
ble, probable or definite, based on the availability of additional information. A defi-
nite diagnosis of CHF is assumed if a firm diagnosiS of heart failure has been made 
by a medical specialist. If the two research physicians disagree on the certainty 
of diagnosis, they re-evaluate these events during a consensus meeting. When dis-
agreement on the certainty of diagnosis remains, a cardiologist makes a final deci-
sion. In addition, a cardiologist re-evaluates all potential cases of CHF on which 
the two research physicians agree during the first evaluation. In this present study, 
participants were only regarded as patients with incident heart failure if there 
was a first diagnosis of definite heart failure and no symptoms that might be com-
patible with prevalent heart failure. Apart from the follow-up procedure of the 
Rotterdam Study, we used hospital discharge diagnoses concerning the study pop-
ulation as gathered from all hospitals in the Rotterdam area. We considered hos-
pital admissions for CHF after January 1" 1993 as incident heart failure if these 
patients had not been admitted to hospital for CHF in the period January 1" 1991-
January 1" 1993. If participants were identified in both the follow-up procedure 
and the hospital discharge data base, we took the first date as the date of incident 
CHF. For the second analysis, we defined a relapse of CHF as a hospital admis-
sion because of heart failure in the patients that were followed since the occur-
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rence of incident heart failure. As of that date, these individuals were considered 
as patients with prevalent heart failure. 
Statistical analysis 
For the data analysis was used a Cox regression model with time-dependent 
covariates. Drug exposure was entered in the model as segmented time-depen-
dent covariates, with different values at different periods in time. The value of the 
time-dependent covariates could be calculated for each individual member of the 
cohort on each day during follow-up by splitting up the follow-up time into periods 
of exposure and non-exposure to the drugs of interest, based on the start date 
of filled drug prescriptions and the end date plus seven days. In the mUltivariate 
analyses, we adjusted for age, gender, concomitant cardiovascular and pulmonary 
medication. 
RESULTS 
General characteristics of the study population (n~7,277) are presented in table I. 
Mean age of the study partiCipants at study entrance was 70 years. Of the study 
population, 62% was female. Mean follow-up was 6.0 years. The average baseline 
serum-creatinine level was 83 micromol/l. A total number of 749 participants had 
a history of myocardial infarction, and 164 patients had atrial fibrillation at study 
Table I: 
General characteristics of the study population. 
Study population 
Age 
Female gender 
Patients with incident heart failure 
Participants who filled at least one NSAIO-prescription 
during follow-up 
Follow-up 
Serum-creatinine (micromolll) 
History of myocardial infarction 
Atrial fibrillation 
7277 
70.2 yr 
4499 
345 
5062 
6.0 yr 
83.0 
749 
164 
SO 9.6 
(62%) 
(70%) 
SO 1.9 
SO 21.7 
(10.3%) 
(2.3%) 
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Table II 
Association between incident CHF and the use of NSAIDs. 
Risk of CHF during current use of NSAIDs in the 
study population (n~7277) 
(events of CHF during follow-up: 345) 
Risk of CHF during current Use of NSAIDs among 
participants who received at least one 
prescription during follow-up (n~5062) 
(events of CHF during follow-up: 263) 
RRcrude 
(95% CI) 
1.51 
(1.00 - 2.27) 
1.40 
(0.93 - 2.12) 
RRadjusted* 
(95%CI) 
1.11 
(0.74 -1.68) 
1.20 
(0.79 - 1.83) 
*adjusted for age, gender, concomitant cardiovascular and pulmonary medication 
entrance. A diagnosis of incident heart failure during follow-up was made in 345 
participants. 
Table II presents the results of the Cox regression model analysis with time-depen-
dent variables. Current use of NSAIDs was univariately associated with the occur-
rence of incident heart failure (RR 1.51; 95% CI; 1.00 - 2.27). Adjusted for age, 
gender, and concomitant medication, the RR of the association between current 
NSAID use and the occurrence of incident heart failure declined to 1.11 (95 % CI; 
0.74-1.68). Among participants who filled at least one NSAID-prescription, these 
risk estimates were respectively 1.40 (95% CI; 0.93 - 2.12) and 1.20 (95% CI; 0.79 
- 1.83). 
Several classes of drugs were associated with the occurrence of incident heart 
failure (table III). Among the classes with the strongest association were digoxin, 
vasodilators (mainly nitrates), loop diuretics, and potassium-sparing diuretics. 
Baseline serum-creatinine was available of 4,882 participants. In patients with 
a serum-creatinine < 1 00 ~Imolll, the univariate RR of the association between 
NSAIDs and CHF was 1.35 (95% CI; 0.75-2.43). In patients with a serum-creati-
nine;> 100 Ilmolll, the RR was 1.97 (95% CI: 1.97-5.50). Adjusted for age, gender, 
and concomitant medication, the risk estimates were respectively 0.96 (95 % CI: 
0.53-1.74) and 1.50 (95% CI: 0.51·4.40). 
In the second analysis (table IV) in patients who were followed since the occur-
rence of incident heart failure during the follow-up period, the overall risk of NSAID-
associated heart failure was 1.38 (95% CI; 0.50-3.82) in the univariate analysis and 
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Table III 
Association between use of cardiovascular and pulmonary medication and the 
occurrence of incident CHF. 
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Digoxin 633 6.58 (5.01 - 8.63) 
Anti-arrhythmics 243 4.96 (3.19 -7.71) 
Vasodilators 1552 5.94 (4.70 - 7.50) 
Thiazides 122 2.31 (0.74 - 7.21) 
Low-ceiling diuretics (thiazides excluded) 245 1.14 (0.43 - 3.07 ) 
Loop diuretics 1244 8.04 (6.37 - 10.15) 
Potassium-sparing diuretics 250 6.49 (4.13 -10.20) 
Loop diuretics or low-ceiling diuretics 1399 1.43 (1.01 - 2.01) 
combined with potassium-sparing diuretic 
Beta-blockers 2121 2.10 (1.66 - 2.65) 
Calcium entry blockers 1293 2.94 (2.26 - 3.82) 
ACE-inhibitors 1352 2.85 (2.19-3.70) 
COPD-medication 1307 2.81 (2.10-3.76) 
Acetylsalicylic acid (platelet aggregation 278 2.78 (2.22 - 3.50) 
inhibitor) 
Table IV 
Association between NSAIDs and relapsing CHF in patients with prevalent 
CHF (patients followed since diagnosis of incident CHF). 
All patients with prevalent CHF (n~292) 
(events of CHF during follow-up: 64) 
Patients with prevalent CHF who filled at least 
one NSAID prescription (n~85) 
(events of CHF during follow-up: 12) 
*adjusted for age, gender, and concomitant medication 
RRc(ude 
(95% CI) 
1.38 
(0.50 - 3.82) 
3.79 
(1.13 -12.73) 
RRadjusted* 
(95%CI) 
1.36 
(0.49 - 3.82) 
9.89 
(1.72 - 57.01) 
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1.36 (95% CI 0.49-3.82) in the adjusted analysis. Among patients with prevalent 
CHF who filled at least one NSAID-prescription since diagnosis of CHF, the crude 
RR of NSAIDs-associated relapsing CHF was 3.79 (95% CI; 1.13-12.73). Adjusted 
for age, gender and concomitant medication, the RR was 9.89 (95% CI; 1.72-57.01). 
DISCUSSION 
The results of this study suggest that current use of NSAIDs is not associated with 
an increased risl< of a first occurrence of heart failure. However, among patients 
who were followed since diagnosis of incident CHF (prevalent heart failure) and 
who filled at least one NSAID-prescription, the use of NSAIDs was associated with 
a substantially increased risk of NSAID-associated relapsing CHF. 
To study the association between NSAIDs and incident CHF appropriately, it is 
of major importance to exclnde all patients who might already have CHF before 
the first diagnosis of CHF (incident heart failure). This may be difficult because 
a substantial part of the patients with left ventricular impairment appears to be 
asymptomatic or are undiagnosed despite signs and symptoms of CHF (15). Our 
study population included 345 patients with a certain diagnosis of incident heart 
failure. We excluded all patients from the study population who might have a pos-
sible or probable diagnosis of CHF. This was achieved by an intensive follow-up 
procedure of all participants of Rotterdam Study, that provided the information on 
which we were able to decide whether participants were truly incident cases of 
CHF. Moreover, we excluded from the analysis 205 patients with a baseline frac-
tional shortening less than 30% that is regarded as the lower limit of normality (16, 
17). Hence, the study population consisted only of patients with either a certain 
diagnosis of truly incident CHF during follow-up or patients without any known 
suspicion of CHF. In this study population, no association between current use of 
NSAIDs and incident CHF was present. 
Adverse effects of NSAIDs on cardiovascular homeostasis are well established (10). 
Particularly in the clinical setting of reduced renal perfusion that can be seen in 
patients with various disorders such as dehydration, cardiovascular disease and 
renal dysfunction, NSAIDs may impair the adequacy of renal prostaglandin pro-
duction. In patients with reduced left ventricular function, renal prostaglandin pro-
duction has a crucial role in compensatory renal hemodynamics (18). Inhibition of 
cyclo-oxygenase enzyme (COX) activity by NSAIDs will have an inhibitory effect on 
prostaglandin synthesis that may deteriorate cardiovascular homeostasis in these 
susceptible patients. Although not statistically Significant, the stratified analysis 
on baseline serum-creatinine also indicated that impaired renal function, defined 
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as serum-creatinine 2 100 MmollJ, seems to be associated with an increased risk of 
NSAIDs-associated CHF. 
Over the years, a number of case reports has been published in which the onset 
of congestive heart failure was attributed to the use of NSAIDs (6-9). In most 
of these reports, patients did have pre-existing cardiovascular disease that may 
have predisposed to the onset of heart failure. An earlier published record-linkage 
study has shown a twofoldly increased risk of a first hospitalisation for CHF during 
concomitant use of NSAIDs and diuretics as compared to use of diuretics only in 
patients older than 55 years (11). As this record-linkage study was carried out 
within a cohort of users of diuretics, it is likely that a number of these patients did 
have symptomatic left ventricular dysfunction in the period preceding the first hos-
pitalisation for CHF. Many elderly patients are treated by their general practitioner 
because of mild to moderate signs and symptoms of CHF before hospital admission 
is indicated. This may explain the finding in the above-mentioned record-linkage 
study that the strongest increase in hospitalisation risk was seen in patients who 
were likely to have pre-existing CHF. Hence, a first hospitalisation for CHF is not 
by definition the same as truly incident CHF. In our study, we included not only 
first hospital admissions but all diagnoses of incident CHF whether admitted to 
hospital or not, and excluded all patients with an uncertain diagnosis of incident 
CHF. 
In a recent matched case-control study (12), use of NSAIDs in the previous week 
was associated with a doubling of the odds ratio of a hospital admission for CHF. 
In patients with a first diagnosis of CHF, a threefoldly increased odds ratio was 
calculated. An even much stronger association was shown in patients with a his-
tory of heart disease. In view of the pathophysiology of NSAID induced CHF (18), it 
seems likely that a substantial part of the cases in this study did have pre-existing 
left ventricular impairment before hospitalisation. In addition, the remarkably high 
consumption of NSAlDs of nearly 30% in the week prior to hospitalisation among 
the cases may imply either recall-bias or significant comorbidity. 
The univariate association between various cardiovascular drugs and the onset 
of heart failure (table III) reflect the presence of pre-existing cardiovascular disor-
ders such as hypertension, atrial fibrillation and ischemic heart disease which pre-
dispose to the development of heart failure. Therefore, these associations can be 
explained by confounding by indication. Although we excluded from the analysis 
all patients who may have prevalent heart failure, we can not exclude the possi-
bility that some patients in the study population did use these drugs because of 
heart failure. The presence in the study population of some patients with prevalent 
heart failure, however, is likely to overestimate the relative risk. Hence, it seems 
plausible that the risk estimate of the association between incident heart falure 
111 
CHAPTER 3.4 
and NSAID use might even be lower if we were able to exclude these patients. The 
findings in this study suggest that NSAIDs do not have a substantial additional 
contribution to the risk of incident CHF but that this is largely caused by cardiovas-
cular comorbidity as reflected by cardiovascular comedication. 
The second analysis in our study in patients who were followed since diagnosis 
of CHF (n~292) demonstrates the different effects of NSAIDs in patients with inci-
dent and prevalent CHF. In patients with prevalent heart failure who filled at least 
one NSAID prescription, current use of NSAIDs was associated with a substantially 
increased risk of relapsing CHF. From a pathophysiological point of view, the dif-
ferent effects of NSAIDs with respect to incident and relapsing CHF seem to be 
plausible, as cardiovascular homeostasis is much more likely to be prostaglandin 
dependent in patients with prevalent CHF as compared to patients with a unim-
paired left ventricular function. 
A cohort study lacks some of the intrinsic limitations of case-control studies. The 
availibility of prospectively collected drug exposure data from the automated 
pharmacies in the study area prevents potential differential misclassification of 
exposure that may occur in case-control studies. Intensive follow-up procedures 
of participants of the Rotterdam Study provided the possibility to include only 
patients with definite incident heart failure and to exclude from the study popula-
tion those with a uncertain diagnosis. However, we can not exclude the possibil-
ity that some patients with asymptomatic left ventricular dysfunction have been 
included in our study population. 
An important source of bias in cohort studies may arise from the degree of accuracy 
with which participants have been classified regarding their exposure and disease 
status. In this present study, a diagnosis of incident heart failure could only be 
made on the basis of information of a medical specialist. Two research physicians 
independently reviewed all available information before rating the event as a defi-
nite diagnosis of CHF. In addition, this decision of the two research physicians 
had to be confirmed by a specialist in cardiovascular medicine. Therefore, major 
misclassification of the diagnosis definite CHF seems to be unlikely. 
Exposure to NSAIDs was based on the information on filled drug prescriptions in 
the three automated phamlacies in the study area. Information on over-the-counter 
use of NSAIDs was not available. In the Netherlands, however, only since 1995 a 
small proportion of total NSAIDs consumption consists of over-the counter drugs. 
Moreover, misclassification of exposure is likely to be non-differential, as signs and 
symptoms of CHF do not give reason to use NSAIDs. 
NSAIDs are drugs that may have several beneficial effects, particularly for mus-
culoskeletal diseases that occur frequently in the elderly. Despite their potential 
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adverse effects, several patients take advantage of the potent analgetic and anti-
inflammatory properties. In view of the risk-benefit profile of drugs, our finding 
that NSAIDs were not associated with an increased risk of incident heart failure 
in a cohort of patients without pre-existing signs or symptoms of CHF is of clinical 
significance. This implies that, regarding the risk of CHF, these drugs can safely be 
prescribed to elderly patients with uncompromised left ventricular and renal func-
tion. 
In conclusion, NSAID use appears not to be associated with incident CHF. In 
patients with prevalent CHF, however, a substantially increased risk of NSAID-
associated CHF was demonstrated, implying that NSAIDs should be prescribed 
with caution to patients with prevalent CHF. 
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non -steroidal anti-inflammatory drugs 
ABSTRACT 
3.5 
Introduction: Several case reports have been published on CHF attributed to the 
use of NSAIDs. Results from an earlier study have demonstrated that concomitant 
use of diuretics and NSAIDs waS associated with a twofoldly increased risk of a first 
hospitalisation for CHF. 
Objective: To assess the risk of relapsing CHF associated with the use of NSAIDs 
in a cohort of patients aged 50 years and older with a history of one hospitalisation 
for CHF. 
Subjects and Methods: Data were used from the PHARMO record linkage system. 
The study population was defined as the cohort of all residents aged 50 years or 
older who had one hospitalisation for CHF. For each individual in the cohort, expo-
sure to NSAIDs and concomitant cardiovascular and pulmonary medication was 
assessed during the follow-up period. Patients were considered to be current users 
of each drug of which the prescription duration overlapped the date of hospitalisa-
tion for relapsing heart failure. The outcome of the study was defined as a readmis-
sion with a primary diagnosis of CHF of a member of the cohort during the study 
period. 
Results: In the cohort of 1,405 CHF patients, the overall risk of hospitalisation for 
relapsing CHF associated with NSAID use was 1.41 (95% CI; 0.97-2.06), adjusted 
for age, gender and concomitant medication. Among patients who had received at 
least one NSAID prescription (n~559) during the follow-up period, use of NSAIDs 
was associated with an overall twofoldly increased risk for rehospitalisation for CHF 
(adjusted RR 2.20; 95% CI 1.44-3.36). A first NSAID prescription was associated 
with an adjusted RR of 3.30 (95% CI; 1.63-6.71), a second to fourth prescription 
with an adjusted RR of 1.85 (95% CI1.00-3.45), and a fifth or more prescription with 
an adjusted RR of 2.18 (95% CI 1.07 -4.46). As compared to non-use, the risks of low 
dosage NSAID « 0.75 DDD/day), medium dosage (0.75-1.24 DDD/day), and high 
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dosage (~ 1.25 DDD/day) were respectively 0.85 (95% CI; 0.35-2.08), 1.07 (95%CI; 
0.58-1.99), and 1.99 (1.32-3.00). The calculated attributable fraction was 22.8%. 
Conclusion: the Use of NSAIDs in patients with a previous hospitalisation for CHF 
was associated with an increased overall risk of rehospitalisation for CHF. Among 
users, a first prescription is associated with a threefoldly increased risk, whereas 
more regular use is associated with a lower risk estimate. This observation may be 
explained by the phenomenon 'depletion of susceptibles'. The calculated attribut-
able fraction indicates that in our study population approximately 23% of the rehos-
pitalisations in patients with a history of CHF may be attributable to the use of 
NSAIDs. 
INTRODUCTION 
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely prescribed, particularly 
in elderly patients with locomotor disease. NSAIDs are very effective in providing 
relief of pain and in suppressing inflammation-mediated processes such as rheu-
matoid arthritis. Most of the pharmacological effects of NSAIDs can be attributed 
to their ability to interfere with the synthesis of prostaglandins by inhibiting the 
enzyme cyclo-oxygenase (COX). 
Apart from their role in inflammatory processes, prostaglandins have a number of 
physiological effects on renal function and are extensively synthesized in renal tis-
sues (1-5). Prostaglandin I, and prostaglandin E, are the most important prostaglan-
dins in the regulation of renal function. 
NSAIDs are associated with a number of renal function disturbances such as fluid 
retention, acute renal failure, and interstitial nephritis. In healthy individuals under 
normal circumstances, prostaglandins have little or no effect on renal haemody-
namics, and the use of NSAIDs is unlikely to affect renal perfusion. In patients with 
congestive heart failure (CHF), however, adequate renal perfusion may be at risk 
as a result of decreased left ventricular output, and prostaglandins may have an 
important role in the maintenance of adequate renal haemodynamics. Hence, inhi-
bition of the synthesis of prostaglandins by NSAIDs may adversely affect cardiovas-
cular homeostasis in heart failure patients (6). 
Several case reports have been published on CHF attributed to the use of NSAIDs 
(7-10). In an earlier study, we demonstrated that in patients without a known his-
tory of CHF, concomitant use of diuretics and NSAIDs is associated with a two-
foldly increased risk of a first hospitalisation for CHF (11). The objective of the 
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current study was to assess the risk of a relapse of CHF associated with the use of 
NSAIDs in a cohort of patients aged 50 years and older with a history of CHF. 
SUBJECTS AND METHODS 
Setting 
Data were used from the PHARMO record linkage system, a database containing 
drug-dispensing records from community pharmacies and linked hospital dis-
charge records of 450,000 residents of 12 population-defined areas in The Nether-
lands (12). Medication records and hospital data were collected during the study 
period January 1986 until January 1996. 
Study population 
The study population was defined as the cohort of all residents aged 50 years or 
older who had one hospitalisation for CHF. Medication records and hospital data 
were collected during the study period that ran from January 1986 until January 
1996. This cohort of patients with CHF was followed from the date of discharge for 
the first hospitalisation for CHF until the end-point of the follow-up period which 
was the first of one of the following events: re-hospitalisation for CHF, a last dis-
pensing of any prescription in the pharmacy indicating that the patient was still 
eligible at that time, or end of the follow-up period which was January 1" 1996. A 
last drug dispensing date before the end of the follow-up period usually indicated 
a move from the study area, institutionalisation or death. To be eligible for the 
study, the time interval between the first hospitalisation for CHF and the first of 
the abovementioned end points of the study had to be at least 180 days for all 
members of the cohort. 
Exposure definition 
For each individual in the cohort, exposure to NSAIDs and concomitant cardio-
vascular and pulmonary medication was assessed during the follow-up period. 
Drugs were coded according to the Anatomical-Therapeutical-Chemical classifi-
cation (ATC-classification). A start date and an end-date were assigned to each 
individual drug prescription, based on the legend duration of the prescription. 
The legend duration (prescription length) was calculated on the basis of the total 
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number of filled tablets or capsules divided by the prescribed daily number. The 
exposure window was defined as the legend duration of a drug prescription plus 
a carry-over period of 7 days. If the exposure window overlapped the start date of 
a next prescription of the same drug, this was considered to be one single period 
of exposure. In this way, the follow-up period for each individual member of the 
cohort could be split up in periods of exposure and non-exposure to the drugs 
of interest. Patients were considered to be current users of each drug of which 
the prescription duration overlapped the date of hospitalisation for relapsing heart 
failure. In addition, we calculated for each patient the total number of NSAID pre-
scriptions during the follow-up. To assess the effect of dosage, we compared the 
NSAlDs dosage in patients who were current users at the time of rehospitalisation 
with the NSAID dosages on a random date in patients who were not readmitted. 
Hereto, all prescribed dosages were expressed in defined daily dosages (DDD), a 
standardized dosing unit which is defined by the World Health Organisation and 
which represents the average daily dosage for the main indication of the drug in 
an adult. This unit facilitates comparisons of dosages between products. 
Outcome definition 
The outcome of the study was defined as a readmission with a primary diagnosis 
of CHF of a member of the cohort during the study period. Hospital discharge diag-
noses were coded according to the International Classification of Diseases (13). 
Statistical analysis 
The statistical analysis was carried out with a Cox regression model with time-
dependent covariates. Drug exposure was entered in the model as segmented 
time-dependent covariates, with different values at different periods in time. For 
each individual member of the cohort, the value of the time-dependent covariates 
could be calculated on each day during follow-up by splitting up the follow-up 
time of each individual cohort member into periods of exposure and periods of 
non-exposure to the drugs of interest, based on the start- and end-dates of filled 
drug prescriptions. We separately evaluated the risk of relapsing CHF associated 
with a first NSAID prescription, a second to fourth NSAID prescription, and a fifth 
or more NSAID prescription which closely resembled a distribution in tertiles. For 
that reason, we added to the model three additional time-dependent covariates 
which defined whether NSAID users were exposed to a first, a second to fourth, 
or a fifth or more NSAID prescription. In the multivariate analyses, we adjusted 
for age, gender, and current use of concomitant cardiovascular and pulmonary 
medication. To evaluate NSAID dosages among users, we compared the prescribed 
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number of ODDs per day (ODDs/day) on the date of rehospitalisation in cases with 
the prescribed ODDs/day on a random date in non-hospitalised patients. The attrib-
utable fraction was determined by calculating the incidence-density (ID) of CHF 
during exposure and during non-exposure to NSAIDs. Therefore, we determined 
the total number of both exposed person-years of follow-up and non-exposed per-
son-years of follow-up. Subsequently, we calculated the attributable fraction with 
the formula (IDexposed - IDunexposed) / IDexposed' 
RESULTS 
During the study period, 1,405 patients were identified in the database with a 
first hospitalisation for congestive heart failure who complied with the eligibility 
criteria of the study. Of these 1,405 patients, 306 patients were rehospitalised 
during the study period because of relapsing CHF. The remaining number of 1,099 
patients were not rehospitalised for CHF during the study period. The general char-
acteristics of the study population are presented in table I. The average age of the 
study population was 74 years and a small majority (51 %) was male. The mean 
follow-up period was 879 days. During the follow-up period, a total number of 3162 
NSAID prescriptions were dispensed to 559 patients (40% of all patients). Of these 
559 patients, 170 patients received one NSAID prescription, 191 patients received 
Table I: 
General characteristics of the study population (n=1405). 
Age (yrs) 74.4 yrs SO: 9.1 
50 - 59 yrs 95 (7%) 
60 - 69 yrs 307 (22%) 
70 - 79 yrs 589 (42%) 
;> 80 yrs 414 (29%) 
Male gender 719 (51%) 
Follow-up (days) 879 SO: 693 
Number of rehospitalisations for CHF during follow-up 306 
Number of NSAIOs prescriptions during the study period 3162 
Number of patients using NSAIOs: 
Patients with no prescription 846 (60%) 
Patients with 1 prescription 170 (12%) 
Patients with 2-4 prescriptions 191 (14%) 
Patients with;> 5 prescriptions 198 (14%) 
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Table II: 
Cox regression analysis with time dependent covariates on the association 
between current use of NSAIDs and the risk of CHF during follow-up. 
Crude RR (95% CI) Adjusted RR* (95% CI) 
All cohort members (n~1405) 1.54 (1.06-2.24) 1.41 (0.97-2.06) 
Ever use of NSAIDs (n~559) 2.57 (1.69-3.89) 2.20 (1.44-3.36) 
1 prescription (n~170) 3.59 (1.77-7.26) 3.30 (1.63-6.71) 
2-4 prescriptions (n~191) 2.18 (1.18-4.03) 1.85 (1.00-3.45) 
,,5 prescriptions (n~198) 2.66 (1.32-5.35) 2.18 (1.07 -4.46) 
* Adjusted for age, gender, and use of digoxin, diuretics, beta-blockers, ACE-inhibitors, 
anti-arrhythmics (class I and III), vasodilators, calcium-entry blockers, salicylic analgetics, 
acetylsalicylic add (platelet aggregation inhibitor) and COPD-medication. Statistically 
significant values are given in bold type 
2-4 NSAID prescriptions and 198 patients received" 5 NSAID prescriptions during 
the follow-up period. 
Table II shows the results of the Cox regression analysis of the association between 
current use of NSAIDs and the risl< of CHF. In the cohort of 1,405 CHF patients, 
the overall risk of hospitalisation for relapsing CHF associated with NSAID use 
was 1.41 (95% CI; 0.97-2.06), adjusted for age, gender and concomitant medica-
tion. In the sub-cohort of patients who had received at least one NSAID prescrip-
tion (n~559) during the follow-up period, use of NSAIDs was associated with an 
overall twofoldly increased risk of rehospitalisation for CHF (adjusted RR 2.20; 95% 
CI 1.44-3.36). A first NSAID prescription was associated with an adjusted RR of 
3_30 (95% CI; 1_63-6.71), a second to fourth prescription with an adjusted RR of 1.85 
(95% CI 1.00-3.45), and a fifth or more prescription with an adjusted RR of 2.18 (95% 
CI1.07-4.46). 
Table III presents the results of the analysis with the concomitant medication. In 
the multivariate analysis, vasodilators and loop diuretics were associated with an 
increased risl< of rehospitalisation. The use of combinations of potassium-sparing 
diuretics with other diuretics was associated with a decreased risk. The most fre-
quently used NSAIDs were diclofenac (45%), ibuprofen (27%), and naproxen (11 %). 
No differences among NSAIDs could be observed with respect to the risl< of rehos-
pitalisation during current use of these agents. Among patients currently using 
NSAIDs at the time of rehospitalisation for CHF (n~26), the average dosage of 
NSAIDs was 1.25 DDDs/day. On a random date in patients who were not rehos-
pitalised, the mean NSAIDs dosage was 1.01 DDDs/day. This difference was not 
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Table III: 
Concomitant medication associated with rehospitalisations for CHF among 
1405 patients with a history of CHF. 
Crude RR Adjusted R R* 
(95%CI) (95% CI) 
Digoxin 1.09 (0.86-1.37) 0.93 (0.73-1.18) 
Anti-arrhythmics 1.35 (0.91-2.03) 1.13 (0.75-1.71) 
Vasodilators 2.16 (1.72-2.71) 2.10 (1.65-2.68) 
Thiazides 0.51 (0.07-3.64) 0.59 (0.08-4.31) 
Low-ceiling diuretics without thiazides 0.88 (0.28-2.74) 1.04 (0.33-3.30) 
Loop diuretics 1.87 (1.45-2.40) 1.41 (1.06-1.89) 
Potassium~sparing diuretics 1.42 (1.08-1.86) 1.16 (0.87-1.55) 
Loop diuretics or low-ceiling diuretcs 
combined with a potassium-sparing 0.44 (0.24-0.81) 0.53 (0.28-0.98) 
diuretic 
Beta-blockers 0.73 (0.49-1.08) 0.68 (0.45-1.01) 
Calcium entry blockers 1.05 (0.79-1.39) 0.89 (0.67-1.20) 
ACE-inhibitors 1.26 (1.01-1.58) 1.05 (0.82-1.34) 
CO PO-medication 
Tracheal sympaticomimetic agents 1.62 (1.13-2.31) 1.43 (0.90-2.26) 
Other tracheal agents 1.38 (0.98-1.94) 1.09 (0.70-1.70) 
Salicylic analgesics 1.58 (0.84-2.97) 1.60 (0.84-3.03) 
Acetylsalicylic acid (platelet aggregation 
1.03 (0.76-1.40) 0.93 (0.68-1.27) inhibitor) 
* Adjusted for age, gender, and other concomitant medication. 
statistically significant (p~0.05). As compared to non use, the risks of low dosage 
« 0.75 DOD/day), medium dosage (0.75-1.24 DDD/day), and high dosage (;0: 1.25 
DDD/day) were respectively 0.85 (95% CI; 0.35-2.08), 1.07 (95%CI; 0.58-1.99), and 
1.99 (1.32-3.00). 
In the total cohort, 26 cases of CHF occurred during 218 person-years of follow-up 
with NSAID-exposure. The remaining 290 cases of CHF occurred during 3164 per-
son-years of non-exposure to NSAIDs, indicating an attributable fraction of 22.8%. 
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DISCUSSION 
The findings in our study indicate that a first prescription of an NSAID in patients 
with a history of CHF is associated with a threefoldly increased risk of rehospitali-
sation for CHF. In patients who use NSAIDs more regularly (2-4 prescriptions and 
? 5 prescriptions during follow-up), a twofoldly increased risk estimate was found. 
High dosages (>1.25 DDDs/day) seem to be associated with an increased risk of 
rehospitalisation for CHF. In addition, the calculated attributable fraction indicates 
that 23% of the rehospitalisations for CHF in our study population may be attribut-
able to NSAIDs. 
The analysis carried out on the complete cohort of 1405 patients revealed a 
small and statistically not significantly increased risk (adjusted RR 1.41 95% CI; 
0.97-2.06). However, this analysis provides a diluted risk estimate as all patients 
who have not been prescribed an NSAID during follow-up (n~846) will not have 
any period of exposure to NSAIDs. 
Studies in record linkage databases have only limited information on potential con-
founders. Apart from age, sex and comedication, additional information on clinical 
parameters is usually not available. There may be differences in general health 
status between users and non-users of NSAIDs that may be associated with the 
risk of relapsing CHF, and there may also be differences in general health status 
among incidental and chronic users of NSAIDs. Therefore, patients within a certain 
stratum of NSAID use are likely to be more similar, which may reduce the influence 
of unknown confounders that may affect the results. Our findings are in agreement 
with an earlier study with data from the PHARMO data base which showed that in 
persons aged 55 years or older taking diuretics, concomitant use of diuretics and 
NSAIDs was associated with a twofoldly increased risk of a first hospitalisation for 
CHF (11). In our study, the interaction between loop diuretics and NSAlDs was not 
associated with an increased risll of rehospitalisation for CHF in the multivariate 
analysis, which may be explained by the fact that the vast majority of patients with 
CHF are using diuretics on a chronic basis. As the negative effects of NSAIDs on 
cardiovascular homeostasis are lillely to be more pronounced in patients with a his-
tory of CHF (6), the finding of a threefoldly increased risk associated with a first 
NSAID prescription in patients with a previous hospitalisation for CHF is biologi-
cally plausible. 
The finding that more regular use of NSAIDs was associated with a lower risll 
increase, may be explained by the occurrence of depletion of susceptibles in our 
study population (14). As a second hospitalisation for CHF was considered as the 
endpoint of follow-up for the cases, patients who are particularly susceptible to the 
adverse effects of NSAIDs on cardiovascular homeostasis will more readily develop 
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a relapse of CHF after receiving a single prescription for NSAIDs. Patients who are 
prescribed NSAIDs and apparently can tolerate these drugs are liIwly to receive 
further prescriptions during the follow-up period. Hence, a lower rislr of rehospitali-
sation for CHF associated with NSAIDs was demonstrated in patients who could 
tolerate the potentially adverse effects of NSAIDs on cardiovascular homeostasis. 
Although this seems to be a plausible explanation, the role of chance can not com-
pletely be excluded because of overlapping confidence intervals. 
The attributable fraction of 23 %, calculated on the basis of differences in incidence 
density of relapsing CHF during exposure and non-exposure to NSAIDs, demon-
strates that NSAIDs may be responsible for a substantial percentage of rehospitali-
sations for CHF. This finding should be regarded as an important indicator that 
NSAID use seems to have a considerable impact on the number of rehospitalisa-
tions in patients with prevalent CHF. 
Validation of hospital discharge diagnoses of CHF which are included in the 
PHARMO data base has been carried out in a separate study (15). The hospital 
discharge diagnoses were compared with 2 validated sets of diagnostic models 
for CHF, the criteria from the Framingham Heart Study and a modification of the 
Boston criteria (16, 17). According to these two diagnostic models, the validity of 
hospital discharge diagnoses was shown to be high. Therefore, it is unlikely that 
misclassification of outcome has affected our study results. Moreover, any misclas-
sification of CHF is likely to be independent of prior exposure to NSAIDs and such 
random misclassification of outcome will not affect the relative risk estimate in 
a cohort study. Misclassification of exposure may result from either the use of 
over-the-counter NSAIDs or non-compliance to the prescribed drug regimen. In 
The Netherlands, the use of over-the-counter preparations is relatively low, and 
NSAIDs have become available as over-the-counter drugs only during the last few 
years of the study period. Misclassification of exposure due to the use of over-the-
counter NSAIDs will result in an underestimation of the risk estimate, as exposed 
patients are regarded as non-exposed on the basis of pharmacy records. In addi-
tion, filled pharmacy prescriptions have shown to provide a reliable estimate of 
actual drug exposure (18, 19). Although misclassification of exposure can not com-
pletely be excluded in this study, it seems unlikely that it had a substantial effect 
on the study results. Apart from the use of NSAIDs, several other factors may be 
associated with the occurrence of relapses of CHF (20-22). The severity of CHF 
should be regarded as a major determinant in the occurrence of relapses. As 
patients with severe CHF use more cardiovascular medication than patients with 
mild CHF, we also adjusted for current use of several classes of cardiovascular 
drugs and medication for chronic obstructive pulmonary disease. 
The negative effect of NSAIDs on cardiovascular homeostasis in patients with CHF 
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might partly be explained by the interaction between NSAIDs and loop diuretics 
(23-25), NSAIDs may attenuate the natriuretic response to loop diuretics by inter-
ference with prostaglandin-mediated mechanisms, In addition, NSAIDs may com-
pete with loop diuretics with respect to active secretion into the proximal tubule 
and alter the pharmacokinetics of loop diuretics, In this present study, however, 
no statistically significant interaction between NSAIDs and loop diuretics could 
be observed, NSAIDs are associated with a variety of renal function abnormalities, 
such as acute renal failure, interstitial nephritis, and papillary necrosis (2, 4, 26-28). 
Use of NSAIDs has been associated with a fourfold increase in risk of hospitalisa-
tion for acute renal failure (27). Renal function impairment may easily lead to 
fluid retention that may precipitate overt heart failure. Patients with elevated base-
line serum creatinine levels are at an increased rislr of adverse renal effects of 
NSAIDs. It has been shown that a serum creatinine level of above 180 [tmol/l 
should be regarded as a risk factor for NSAIDs-induced renal failure (29). Patients 
with an ineffective circulatory volume, including CHF, have also shown to be at an 
increased risk of NSAID-induced renal function impairment. Future studies with 
more extensive clinical information should be carried out to evaluate in more detail 
the effect of renal function on the association between NSAIDs and CHF. The dose-
effect relation in our study provides additional evidence for a direct pharmacologi-
cal effect. As particularly patients using high dosages seem to be at an increased 
risk, NSAID dosages should preferably not exceed the defined daily dosage, 
In conclusion, the use of NSAIDs in patients with a previous hospitalisation for CHF 
were associated with an increased risk of rehospitalisation for CHF. A first pre-
scription was associated with a threefoldly increased risk, whereas more regular 
use was associated with a lower risk increase, Which may be explained by deple-
tion of susceptibles, Therefore, patients who do not experience a relapse of CHF 
while using a first prescription of NSAIDs are likely to have a better tolerance of 
these agents, although these patients are still at an increased risk of relapsing CHF 
during current use of subsequent NSAID prescriptions. 
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Risk factors for mortality 
in users of ibopamine 
ABSTRACT 
4.1 
Background: In September 1995, the indication for the oral dopamine agonist ibo-
pamine was restricted in the Netherlands and in several other European countries 
to patients with NYHA-c1ass II heart failure as a result of an interim analysis of the 
PRIME-II trial. This trial demonstrated an increased risk of mortality in patients with 
NYHA-c1ass III/IV heart failure on ibopamine. In September 1995, we initiated a 
nationwide retrospective cohort study to assess the effects of ibopamine under 
everyday circumstances in a cohort of users of ibopamine in all NYHA-c1asses. 
Methods: All 2147 community pharmacies and drug dispensing general practitio-
ners received a request to list all patients to whom they had dispensed ibopamine 
in the preceding years. All responding drug dispensing outlets (000) received 
a questionnaire on cardiovascular risk factors and mortality for the general practi-
tioner of a random sample of these patients. 000 were also requested to send 
an anonymised printout of the complete medication record. On the end-date of 
follow-up, February 15 th 1996, mortality rates were compared across categories 
of ibopamine use, adjusted for potential confounders. To assess medication use, 
drug exposure was compared in a three-months period before date of death in the 
deceased, and before a random date in those patients who were still alive. 
Results: In patients with NYHA-c1ass III / IV heart failure, multivariate analysis indi-
cated that current use of ibopamine was significantly associated with mortality 
(RR 1.37 ;95% CI: 1.15-1.64). In patients with NYHA-c1ass JIll heart failure, how-
ever, multivariate analysis showed a 2.03 (95% CI: 1.10-3.72) risk of mortality in cur-
rent users of ibopamine. Apart from current use of ibopamine, male gender and 
increased serum creatinine were also independent risk factors for mortality in all 
NYHA-c1asses. No statistically significant association was found between mortality 
and current use of amiodarone or use of amiodarone at baseline. 
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Conclusion: The increased risk of mortality in patients with NYHA-class III and IV 
heart failure on ibopamine seems to confirm the main finding of the recently pub-
lished PRIME-II trial. However, our results indicate that also patients with NYHA-
class 1111 heart failure may be at an increased risk of mortality when using ibopamine. 
Additional research on the effects of ibopamine in these patients is warranted and 
the use of ibopamine in NYHA-class II heart failure patients may have to be recon-
sidered. 
INTRODUCTION 
Ibopamine is an orally administered dopamine agonist which was registered in 
the Netherlands in 1991 for the treatment of mild congestive heart failure (CHF) in 
combination with diuretics, and for moderate to severe heart failure in combination 
with diuretics, angiotensin converting enzyme (ACE) inhibitors or digoxin. Ibopa-
mine has peripheral and renal vasodilatory properties, both in healthy volunteers 
as well as in patients with congestive heart failure (1, 2). Other pharmacological 
properties of ibopamine are mild positive inotropic activity, increased diuresis 
and inhibition of both renine-angiotensin-aldosteron activity and noradrenalin 
plasma levels when elevated at baseline (1-4). The inhibition of the neurohormonal 
response in patients with congestive heart failure was considered to be the main 
mechanism to which the favourable effects of ibopamine were attributed. 
In view of the increasing prevalence and incidence of congestive heart failure in 
western countries, the introduction of ibopamine was regarded as a promising 
pharmacotherapeutic contribution to the treatment of patients with congestive 
heart failure (5, 6). Several studies confirmed the beneficial haemodynamic and 
neurohormonal effects of ibopamine in patients with congestive heart failure with-
out revealing major adverse effects, although previous experiences with new 
drugs such as milrinone and vesnarinone urged caution with respect to ultimate 
effects on survival (7-10). 
Until August 1995, only limited data were available on the effects of ibopamine 
on mortality (11). At that time, however, results from an interim analysis of the 
PRIME-II trial (Prospective Randomized studies of Ibopamine on Mortality and Effi-
cacy) indicated a significantly increased risll of mortality in the group treated with 
ibopamine as compared to the control group. As a consequence, the safety com-
mittee decided to terminate the PRIME-II trial. This randomised placebo-controlled 
trial was started in 1992 in several European countries to study the effects on mor-
tality and morbidity in patients with moderate to severe congestive heart failure 
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(New York Heart Association classes III and IV) during long-term ibopamine treat-
ment. Recently, the final findings of the PRIME-II study were published (12). 
In response to the findings of the interim analysis of the PRIME-II study in August 
1995, the indication for ibopamine in the Netherlands was restricted to heart fail-
ure NYHA-class II patients only. At that same time, the Inspectorate for Health 
Care in the Netherlands initiated a nationwide retrospective cohort study, which 
aim was to provide information on utilization of ibopamine and on mortality and 
associated risk factors in patients treated with ibopamine. As we were especially 
interested in the effects of the use of ibopamine under everyday circumstances, we 
included patients of all NYHA -classes in our study. 
PATIENTS AND METHODS 
Early September 1995, all 2147 community-based drug dispensing outlets (DDO) in 
the Netherlands received a request to list all patients to whom they had dispensed 
ibopamine in the preceding years. These 2147 DDO comprised 1516 community 
pharmacies and 631 drug dispensing general practitioners (GP). A reminder was 
sent in November 1995. The 1983 responding DDO (92%) had dispensed ibopamine 
to 14,024 patients. Subsequently, all GPs with a DDO who had dispensed ibopa-
mine to a total of 1573 patients received a questionnaire for each of these patients. 
In addition, a random sample of 1573 patients was drawn out of the remaining 
12,451 patients to whom ibopamine was dispensed by their community pharmacist. 
The same questionnaire was sent to the community pharmacist of the patients in 
this sample with the request to forward the questionnaire to the patient's GP. This 
procedure was necessary because we did not dispose of the names of the GPs of 
the patients to whom ibopamine was dispensed by the community pharmacist. In 
this way, a total of 3146 questionnaires were sent to the GPs of patients to whom 
ibopamine was dispensed. The GPs were asl{ed to complete the questionnaire and 
return it to the Inspectorate for Health Care. The questionnaire concerned questi-
ons on cardiovascular risk factors, such as previous myocardial infarction, angina 
pectoris, atrial fibrillation and diabetes mellitus, indication for ibopamine (NYHA-
class), current use of ibopamine and mortality. 
The DDOs were also asked to return a printout of the complete medication record 
of these patients to the Inspectorate for Health Care. Patients were followed from 
the date of the first prescription until death or the end of the study period which 
was February 15th , 1996, whichever came first. In order to assess medication use, 
a drug exposure window of three months was defined in each patient of whom a 
printout of the medication record was available (n~1146). Every patient still alive 
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at the end of the study period was assigned a random date in the printout of the 
medication record. Drug exposure within three months before the date of death 
in deceased patients was taken and compared to drug exposure in a similar three-
months period preceding the random date in those patients who were still alive on 
February 15th 1996. For every prescription, tile legend duration was calculated on 
the basis of tile ratio of the total number of tablets or capsules and the prescribed 
daily number of tablets or capsules. A patient was considered to be exposed to 
every drug for whicll tile date of a filled prescription fell within tile tllree months 
drug exposure window or for wllicll tile end date of tile legend duration overlap-
ped tile date of deatll in deceased patients or the random date in non-deceased 
patients. As mortality from all causes was the primary end point of interest, as 
it was in tile PRIME II trial, we analysed risk factors for mortality in deceased 
patients and in tllose patients wllo were still alive at tile end of the study period. 
Continuous variables were analysed witll a Student-t test or Mann-Wllitney test 
when non-normally distributed. The prevalence of risk factors in both deceased 
and non-deceased patients were analysed and expressed as a relative risk witll 
a 95% confidence interval (95%CI). Apart from crude and stratified univariate rela-
tive risk estimates, we performed multivariate analysis on tile complete dataset 
witll a risk ratio regression model using tile GENMOD procedure of tile SAS sta-
tistical software paclmge. All variables wllicll were significantly associated with 
mortality in tile univariate analysis were entered into tile model. In a second multi-
variate analysis, carried out in a forward stepwise fasllion witll the risk ratio regres-
sion model, we introduced dummy variables to adjust for confounding whicll migllt 
result from missing values. In tile subset for wllicll we obtained botll question-
naire data and a printout of tile medication record, additional multivariate analy-
ses were performed to correct for potential confounding by severity. Hereto, we 
made extra dicllotomous variables on tile basis of two indicators of tile severity of 
CHF. Tllese two severity indicators were based on tile simultaneous use witllin 
tile tllree montlls drug exposure window of respectively: 1. an ACE-inllibitor, loop-
diuretic and digoxin and 2. an ACE-inllibitor, loop-diuretic, digoxin, and a vasodi-
latory agent. All tests were two-sided with rejection of tile null Ilypotllesis at a 
p-value < 0.05. 
RESULTS 
More tllan 92 % of tile DDO responded to our request to list all patients to wllom ibo-
pamine was dispensed. Based on tile 14,024 patients listed by the reacting DDO, 
tile number of patients treated with ibopamine in tile preceding years could be 
estimated at approximately 15,000. Tile mean number of patients per community 
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pharmacy was 9 (median:6; range 0-145), and per GP with a DDO 3 (median:l; 
range:0-20). Completely filled in questionnaires were obtained from the GPs on 
2246 patients (71 %), of which 1049 came from GPs via phamlacists (66%) and 1197 
(76%) from mug dispensing GPs. Printouts of the computerised medication records 
were available of 1304 patients (41 %). The analysis of risk factors for mortality 
apart from medication use was based on 2246 patients, while in a subset of 1146 
patients for whom both a questionnaire and a printout of the medication record 
were available, the association between mortality and medication use could be 
studied in more detail. In table I, general characteristics are given of all 2246 
patients on whom a questionnaire was obtained. Analyses were based on patients 
deceased before February 15th 1996 (n~625; mean follow-up 395 days) and those 
patients who were still alive on that date (n~1621; mean follow-up 679 days). 
Of the patients deceased before February 15'" 1996, 58% was male compared to 
49% of the non-deceased (Table I). The average age of the deceased was 78,5 
years compared to 75,6 years of the non-deceased. According to the GP, 47% of 
the deceased died from cardiac failure and 21 % from sudden death. The remaining 
32 % died from other causes, or the cause of death was unknown. At least 75 % of 
all patients treated with ibopamine were in NYHA class III or IV. The risk of mortal-
ity was strongly related to NYHA-class. Compared to patients in NYHA-class 1/11, 
patients in NYHA-class III and NYHA-class IV had a relative risl( of mortality of 1.86 
(95% CI: 1.41-2.45) and 3.31 (95% CI: 2.52-4.33) respectively. Coronary artery dis-
ease and idiopathic cardiomyopathy as primary causes of heart failure were both 
significantly more prevalent in the deceased, with a relative risk of 1.17 (95% CI: 
1.02-1.35) and 1.19 (95% CI: 1.03-1.37) respectively. Several other cardiovascnlar 
risk factors were significantly more prevalent in the group of deceased patients. A 
history of myocardial infarction, syncope within the last 5 years, angina pectoris, 
atrial fibrillation, chronic obstructive pulmonary disease (COPD) and diabetes melli-
tus were all significantly more frequent in deceased patients. Increased serum cre-
atinine levels were also associated with a higher risk of mortality, especially when 
serum creatinine levels were above 15111molll. Failure ofibopamine to improve car-
diac status within 2 months after starting and a history of re-admissions to hospital 
for congestive heart failure were also associated with an increased risk of mortal-
ity. Current use of ibopamine was associated with a crude relative risk of 1.82 (95% 
CI: 1.57-2.12). 
Table II describes drug exposure of 1146 patients of whom both a questionnaire 
and a printout of the medication record were available. Medication use within a 
drug exposure window of three months before decease or the random date was 
analysed in both deceased patients and patients who were still alive on February 
15'" 1996, the end of the study period. Cardiovascular drugs, such as nitrates, 
digoxin and loop diuretics, were all significantly more frequently used by deceased 
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.. Table I: :c l> 
Descriptives of 2246 users of ibopamine -0 n:i 
'" deceased patients non-deceased patients Relative risk [95% CI] / ". 
(n ~ 625) (n~1621) p-value 
Mean daily dose 315 mg (11.7)* 310 mg (6.1) p~0.6 
Mean follow-up 395 days (62,8) 679 days (43.2) p<O.OO1 
Age (years) 78.5 (0.4) 75.6 (0.3) p<O.OO1 
:0; 64 years 59 223 1.0 [reference] 
65-74 years 124 452 1.03 [0.78-1.36] 
75-84 years 262 599 1.45 [1.13-1.86] 
~ 85 years 180 347 1.63 [1.26-2.11] 
Gender: 
female 263 (42%) 824 (50,8%) 1.0 [reference] 
male 362 (58%) 795 (49,1%) 1.29 [1.13-1.48] 
unknown 2 (0,1%) 
Cause of death: 
cardiac failure 295 (47%) 
sudden death 128 (21%) 
other causes 145 (23%) 
unknown 57 (9%) 
NYHA- class 
NYHA 1111 52 (8%) 359 (22%) 1.0 [reference] 
NYHAIII 254 (41%) 827 (51%) 1.86 [1.41-2.45] 
NYHAIV 253 (40%) 352 (22%) 3.31 [2.52-4.33] 
unknown 66 (11%) 83 (5%) 
w 
<.n 
Primary cause CHF 
coronary artery disease 333 (53%) 819 (41%) 1.17 [1.02-1.35J 
hypertension 93 (5%) 312 (31%) 0.83 [0.68-1.00J 
cardiomyopathy 206 (33%) 475 (24%) 1.19 [1.03-1.37J 
History of myocardial infarction 311 (49%) 706 (44%) 1.31 [1.14-1.51J 
Syncope < 5 years 136 (22%) 256 (16%) 1.42 [1.21-1.66J 
Angina pectoris 349 (56%) 850 (52%) 1.18 [1.02-1.37J 
Atrial fibrillation 253 (40%) 547 (34%) 1.34 [1.16-1.55J 
CO PO 195 (31%) 451 (28%) 1.21 [1.04-1.40J 
Diabetes mellitus 170 (27%) 370 (23%) 1.23 [1.06-1.43J 
Serum-creatinine (J.lmolll) 157.5 (4.3) 124.3 (1,7) p<0.001 
< 94 J.lmolll 67 (11%) 366 (22%) 1.0 [reference] 
94 - 115 J.lmol/l 92 (15%) 321 (20%) 1.44 [1.08-1.91J 
116-151 J.lmol/l 115 (18%) 320 (20%) 1.71 [1.30-2.24J 
> 151 J.lmolll 173 (28%) 256 (16%) 2.61 [2.03-3.34J 
unknown 178 (28%) 358 (22%) 
Ibopamine improved cardiac status within 2 250 (40%) 938 (58%) 0.58 [0.50-0.67J 
months 
History of readmissions to hospital for heart 217 (35%) 317 (20%) 1.89 [1.64-2.17J failure during the use of ibopamine 
Current use of ibopamine according to the 
339 (54%) 675 (42%) 1.82 [1.57-2.12J GP** 
* Va!ues are means (SE) or numbers (%). 
** Current use of ibopamine is defined as exposure to ibopamine on the date of death in deceased patients and on the end-date of the 
study in non-deceased patients. 
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Table II: 
Medication use in 1146 patients based on drug-prescriptions within three 
months before the date of death in deceased patients or random date in non-
deceased patients. 
Drug deceased non-deceased RR [95% CIl (n~289) (n~857) 
Coumarins 79 229 1.02 [0.82-1.28) 
HMG-CoA-reductase-inhibitors 3 36 0.30 [0.10-0.89) 
T rombocyte-aggregation- 56 176 0.95 [0.73-1.22) 
inhibitors 
Digoxin 121 297 1.25 [1.03-1.53) 
Anti-arrhythmics (class III) 22 52 1.19 [0.83-1.72) 
Nitrates 118 283 1.28 [1.05-1.57) 
Loop diuretics 216 525 1.62 [1.28-2.05) 
Other diuretics 81 233 1.07 [0.86-1.331 
Beta-blockers 22 114 0.61 [0.41-0.911 
ACE-inhibitors 138 361 1.18 [0.97-1.451 
Glucocorticoids 31 53 1.52 [1.13-2.051 
Opioids 40 6 3.84 [3.29-4.491 
Salicylates 13 9 2.41 [1.67-3.46) 
Inhalation corticoids 44 82 1.45 [1.12-1.89) 
patients. Beta-blockers and HMG-CoA-reductase-inhibitors, however, were signifi-
cantly more frequently used by non-deceased patients. Apart from cardiovascular 
drugs, glucocorticoids, opioids, salicylates and inhalation corticoids were all sig-
nificantly more frequently used by deceased patients. Other categories of drugs 
did not reveal significant differences between both groups. In particular, no sta-
tistically significant difference was present between deceased and non-deceased 
patients with respect to use of anti-arrhythmics (e.g. amiodarone) during the drug 
exposure window. 
In a separate analysis stratified for NYHA-class JIll and JJJ/lV, crude relative risk 
estimates of mortality in current users of ibopamine according to the GP were sta-
tistically significant in both NYHA-class JIll patients (RR 2.30 95% CI: 1.33-3.99) 
and NYHA-class JIl/lV patients (RR 1.74 95% CI: 1.48-2.04) (Table JIl) . Further-
more, risk of mortality increased within each stratum of increased serum creatinine 
level. In patients with NYHA-class IIJI congestive heart failure, renal impairment 
increased the risk of death more than in patients with NYHA class JJJ/IV congestive 
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heart failure. 
As we had a special interest in the adjusted relative risks of mortality in the pooled 
NYHA-classes IIII (n~411) and IIIIIV (n~1686), the risk ratio regression models for 
these groups were built separately (Table IV). In NYHA-class IIII, the univariately 
significant variables age (in 4 classes), gender, cardiomyopathy, syncope < 5 years, 
serum creatinine (in 4 classes), and current use of ibopamine according to the GP 
were entered in the model. Only gender, serum creatinine> 151 flmol/l and current 
use of ibopamine according to the GP remained statistically significantly associa-
ted with mortality. This led to an adjusted relative risk of mortality of 2.03 (95% 
CI: 1.10-3.72) for current use of ibopamine in patients with NYHA-class IIII CHF. 
In NYHA-class IIIIIV, the univariately significant variables age, gender, history of 
myocardial infarction, syncope < 5 years, atrial fibrillation, serum creatinine, and 
current use of ibopamine according to the GP were entered in the model. After 
adjustment in the risl< ratio model, gender, history of myocardial infarction, serum 
creatinine > 115 flmol/l and current use of ibopamine according to the GP were 
statistically significantly associated with mortality. The adjusted relative risk of 
mortality was 1.37 (95% CI: 1.15-1.64) for current use of ibopamine. In a second 
multivariate analysis, we used dummy variables to adjust for potential confoun-
ding by missing values. This led to an adjusted relative risk of mortality of 1.97 
(95% CI: 1.22-3.16) in patients with NYHA-class IIII, whereas the adjusted relative 
risk in patients with NYHA-class IIIIIV remained actually unchanged (1.38 ;95% 
CI:1.22-1.56). 
DISCUSSION 
In accordance with a large randomized trial (12), we found an increased risk of mor-
tality during use of ibopamine in patients with NYHA-class III and IV at baseline. 
Our relative risk estimation of 1.37 was only slightly higher than the 1.26 found 
in the trial. Although most trials are remote from the situation of drug use under 
everyday circumstances, the results from our cohort study support the trial results. 
Importantly, we also found a statistically significantly increased risk of mortality in 
patients with NYHA -class IIII at baseline, patients that were not included in the 
PRIME-II trial. 
Several other risk factors for mortality in patients with congestive heart failure 
could be distinguished in the overall univariate analysis (Table I). Patients with 
a history of angina pectoris, myocardial infarction, atrial fibrillation, diabetes and 
COPD had an increased risk of mortality in our study. These findings are in 
accordance with several prospective follow-up studies in which patients with con-
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Univariate analysis of risk factors for mortality in a cohort of users of ibopaminel according to NYHA-dass. ." rri 
=0 
NYHAdass 1111 (n~411) NYHA dass IIIIIV (n~1686) ,. 
deceased non- deceased non-
(n~52) deceased crude RR [95% el] (n~507) deceased crude RR [95% el] (n~359) (n~1179) 
Age 80.0 (1.4) 76.3 (0.5) p~0.015 78.3 (0.5) 75.5 (0.3) p<0.001 
,; 64 years 4 42 reference 49 161 reference 
65-74 years 8 92 0.92 [0.29-2.90] 104 343 1.00 [0.74-1.34] 
75-84 years 22 151 1.46 [0.53-4.03] 208 416 1.43 [1.09-1.87] 
;, 85 years 18 74 2.25 [0.81-6.26] 146 259 1.54 [1.17-2.04] 
Gender: 
Female 17 193 reference 210 593 reference 
male 35 166 2.15 [1.25 - 3.71] 297 584 1.29 [1.11-1.50] 
Primary cause CHF 
coronary artery disease 21 148 0.97 [0.58-1.62] 292 635 1.11 [0.96-1.29] 
hypertension 6 78 0.55 [0.22-1.15] 80 221 0.86 [0.70-1.06] 
cardiomyopathy 22 99 1.75 [1.05-2.91] 176 360 1.14 [0.98-1.33] 
history of MI 21 121 1.30 [0.77-2.19] 274 541 1.28 [1.10-1.48] 
syncope < 5 year 14 52 1.97 [1.13-3.44] 115 198 1.32 [1.11-1.56] 
angina pectoris 24 145 1.17 [0.70-1.96] 305 670 1.08 [0.93-1.26] 
atrial fibrillation 19 101 1.41 [0.82-2.41] 221 442 1.28 [1.10-1.49] 
eOPD 15 82 1.31 [0.74-2.29] 168 352 1.13 [0.97-1.32] 
diabetes 13 61 1.47 [0.82-2.63] 145 295 1.13 [0.96-1.33] 
w 
-.0 
serum creatinine: 
<94 ~mol/I 5 
94 -115 ~mol/I 5 
116-151 ~mol/I 11 
>151 ~mol/I 10 
missing 21 
current use of 
ibopamine according 30 
to the GP* 
109 
65 
55 
26 
104 
138 
reference 
1.63 [0.49-5.43J 
3_80 [1.38-10.46J 
6.33 [2.32-17.32J 
2.30 [1.33-3-99J 
55 
79 
102 
158 
113 
293 
243 
243 
243 
220 
230 
507 
reference 
1.33 [0.98-1.81J 
1.60 [1.20-2.14J 
2.26 [1.73-2.96J 
1.74 [1.48-2.04J 
"* Current use of ibopamine is defined as exposure to ibopamine on the date of death in deceased patients and on the end-date of the 
study in non-deceased patients. 
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Table IV 
Multivariate analysis of risk factors for mortality in a cohort of users of 
ibopamine, according to NYHA-class. 
Age: 
,; 64 years 
65-74 years 
75-84 years 
;, 85 years 
Gender: 
female 
male 
Primary cause CHF: 
cardiomyopathy 
history of MI 
syncope < 5 year 
atrial fibrillation 
serum creatinine: 
<94 rlmol/l 
94 - 115 rlmol/l 
116-151 rlmolll 
>151 rlmol/l 
current use of 
ibopamine according 
to the GP* 
NYHA class 1/11 (n~411) 
adjusted RR 
reference 
1.35 [0.30-6.21) 
2.39 [0.57-9.98) 
2.97 [0.67-13.12) 
reference 
2.03 [1.02-4.04] 
1.68 [0.89-3.17) 
1.80 [0.90-3.63) 
reference 
1.16 [0.44-3.07) 
2.08 [0.85-5.09) 
2.86 [1.19-6.85] 
2.03 [1.10-3.72) 
NYHA class IIIIIV (n~1686) 
adjusted RR 
reference 
0.86 [0.60-1.22) 
1.19 [0.87-1.65) 
1.36 [0.98-1.90) 
reference 
1.23 [1.02-1.49] 
1.28 [1.07-1.52] 
1.17 [0.96-1.43) 
1.07 [0.90-1.28] 
reference 
1.25 [0.90-1.72] 
1.47 [1.08-2.00] 
1.82 [1.35-2.44] 
1.37 [1.15-1.64) 
* Current use of ibopamine is defined as exposure to ibopamine on the date of death in 
deceased patients and on the end-date of the study in non-deceased patients. 
gestive heart failure were involved (13-18). Consistent with our findings, use of 
nitrates and inhalation corticoids was more frequently encountered in deceased 
patients as compared to the non-deceased. Not suprisingly, a very strong associa-
tion was found with opioids in the deceased, as these drugs are frequently pre-
scribed in the terminal stage of heart failure to relieve symptoms of respiratory 
distress. Jbopamine improved cardiac status within two months after the first pre-
scription significantly more frequently in non-deceased patients as compared to 
the deceased. Hence, a rapid therapeutic response to ibopamine seems to be pro-
tective with respect to mortality, although this finding may have been subject to 
recall bias by its retrospective and subjective nature. A history of readmissions to 
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hospital for congestive heart failure and current use of ibopamine were also signifi-
cantly more frequent in deceased patients. As the associations remained present 
in the analysis stratified for NYHA-class, the severity of congestive heart failure 
and thereby the liability of physicians to continue treatment in the most severe 
patients does not seem to be the sole explanation for these associations, as also 
in patients with NYHA class I / II at baseline death was associated with current 
use of ibopamine. It should be emphasized, however, that the NYHA-classification 
has limitations in correctly estimating the severity of congestive heart failure. In 
patients with NYHA-class 1111, significantly more patients died from other courses, 
such as cachexia or malignancies. 
Interestingly, increased serum creatinine levels were associated with the risk of 
death in the stratified analysis independently from NYHA-class (Table 1lI). In par-
ticular in patients with mild congestive heart failure (NYHA class 1/11), a statisti-
cally significant association was found between various levels of renal impairment 
and the risk of death, also after adjustment for other risk factors. In patients with 
moderate to severe congestive heart failure, a similar association was found, albeit 
less explicit. In the recently published report on the PRIME-II trial, the role of renal 
function was not discussed. It has been suggested that impaired renal function 
might lead to high levels of epinine, the active metabolite of ibopamine, and that 
these high plasma concentrations might account for the increased mortality in 
patients treated with ibopamine (19). 
With respect to concomitant medication, nitrates, glucocorticoids and inhalation 
corticoids were significantly more frequently used in deceased patients, but this 
finding can be explained by the higher prevalence of angina pectoris and COPD in 
the deceased. Loop diuretics and digoxin were significantly more frequently used 
by deceased patients, whereas beta-blockers seemed to have a protective effect 
with respect to mortality. These findings might be compatible with the assump-
tion that the severity of CHF explains the increased risk of mortality during use of 
ibopamine. Adjustment in the multivariate analysis for severity of CHF, however, 
did not substantially change the risk estimate. 
In a subgroup analysis of the PRIME-II trial, therapy with amiodarone at baseline 
was identified as an independent predictor of mortality in patients treated with 
ibopamine. We were able to analyse current use of amiodarone both in deceased 
and non-deceased patients within the drug exposure window as well as the con-
current use of amiodarone at baseline. Both at baseline as well as within the drug 
exposure window, no significant differences in the use of amiodarone between 
deceased and non-deceased patients could be observed. Therefore, our findings do 
not confirm the hypothesis of the investigators of the PRIME-II trial that a possible 
interaction between ibopamine and the anti-arrhythmic drug amiodarone might 
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contribute to the increased mortality to ibopamine. 
The validity of epidemiological studies may be jeopardized by selection bias, infor-
mation bias or confounding. Selection bias might explain a high mortality in the 
total cohort because of selective prescribing of ibopamine to high risk patients 
with heart failure. As we used non-deceased as a reference group of patients who 
had been subject to the same prescribing habits as the deceased, selection bias 
is not very lil{8ly. This is endorsed by the fact that the relative risk estimates of 
mortality during the use of ibopamine of 1.37 (GP-information) in NYHA-classes 
JIl/lV was very close to the risl! estimate of 1.26 in the trial (12). Information bias of 
GP might be present if they have a different recall of concurrent illnesses or drug 
use of deceased patients as compared to non-deceased patients. As the pharmacy 
data on ibopamine use showed the same trend this is also unlikely, especially as 
such data were gathered unbiased and before disease onset. Because filled pres-
criptions are not always used, however, we think that the GP will have a more 
reliable picture of the medicines which have actually been taken by patients in 
the terminal phase of their illness. Misclassification of outcome (death) is unlikely, 
whereas random misclassification of exposure would result in a conservative esti-
mate of the relative risk. The calculated relative risk of mortality may have been 
influenced by the fact that the questionnaires were filled in after the announce-
ment that the indication of ibopamine had been restricted to patients with NYHA 
class II CHF only. However, we were able to perform an additional analysis which 
was based on the prescription data of the medication records and restricted to only 
these patients with a date of death or random index date before 1 september 1995. 
Based on this analysis, the use of ibopamine within the three months drug expo-
sure window was associated with mortality in both patients with NYHA IIII CHF 
as well as NYHA class JII/1V CHF, with a relative risl! of 4.48 (95% CI 1.11-21.20) 
and 2.94 (95%CI1.99-4.33) respectively. As this analysis pertains to a period before 
the results of the interim-analysis of the PRIME-II trial came available, the results 
of this analysis can not be influenced by any negative publicity with respect to 
ibopamine. 
Potential confounding was dealt with by adjusting for all known independent risk 
factors for mortality in patients with heart failure. As the analysis with dummy 
variables for all variables with missing values yielded similar results, these can not 
be regarded as a source of substantial confounding. The non-response of GPs to 
questionnaires was 34% when sent via pharmacies, and 24% when sent directly 
to drug dispensing GPs. Although this was significantly different, it was not associ-
ated with a difference in mortality and adjustment did not change the risk estima-
tes. Also, there was no substantial difference in overall mortality or risk factors 
for those patients of whom we had only a questionnaire, and those of whom we 
had both a questionnaire and a medication printout. Due to negative publicity, sur-
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vivors might have gradually been withdrawn from ibopamine before the end of the 
study period and this could have overestimated the relative risk. For this reason, 
we used a random end-date in the non-deceased which showed that publicity did 
not bias our risk estimates. Finally, we were unable to validate the information on 
cardiovascular risk factors provided by the GP. However, as the vast majority of 
patients on ibopamine are also regularly seen by a cardiologist, it is likely that most 
information provided by the GPs came from consultant cardiologists. 
In conclusion, in our nationwide cohort study we found similar risk estimates for 
mortality during current use of ibopamine in patients with NYHA-classes IIUIV 
heart failure as found in the PRIME-II trial. In addition, we also found an increased 
risk of mortality in patients with NYHA-classes UII heart failure. Although defini-
tive proof of the causal nature of this association can only come from another ran-
domized trial, we think that additional studies on ihopamine are warranted and 
that its therapeutic role in NYHA class IIII patients should be reconsidered. 
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Confounding by contraindication in a study 
on mortality risk of ibopamine use 
ABSTRACT 
Background: Confounding by contraindication pertains to differences in outcome 
between treated and untreated patients which may be attributed to the presence 
of a contraindication for treatment in untreated patients. To have a confounding 
effect, this contraindication should be independently associated with the outcome 
of interest. 
Objective: To evaluate in detail the effects of confounding by contraindication in 
the analysis of a cohort study on risk factors for mortality in users of ibopamine 
which resulted from a restriction of the indication of ibopamine early Septem-
ber1995. 
Design: Retrospective cohort study 
Setting: General practitioners and pharmacists in the Netherlands 
Patients and methods: The study cohort consisted of 1146 patients with conges-
tive heart failure who had received at least one prescription of ibopamine. Cardio-
vascular risk factors and clinical characteristics were assessed by a questionnairel 
filled in by the general practitioner. Information on medication use was obtained 
from print-outs of the computerised medication records. Each patient was assigned 
an index date, which was the date of death in deceased patients or a random date 
in the medication record for patients still alive at the end of the study period. Sepa-
rate analyses were carried out on the association between the use of ibopamine 
and mortality for patients with an index date before and after September 8th 
1995. 
Results: In patients with an index date before September 8th 1995, current use 
of ibopamine was univariately associated with a relative risk of mortality of 3.02 
(95% CI: 2.12-4.30), whereas in patients with an index date after September 8th 
1995, the relative risk of mortality during current use of ibopamine was 0.71 (95% 
CI: 0.53-0.96). In a multivariate analysis, these associations were 2.62 (95% CI: 
1.76-3.90) and 0.93 (95%CI: 0.84-1.02) respectively. 
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Conclusions: In the absence of any other likely alternative explanation, the marked 
inversion of the relative risk estimate can be regarded as a practical example of 
confounding by contraindication in an epidemiological study. 
INTRODUCTION 
Confounding is one of the major threats to validity in epidemiological studies. The 
popularity of randomised clinical trials follows from the rigorous restriction of the 
potential for confounding by nature of this study design. In spite of the attraction of 
randomisation in research on drug effects, several research questions, particularly 
with respect to drug safety issues, can only be addressed efficiently with an obser-
vational study (1). Careful study design and appropriate data analysis may, how-
ever, strongly reduce the effects of potential confounding in observational studies 
(2). In particular confounding by indication and contraindication should be con-
sidered as major threats to validity in non-randomised comparisons of treatment 
effects (3). Confounding by indication pertains to differences in outcome between 
treated and untreated patients which are not attributed to the treatment effect, but 
which may occur when the indication for treatment is an independent risk factor 
for the study outcome. Then, non-comparability with respect to the indication for 
treatment between treated and untreated patients may account, at least in part, for 
the observed differences in outcome. Alternatively, in confounding by contraindica-
tion, differences in outcome between treated and untreated patients are, at least in 
part, attributed to the presence of a contraindication for treatment in the untreated 
patients. Confounding by contraindication will mostly lead to an underestimation 
of the relative risk, because patients at risk for the outcome of interest are withheld 
from treatment. 
Recently, we completed a cohort study in the Netherlands on risk factors for mortal-
ity in users of ibopamine, an orally administered dopamine agonist (4). This cohort 
study was initiated in response to the results of an interim analysis of the PRIME-II 
trial (Prospective Randomised studies of Ibopamine on Mortality and Efficacy) in 
August 1995. These results indicated a significantly increased risk of mortality in 
patients with moderate to severe congestive heart failure (NYHA III-IV) treated 
with ibopamine as compared to placebo (5). Therefore, early September 1995, the 
indication for ibopamine in the Netherlands was restricted to patients with NYHA 
II heart failure only (6). In the cohort study, emphasis was given to the putative 
association between the use of ibopamine and the increased risk of mortality. The 
study was conducted retrospectively for a period running from the date of the first 
prescription of ibopamine until death or the end of the study period on February 
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15th 1996, whichever came first. As the date of the restriction of the indication of 
ibopamine, September 1" 1995, fell within the study period, this offered a unique 
opportunity to study the influence of the restriction of the indication for ibopamine 
on the association between the use of ibopamine and the risk of mortality. 
In most studies in which confounding by contraindication is suspected, the extent 
to which this might have influenced the results is difficult to quantify. Therefore, 
the concept of confounding by contraindication is commonly discussed in merely 
theoretical terms. In the present study, however, we were able to quantify the 
effect of confounding by contraindication by covering a period with a known and 
abrupt change of the registered indication and contraindications. 
PATIENTS AND METHODS 
The methods of this retrospective cohort study have been described in more detail 
elsewhere (4). In summary, all 2147 community-based drug dispensing outlets 
(DDO) in the Netherlands were requested early September 1995 to list all patients 
to whom they had dispensed ibopamine in the preceding years. The 1983 respon-
ding DDO (92%) had dispensed ibopamine to 14,024 patients. Subsequently, all 
general practitioners (GP) with a DDO who had dispensed ibopamine to a total of 
1573 patients received a questionnaire for each of these patients. In addition, a 
random sample of 1573 patients was taken from the remaining 12,451 patients to 
whom ibopamine was dispensed by their community pharmacist. The same ques-
tionnaire was sent to the GPs of the 1573 patients in this random sample. The 
questionnaire concerned questions on cardiovascular risk factors, indication for 
ibopamine (NYHA-class), current use of ibopamine and mortality. The DDOs were 
also asked to return a printout of the complete computerised medication record of 
these patients. Patients were followed from the date of the first prescription until 
death or the end of the study period (February 15th 1996), whichever came first. 
The first prescription of ibopamine for a patient in the cohort was on April1't 1991-
To assess medication use, a drug exposure window of three months preceding 
an index date was defined for each patient of whom both a questionnaire and a 
printout of the medication record was available (n~1146). Every patient still alive 
at the end of the study period was assigned a random date in the printout of the 
medication record. The index date was defined as the date of death in deceased 
patients or the random date in non-deceased patients. Drug exposure within three 
months before the index date in deceased patients was compared to drug expo-
sure in a similar tbree-months period preceding the index date in those patients 
who were still alive on February 15th 1996. Patients were considered to be current 
users of every drug for which the date of a filled prescription fell within the three 
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months drug exposure window or for which the end date of the legend duration 
overlapped the index date, i.e. the date of death in deceased patients or the 
random date in non· deceased patients. 
In the present study, we evaluated the potential influence of confounding by con-
traindication as a result of the restriction of the indication of ibopamine early Sep· 
tember 1995 in 1146 patients of whom both a questionnaire and a printout of the 
medication record were available. We carried out separate analyses for patients 
with an index date before September 8th 1995 (n~739) and for patients with an 
index date after September 8th 1995 (n~407). On that date, all pharmacists and GPs 
with a drug dispensing outlet received a letter from the Inspectorate for Health 
Care in the Netherlands with the request to contact the prescribers of ibopamine 
of all patients to whom they were dispensing ibopamine and to discuss with the 
prescribers whether further continuation of ibopamine was still indicated in these 
patients. 
Apart from crude and stratified univariate relative risk estimates, we performed 
multivariate analyses with a risk ratio regression model using the GENMOD proce-
dure of the SAS statistical software package. All variables which were significantly 
associated with mortality in the univariate analysis were entered into the model. 
Additional multivariate analyses were performed to correct for potential confoun-
ding by severity. Potential confounding by severity was addressed by introducing 
two severity indicators into the statistical model which were based on actual drug 
use within the drug exposure window. These two severity indicators reflected the 
simultaneous use within the three months drug exposure window of respectively: 
1. an ACE-inhibitor, loop-diuretic and digoxin and 2. an ACE-inhibitor, loop·diuretic, 
digoxin, and a vasodilatory agent. 
RESULTS 
Table I gives the characteristics of users of ibopamine with an index date before 
September 8th 1995 (n~739) and those with an index date after September 8th 1995 
(n~407). No statistically significant differences in age, gender, NYHA-classification 
at baseline, any of the cardiovascular risk factors, and the numbers of missing 
values could be observed between both groups of patients. In table II, univariate 
analyses of risk factors of mortality are shown for deceased and non-deceased 
patients, stratified for index date before and after September 8th 1995. Male gender, 
NYHA-classification at baseline, history of myocardial infarction and increased 
serum creatinine were associated with an increased risk of mortality in both 
groups of patients. Increased age, the presence of severity indicator 2, and syn· 
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Table I 
Characteristics of the cohort of 1146 users of ibopamine stratified for index 
date before and after September 8th 1995. 
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Age 7404 (004)* 75.6 (0.6) p~0.08 
Male gender 366 (49.5%) 191 (47%) 1.04 (0.95-1,13) 
missing 1 (0.1%) 
NYHA-I/II 125 (17%) 78 (19%) 0.95 (0.84-1.06) 
NYHA-III 362 (49%) 206 (51%) 0.98 (0,90-1,06) 
NYHA-IV 208 (28%) 96 (24%) 1.08 (0.99-1 .19) 
missing 44 (6%) 27 (6%) 0.96 (0.79-1.16) 
History of myocardial infarction 355 (48%) 175 (43%) 1,07 (0.99-1,17) 
missing 14 (2%) 7 (2%) 1.03 (0.76-1.40) 
syncope <5 years 151 (20%) 71 (17%) 1.07 (0,96-1,18) 
missing 39 (5%) 16 (4%) 1,11 (0.93-1.32) 
angina pectoris 415 (56%) 213 (52%) 1.06 (0,97-1,15) 
missing 53 (7%) 28 (7%) 1.02 (0.86-1.20) 
atrial fibrillation 271 (37%) 140 (34%) 1.04 (0.95-1.13) 
missing 67 (9%) 43 (11%) 0.94 (0.80-1.10) 
COPD 218 (30%) 105 (26%) 1.07 (0.97-1.17) 
missing 69 (9%) 34 (8%) 1,04 (0,90-1.20) 
diabetes mellitus 161 (22%) 91 (22%) 0,99 (0,89-1.10) 
missing 67 (9%) 35 (9%) 1.02 (0,88-1.18) 
Serum~creatinine: 129 ~mol/I (2.8) 135 pmolll (4,2) p~0.22 
missing 170 87 1,03 (0.93-1.15) 
severity indicator 1 79 (11%) 34 (8%) 1.09 (0,96-1.25) 
severity indicator 2 70 (10%) 41 (10%) 0.98 (0.84-1.13) 
* values are means (S,E,) or numbers (%), 
cope within the last 5 years were statistically significantly associated with an incre-
ased risk of mortality in patients with an index date before September 8th 1995. 
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Univariate analysis of risk factors for mortality in 1146 ever users of ibopamine, stratified for index date. ." 
n:: 
'" patients with index date patients with index date 
"'" before September 8'h 1995 (n=739) after September 8'h 1995 (n=407) 
" 
Deceased non- deceased non-
(n=165) deceased RR (95% Cl) (n=124) deceased RR (95% Cl) (n=574) (n=283) 
Age: ::; 64 years 25 (15%) 88 (15%) reference 14(11%) 37 (13%) reference 
65-74 years 32 (19%) 185 (32%) 0.67 (0.42-1.07) 28 (23%) 90 (32%) 0.86 (0.50-1.50) 
75-84 years 70 (43%) 214 (37%) 1.11 (0.75-1.66) 49 (39%) 99 (35%) 1.21 (0.73-1.99) 
;;:: 85 years 38 (23%) 84 (15%) 1.41 (0.91-2.18) 32 (26%) 55 (19%) 1.34 (0.79-2.26) 
missing 3 (1%) 1 (1%) 2 (1%) 
mean age 76.8 (0.8) 73.7 (0.5) P = 0.002 77.0 (0.9) 75.0 (0.7) P = 0.09 
Male gender: 96 (58%) 270 (47%) 1.41 (1.08-1.86) 68 (55%) 123 (44%) 1.37 (1.02-1.84) 
NYHA-l/ll 12 (7%) 113 (20%) reference 12 (10%) 66 (23%) reference 
NYHA-lll 64 (39%) 298 (52%) 1.84 (1.03-3.30) 53 (43%) 153 (54%) 1.67 (0.95-2.96) 
NYHA-IV 73 (44%) 135 (23%) 3.66 (2.07-6.46) 49 (39%) 47 (17%) 3.32 (1.90-5.79) 
Missing 16 (10%) 28 (5%) 10 (8%) 17 (6%) 
History of myoca rdial 93 (56%) 262 (46%) 1.49 (1.13-1.98) 66 (53%) 109 (39%) 1.54 (1.14-2.08) 
infarction 
syncope <5 years 45 (27%) 106 (19%) 1.54 (1.15-2.08) 23 (19%) 48 (17%) 1.13 (0.77-1.64) 
angina pectoris 101 (61%) 314 (55%) 1.29 (0.96-1.75) 65 (52%) 148 (52%) 0.96 (0.71-1.29) 
atrial fibrillation 62 (38%) 209 (36%) 1.09 (0.82-1.46) 56 (45%) 84 (30%) 1.63 (1.20-2.21) 
COPO 57 (35%) 161 (28%) 1.33 (0.99-1.78) 30 (24%) 75 (27%) 0.95 (0.66-1.35) 
diabetes mellitus 43 (26%) 118 (21%) 1.29 (0.95-1.75) 35 (28%) 56 (20%) 1.35 (0.98-1.86) 
Serum-creatinine (~mol/I) 
in quartiles 
< 94 ~mol!l 16 (10%) 134 (23%) reference 
94 - 115 ~mol!l 34 (21%) 119(21%) 2.08 (1.20-3.61) 
116-151 ~mol/l 28 (17%) 101 (17%) 2.03 (1.15-3.59) 
>151 ~mol/l 47 (28%) 90 (16%) 3.22 (1.92-5.40) 
missing 40 (24%) 130 (23%) 
mean serum-creatinine 152 (7.6) 123 (2.8) p<0.001 
severity indicator 1 17 (10%) 62 (11%) 0.96 (0.62-1.50) 
severity indicator 2 22 (13%) 48 (8%) 1.47 (1.01-2.14) 
current use of ibopamine 132 (80%) 289 (50%) 3.02 (2.12-4.30) 
"" 
18 (14%) 66 (23%) 
16 (13%) 48 (17%) 
24 (19"10) 66 (23%) 
38 (31%) 44 (16%) 
28 (23%) 59 (21%) 
161 (11.3) 124 (3.3) 
15 (12%) 19 (7%) 
13 (11%) 28 (10%) 
56 (45%) 162 (57%) 
reference 
1.17 (0.65-2.10) 
1.24 (0.73-2.12) 
2.16 (1.35-3.46) 
p = 0.002 
1.51 (1.00-2.27) 
1.05 (0.65-1.68) 
0.71 (0.53-0.96) 
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Current use of ibopamine was associated with a relative risk of mortality of 3.02 
(95% CI: 2.12-4.30) in patients with an index date before September 8'h 1995, 
whereas in patients with an index date after September 8'h 1995, the relative risk of 
mortality during current use of ibopamine was 0.71 (95% CI: 0.53-0.96). In patients 
with an index date after September 8th 1995 who received a new prescription of 
ibopamine after this date, the relative risk of mortality was 0.66 (95% CI 0.48-0.91) 
when compared to patients who did not receive a new prescription after Sep-
tember 8th 1995. These new prescriptions of ibopamine were mostly refills of a 
treatment initiated before September 8'h 1995, and apparently continued by the 
prescriber in spite of the Inspectorate's warning. Severity indicators were present 
in 115 (27%) of the 421 current users of ibopamine with an index date before Sep-
tember 8'h 1995 compared to 46 (21 %) of the 218 current users of ibopamine with 
an index date after September 8'" 1995 (RR 1.29 95%CI: 0.96-1.75). Results of the 
multivariate analyses (table III), in which all univariately significant variables were 
included in combination with both severity indicators, demonstrated for patients 
with an index date before September 8'h 1995 an adjusted relative risk of mortality 
during current use of ibopamine of 2.62 (95% CI 1.76-3.90), and in patients with 
an index date after September 8'h 1995 a relative risl( of 0.93 (95% CI 0.84-1.02). In 
table IV, statistically significant differences are shown between current and past 
users of ibopamine, stratified for index date. In patients with an index date before 
September 8'h 1995, current use of ibopamine was statistically significantly asso-
ciated with the presence of both severity indicators, increased serum creatinine 
levels and an increased number of hospital admissions for CHF during the use of 
ibopamine. None of these associations remained statistically significant in patients 
with an index date after September 8'h 1995. Serum creatinine level was statisti-
cally significantly higher in current users of ibopamine with an index date before 
September 8'h 1995 (136 I.lmolll versus 119 I.lmolll), whereas in patients with an 
index date after September 8'h 1995, no statistically significant differences in serum 
creatinine level between current and past users of ibopamine could be demonstra-
ted. 
Information on the actual use of ibopamine until the date of death was based on 
the questionnaires which were completed by the GPs. In 253 of the 289 deceased 
patients (88%), the GP was able to provide detailed information on the use of ibopa-
mine until the date of death. In deceased patients with an index date before Sep-
tember 8'h 1995, 76% used ibopamine until the date of death, whereas in deceased 
patients with an index date after September 8'" 1995, 46% was on ibopamine until 
the date of death. Figure I shows the percentage of patients using ibopamine until 
the date of death of those patients who deceased in the last 7 months of 1995. 
In the months preceding September 8'" 1995, most deceased patients used ibopa-
mine until the date of death. After September 8'h 1995, the percentage of deceased 
patients who used ibopamine until the date of death showed a clear decline. Mean 
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Table III 
Adjusted relative risk of mortality in 1146 ever users of ibopamine with index 
date before and after September 8th 1995. 
patients with index patients with index 
date before date after 
September 8th September 8th 
1995 (n~739) 1995 (n~407) 
RR (95% CI) RR (95% CI) 
Age: ,; 64 years Reference reference 
65-74 years 0.54 (0.32·0.91) 0.93 (0.78·1.10) 
75-84 years 1.07 (0.70-1.61) 1.01 (0.85-1.18) 
;> 85 years 1.48 (0.90-2.44) 1.05 (0.88·1.26) 
Sex: female Reference reference) 
Male 1.50 (1.08·2.08) 1.08 (0.98-1.20) 
NYHA-I/II Reference reference 
NYHA·1I1 1.24 (0.65-2.37) 1.24 (1.04·1.48) 
NYHA-IV 2.14 (1.13·4.06) 1.41 (1.17·1.69) 
History of myocardial infarction 1.36 (1.01·1.84) 1.07 (0.96-1.19) 
syncope <5 years 0.93 (0.67-1.27) -----------
severity indicator 1 0.78 (0.48-1.25) 1.08 (0.88-1.32) 
severity indicator 2 1.32 (0.90-2.44) 0.97 (0.82-1.13) 
Serum-creatinine (Jlmolll) in quartiles: 
< 94 Jlmolll Reference reference 
94-115 Jlmol/l 1.60 (0.91·2.82) 1.05 (0.90-1.23) 
116-151 Jlmolll 1.31 (0.73-2.38) 1.04 (0.90-1.20) 
> 151 Jlmolll 2.32 (1.35·3.97) 1.09 (0.93-1.26) 
current use of ibopamine 2.62 (1.76·3.90) 0.93 (0.84-1.02) 
dosage of ibopamine in patients with an index date before September 8th 1995 
was 319 mg/day, whereas in patients with an index date after September 8th 1995, 
mean dosage of ibopamine slightly decreased towards 293 mg/day (p~0.03). 
DISCUSSION 
In current users of ibopamine with an index date before September 8th 1995 (n~739), 
a statistically significantly increased risl{ (adjusted RR 2.62; 95% CI: 1.76·3.90) of 
mortality could be demonstrated. In patients with an index date after September 
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Univariate analysis of statistically significantly associated risk factors for mortality in current and past users of ibopamine, -" ;:;: 
stratified for index date. 
'" ".
patients with index date patients with index date ,"> 
before September 8'h 1995 (n~ 739) after September 8'h 1995 (n~407) 
Current Past users of Current Past users of 
users of ibopamine RR (95% CI) users of ibopamine RR (95% CI) ibopamine ibopamine 
(n~421) (n~318) (n~218) (n~189) 
severity indicator 1 63 (15%) 16 (5%) 2.97 (1.75-5.05) 20 (9%) 14 (7%) 1.24 (0.64-2.38) 
severity indicator 2 52 (12%) 18 (6%) 2.18 (1.30-3.66) 26 (12%) 15 (8%) 1.50 (0.82-2.75) 
Serum-creatinine (J.lmolll) 
in quartiles 
< 94 ~mol/I 74 (17%) 76 (24%) reference 47 (22%) 37 (19%) reference 
94-115 ~mol/I 87 (21%) 66 (21%) 1.16 (0.93-1.46) 44 (20%) 20 (11%) 1.38 (0.91-2.08) 
116-151 ~mol/I 88 (21%) 41 (13%) 1.55 (1.17-2.06) 41 (19%) 49 (26%) 0.82 (0.61-1.09) 
>151 ~mol/I 84 (20%) 53 (16%) 1.29 (1.00-1.67) 40 (18%) 42 (22%) 0.86 (0.64-1.18) 
missing 88 (21%) 82 (26%) 0.81 (0.62-1.05) 46 (21%) 41 (22%) 0.94 (0.70-1.26) 
mean serum-creatinine 136 (4.2) 119(2.9) p~O.001 133 (6.5) 138 (5.1) p~0.58 
no. of hospital admis-
sions for CHF during use 
of ibopamine: 
0 332 (79%) 266 (84%) reference 175 (80%) 156 (83%) reference 
1 49 (12%) 36 (11%) 1.08 (0.72-1.61) 28 (13%) 19 (10%) 1.27 (0.74-2.19) 
;,2 40 (9%) 16 (5%) 1.90 (1.08-3.31) 15 (7%) 14 (7%) 0.96 (0.48-1.93) 
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8'h 1995 (n~407), however, current use of ibopamine was associated with a neutral 
or even a protective effect with respect to mortality, although not statistically sig-
nificant in the multivariate analysis (adjusted RR 0.93; 95% CI: 0.84-1.02). These 
seemingly contradictory findings can be explained by confounding by contraindica-
tion, resulting from the restriction of the indication of ibopamine early September 
1995, and two direct mailings with regard to this issue to physicians and pharma-
cists by the Inspectorate for Health Care in the Netherlands. Until September 1995, 
ibopamine was regarded (and marketed) as a useful drug in the treatment of CHF. 
Therefore, the analysis of patients with an index date before september 8'h could 
not have been influenced by the negative publicity on ibopamine. The unexpected 
reversal of the relative risk towards a neutral or even protective effect of ibopamine 
with respect to mortality in current users of ibopamine with an index date after 
September 8'h 1995 constitutes, in the absence of any other likely explanation, a 
practical example of confounding by contraindication in an epidemiological study. 
In the current study, confounding by contraindication led to an underestimation of 
the relative risk. Theoretically, confounding by contra-indication may also lead to 
an overestimation of the relative risk if the contraindication has an effect on the 
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outcome into the same direction as treatment. We think, however, that such a situ-
ation is likely to be less common than the opposite. 
Although the restriction of the indication was officially implemented on September 
1" 1995, earlier experience with acute drug safety issues such as with acitretine 
has learned that prescribers themselves are unable to track all patients to whom 
they have prescribed a specific drug (7). Therefore, we used in our analyses Sep-
tember Sth 1995 as a cut-off date, as around that date all pharmacists and GPs with 
a DDO were requested to contact the prescribers of ibopamine of all patients to 
whom they were dispensing ibopamine. 
Until September Sth 1995, ibopamine seemed to have been used relatively more 
frequently in patients with severe CHF as compared to patients with less severe 
complaints. Additional analyses of our data support this hypothesis. In patients 
with an index date before September Sth 1995, both severity indicators were statis-
tically Significantly associated with current use of ibopamine (crude RRs respecti-
vely 2.97; 95% CI1.75-5.05 and 2.1S; 95% CI1.30-3.66), whereas in patients with 
an index date after September Sth 1995, no statistically sigificant association bet-
ween the presence of severity indicators and current use of ibopamine could be 
observed. In addition, there is a trend towards a higher prevalence of severity 
indicators in current users of ibopamine with an index date before September Sth 
(27%) compared to current users of ibopamine with an index date after September 
S'" 1995 (21 %) (RR 1.29; 95% CI: 0.96-1.75). In patients with an index date before 
September Sth 1995, current use of ibopamine was statistically significantly asso-
ciated with ;, 2 hospital admissions for CHF during the use of ibopamine (RR 
1.90; 95% CI: 1.08-3.31) and increased mean serum creatinine levels (136 ).lmolll 
in current users versus 119 pmolll in past users; p<O.OOl). These effects were not 
demonstrable in patients with an index date after September 8th 1995. In the ques-
tionnaire, we asked for NYHA-classification on the date of the first prescription of 
ibopamine. In more than 98% of the patients, this date fell before the restriction of 
the indication of ibopamine early September 1995. Therefore, the first prescription 
of ibopamine has been based on similar considerations and indications in nearly 
all patients. Consequently, major differences in the distribution of NYHA -class bet-
ween patients with an index date before or after September 8th 1995 could not be 
demonstrated (Table I). 
Apart from demonstrating the phenomenon of confounding by contraindication, 
our data also gave the opportunity to gain insight into the effect of the restriction 
of the indication on the use of ibopamine after early September 1995. According to 
the information obtained from the GPs, 76% of the patients who deceased before 
September 8'" 1995 used ibopamine until the date of death, whereas after Septem-
ber 8'" 1995, only 46 % of the deceased patients used ibopamine until the date 
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of death (p<O.OOl). As patients with severe CHF are most susceptible to dying, this 
finding indicated that patients with severe CHF were gradually withdrawn from 
ibopamine after September 8'" 1995 (Figure I). This also nicely illustrates the phe-
nomenon of depletion of susceptibles, a concept which directly relates to confoun-
ding by contraindication. Patients who are most susceptible to the outcome of 
interest, i.e. death, are withdrawn from exposure, i.e. the use of ibopamine, and 
move to the untreated category. Consequently, the association between exposure 
and outcome may disappear or even a seemingly protective effect of the exposure 
of interest may result, as shown in the analysis of patients with an index date after 
September 8'" 1995. 
Apart from the potential effect of depletion of susceptibles, it seems plausible that 
since September 8'" 1995, ibopamine is preferably prescribed to patients who 
experience a substantial relief of symptoms when using this drug. Discontinua-
tion of ibopamine was considered to be undesirable in these patients. This hypo-
thesis is supported by the observation that after September 8th 1995, current 
use of ibopamine was statistically significantly associated with improvement of 
symptoms during the first two months of treatment with ibopamine (RR 1.57; 95% 
CI: 1.24-1.99), whereas such association was not found before September 8th 1995 
(RR 1.06; 95% CI: 0.92-1.22). Apparently, after September 8th 1995, ibopamine was 
discontinued in users of ibopamine who did not experience favourable subjective 
effects of ibopamine. The mean dosage of ibopamine appeared to be higher in 
patients with an index date before September 8th 1995 compared to those with an 
index date after September 8th 1995 (319 mg/day versus 293 mg/day p~O.03)_ Appa-
rently, apart from stopping ibopamine after the safety warning of the Inspectorate 
of Health Care, there has also been a small reduction in the mean dosage of ibopa-
mine in those patients still using ibopamine after September 8th 1995 . Although 
statistically significant, this reduction in mean dosage of ibopamine after Septem-
ber 8'" 1995 is only 8%_ Therefore, it is very unlikely that this slight dose reduction 
may have influenced the results of our study substantially. 
One of the strenghts of this study is the unbiased collection of data on both expo-
sure and outcome. Information on medication use came from the computerised 
printouts of the medication record and can be considered as unbiased, as this 
information was gathered and automated before the occurrence of the outcome 
of interest. Although filled prescriptions do not guarantee medication compliance, 
exposure based on the legend duration of filled prescriptions provides a valid 
approximation of the actual drug exposure (8). Although substantial misclassifica-
tion of exposure seems unlikely, it will probably be random and will lead to a more 
conservative risk estimate. Substantial bias with respect to the outcome death 
should be considered as unlikely. 
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In the period between September and December 1995, current use of ibopamine 
based on the legend duration in the medication record may have overestimated the 
actual use of ibopamine, as ibopamine may have been discontinued in the mean-
time due to the negative publicity early September 1995. In an univariate analysis 
restricted to patients with an index date after September 81", the relative risk of 
mortality in patients with CHF who obtained a new prescription of ibopamine after 
September 81h 1995 was 0.66 (95% CI; 0.48-0.91), which confimls the hypothesis 
that after September 81h 1995, ibopamine was predominantly started or continued 
in patients who were at a lower mortality risk. 
In conclusion, confounding by contraindication may have a profound effect on the 
risl( estimates in epidemiological studies. In most studies, however, the data do 
not offer the opportunity for a detailed quantification of this confounding effect 
and its impact remains speculative. Thanks to widespread communication of an 
abrupt regulatory decision, we were able to quantify the effects of confounding by 
contraindication on the risk estimates. 
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Heart failure treatments: issues of safety 
versus issues of quality of life 
ABSTRACT 
Congestive heart failure (CHF) is an important cause of morbidity and mortality in 
western countries. The profound impact that CHF has on life expectancy and qual-
ity of life has been a continuous stimulus for the development of new drugs for the 
treatment of this condition. Despite favourable effects on (aspects of) quality of 
life in short-term studies, several of these new agents have been shown to reduce 
survival in mortality trials. 
However, patients with severe CHF may experience such incapacitating symptoms 
that the question should be raised as to whether an improvement of quality of life 
makes the increased risk of mortality associated with these new agents acceptable. 
Drugs which improve quality of life at the expense of an increased risk of mortal-
ity can be of value in the treatment of patients with severe CHF. However, this 
is only the case if the probability of improvement in quality of life and prolonga-
tion of life expectancy for those using the drug exceeds the probability of improve-
ment in quality of life and prolongation of life expectancy for those not using the 
drug. Unfortunately, most clinical trials in which both mortality and quality of life 
are evaluated fail to provide information on this composite probability. 
Despite disappointing results of some recent mortality trials on new pharmacologi-
cal treatments of CHF, sound and well-designed clinical trials on innovative heart 
failure treatments in which these composite probabilities are also assessed should 
be carried out. 
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INTRODUCTION 
Congestive heart failure (CHF) has a profound impact on quality of life and life 
expectancy. Dyspnea and exercise intolerance pose major limitations to the daily 
activities of patients with CHF. In the management of CHF, loop diuretics and 
angiotensin converting enzyme (ACE)-inhibitors are the mainstays of therapy. 
Depending on the characteristics of the disease for the individual patient, a ben-
eficial effect may also be obtained by adding digoxin and vasodilators to the 
treatment regimen. However, even with the most optimal treatment currently avail-
able, many patients experience incapacitating symptoms and their life expectancy 
is reduced significantly. Furthermore, epidemiological studies indicate a marked 
increase with age in both the incidence and the prevalence of CHF (1-4). Apart 
from the therapeutic progress made with the introduction of the ACE-inhibitors, 
the expanding knowledge of the pathophysiology of CHF has failed to provide 
substantial progress to the usual pharmacotherapeutic treatment of this condition. 
Hence, the prognosis of patients with CHF has remained poor, both in terms of life 
expectancy and quality of life. 
Over the years, several promising new drugs developed for the treatment of CHF 
have been shown to decrease survival in double-blinded randomised clinical trials 
(table I). Regardless of the pharmacological differences among agents such as 
xamoterol, milrinone, flosequinan and ibopamine, their ultimate effect on survival 
in patients with CHF can only be considered as unfavourable. Despite the inability 
Table I 
Double-blinded randomised clinical trials on drugs associated with a 
statistically significantly increased risk of mortality in patients with CHF. 
Total number 
Trial of patients in Drug 
the trial 
Xamoterol (28) 516 Xamoterol 200 mg 2dd1 
Enoximone (22) 151 Enoximone 50-100 mg 3dd1 
PRIME-II (24) 1906 Ibopamine 100 mg 3dd1 
PROMISE (29) 1088 Milrinone 40 mg/day 
VEST (30) 3833 Vesnarinone 30 mg/day 
Vesnarinone 60 mg/day 
PROFILE (31) 2304 Flosequinan 75-100 mg/day 
FIRST (32) 471 Epoprostenol (median dose 4 ng/kg/min) 
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of these drugs to exert favourable or even neutral effects on survival in patients 
with CHF, many of them may improve exercise tolerance and relieve symptoms. 
This raises the key question as to whether we are willing to accept improved qual-
ity of life at the expense of decreased survival, assuming that both the beneficial 
effect on quality of life and the unfavourable effect on survival of the drug involved 
have unequivocally been demonstrated. 
SAFETY OF PHARMACOLOGICAL TREATMENT OF HEART 
FAILURE 
Safety, effectiveness and efficacy are central issues in the development of new 
drugs. Safety can be regarded as a measure of the absence of adverse drug effects, 
but is always considered in relation to effectiveness, that is, the wanted pharmaco-
logical effect ofthe drug. Efficacy of the pharmacological treatment of CHF is essen-
tially characterised by two aspects: improvement of symptoms and prolongation 
of life expectancy. In the evaluation of CHF treatment, a strict distinction between 
efficacy and safety is of little relevance, as both concepts refer largely to similar 
effects. 
In CHF, prolongation of survival has been demonstrated with ACE-inhibitors 
and the combination of hydralazine and isosorbide dinitrate (5-7). Furthermore, 
results from recent trials with beta-blockers indicate favourable effects on mortal-
ity, although the effect may depend on the aetiology of CHF and on characteristics 
of the beta-blocker involved (8-10). Results from a recently published meta-analy-
sis have confirmed the favourable effect of beta-blockade on all-cause mortality in 
patients with CHF (11). 
The effect of diuretics on survival in patients with CHF has not been subject to 
randomised double-blind placebo-controlled studies, as these drugs are the cor-
nerstone of the treatment of fluid retention in patients with CHF and a placebo-
controlled study would be unethical. Moreover, their beneficial effects are not 
seriously questioned (12). Results from a recent trial on the effect of digitalis on 
mortality and morbidity in patients with CHF indicated that digoxin did reduce 
the rate of hospitalisation both overall and for worsening heart failure, but did not 
affect mortality during 4 years of follow-up (13). 
In response to disappointing results of recent mortality trials on several new 
agents which were assumed to have, at least theoretically, beneficial effects on 
the failing heart (table I), it has recently been suggested that it is now time for 
a moratorium on human studies that investigate drugs which stimulate the cat-
echolamine receptor and their post-receptor pathways until convincing animal 
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data endorse a beneficial effect on sUIvival (14). In our opinion, however, the 
judgement of heart failure treatments deserves a more balanced approach. First, 
comparability between human and animal studies is subject to limitations. For 
instance, differences in catecholamine receptors among species may restrict any 
valid extrapolation from animal studies towards the human situation and is only 
one example why mortality in animals may differ from mortality in human beings. 
Second, the establishment of such a moratorium may give rise to serious delays in 
the development of innovative pharmacological approaches to CHF. Since we face 
an important increase in the prevalence of CHF, such a delay in the development of 
new drugs is undesirable. Third, prolongation of survival should not be regarded 
as the only objective in the treatment of CHF. In particular, patients with severe 
CHF may experience such incapacitating symptoms that improvement in their clini-
cal condition by a new pharmacological treatment may counterbalance the possi-
bly unfavourable effect on survival. In some patients with severe CHF, the wish for 
relief of symptoms (quality of life) may even strongly dominate the wish to prolong 
life (quantity of life). 
QUALITY OF LIFE IN PATIENTS WITH CHF 
Quality of life is a broad concept that can be considered as the sum of all negatively 
and positively valued aspects of life. Although mental and physical health status 
are dominant determinants of quality of life, other aspects of life such as the 
socio-economic situation, the presence of relatives and satisfying social contacts, 
and religious conviction may also contribute to quality of life. The appreciation of 
these aspects, however, can easily be influenced by changes in physical health 
status. Therefore, quality of life is generally considered as strongly physical health-
related. 
Improvement of quality of life is a very important aspect of CHF treatment. Several 
tests can be applied to measure (aspects of) quality of life in patient with CHF, 
such as the 6-minute walk test, the chronic heart failure questionnaire, and the 
Minnesota Living with Heart Failure Questionnaire (15, 16). In the past, patient 
self-assessment of quality of life was considered to be of little relevance in clinical 
trials and emphasis was given to objective clinical outcomes. Nowadays, however, 
qUestionnaires on quality of life are increasingly included in the evaluation of the 
efficacy of CHF treatments. Symptomatic well-being of patients is much better 
reflected by quality of life questionnaires than by objective measurements of car-
diac function (e.g., left ventricular ejection fraction). In a study on quality of life in 
patients with advanced heart failure (predominantly NYHA III-IV), no significant 
association could be found between left ventricular ejection fraction and measures 
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of quality of life, such as functional status, physical symptoms, emotional state, 
and psychosocial adaptation (17). Among the numerous questionnaires available 
for the assessment of quality of life, the Minnesota Living with Heart Failure Ques-
tionnaire appears to provide the most suitable measurement of quality of life in 
patients with CHF (15, 16, 18). 
Effects on quality of life have been examined during treatment with ACE-inhibi-
tors, a class of drugs for which a favourable effect on survival in patients with CHF 
has unequivocally been established (19, 20). Valid comparisons among trials of the 
effect of ACE-inhibitors on quality of life are almost impossible as a result of the 
various measures of quality of life. However, the overall impression is that ACE-
inhibitors exert a modest but consistent improvement of quality of life as compared 
with placebo. Beneficial effects on quality of life, additional to the improvement of 
quality of life achieved by optimal treatment with ACE-inhibitors, have also been 
reported with flosequinan and with enoximone. Unfortunately, both flosequinan 
and enoximone were associated with increased mortality (21-23). As a matter of 
fact, the results of the large-scale mortality trial on flosequinan (PROFILE-trial) 
have never even been properly published in an official medical journal, something 
which can only be regarded as regrettable. The recent results of the PRIME-IHrial 
on mortality and efficacy of ibopamine in patients with NYHA 1II and IV CHF indi-
cated that mortality increased with 26% in patients treated with ibopamine as com-
pared to placebo (24). These findings have once again demonstrated that most of 
the newer CHF treatments fail to combine short term improvement of quality of life 
with long term improvement of survival. 
SAFETY VERSUS QUALITY OF LIFE 
Improvement of quality of life and prolongation of life expectancy (quantity of 
life) are the main objectives in CHF treatment. As pointed out before, some of 
the newer treatments of CHF have been shown to improve quality of life at the 
expense of increased mortality. When treating an individual patient with CHF, phy-
sicians should decide on the primary aim of the treatment of that specific patient. 
This actually implies a translation of state-of-the-art knowledge on safety and qual-
ity of life issues into a therapeutical approach in which all the relevant patient 
characteristics are also taken into account. Of course, the patient must have an 
important role in this decision process. Obviously, an increased risl{ of mortality in 
a clinical trial does not necessarily mean that every individual patient with CHF 
will die earlier. Likewise, an average improvement of quality of life in a clinical trial 
does not necessarily mean that every individual patient will experience relief of 
symptoms. The prescription of drugs which have been demonstrated to decrease 
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survival in patients with CHF can only be accepted, however, when the probability 
of improvement of quality of life and prolongation of life expectancy for those using 
the drug exceeds the probability of improvement of quality of life and prolongation 
of life expectancy for those not using the drug. 
In table II, the intention-to-treat analysis of exercise capacity data from the PICO-
trial demonstrates that, despite a trend towards higher mortality in patients started 
on pimobendan, this probability is larger for those using the drug (63%) as com-
pared to those not using the drug (59%). Unfortunately, only few clinical trials in 
which both survival and (aspects of) quality of life were evaluated offer the pos-
sibility for such a comparison (25). The adoption of an intention-to-treat approach 
to design and analysis instead of a per-protocol approach in the evaluation of 
repeated measurements of (aspects of) quality of life (e.g., exercise capacity), and 
the use of composite ranked endpoints as in the PICO-trial, may contribute to a 
joined evaluation of the actual drug effect (26). It should be stressed that this analy-
sis is only possible when all patients are followed until the planned end of the trial 
and, depending on clinical condition, the quality of life measures are obtained irre-
spective of study medication status. 
Prescribing the most suitable treatment for patients with CHF implies a careful 
process of weighing the pros and cons of the therapeutical strategies against each 
other, in relation to the individual needs of the patient. In this process, there should 
be no a priori hierarchy between quality of life and prolongation of life expectancy 
in all patients with CHF. To combine the dimensions quality and quantity of life, 
the concept of quality-adjusted life years (QALY) has been introduced in the field of 
clinical decision analysis. Quality-adjusted life years renect the number of years in 
full health that would be valued equivalently to the number of years of survival that 
Table II 
Data adapted from the pimobendan in congestive heart failure (PICO) trial 
(25). Intention-to-treat analysis of exercise capacity after 24 weeks of 
treatment with pimobendan 2.5-5 mg or placebo. 
Placebo pimobendan 
Exercise capacity maintained or improved 64 (59%) 132 (63%) 
Exercise capacity deteriorated 34 (31%) 48 (23%) 
Too sick to exercise 4 (4%) 5 (2%) 
Dead 6 (6%) 24 (12%) 
Total 108 (100%) 209 (100%) 
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are expected, including any morbidity during these years. This concept implies 
that the patient values the various health states on a scale of 1 to 0, where perfect 
health would be assigned the value 1 and a state as bad as death a value near 0. 
Multiplication of life expectancy in a certain health status with the appreciation of 
the health status as represented on the 1 to ° scale, usually called the utility of the 
health state, leads to the number of quality-adjusted life years (quality adjusted life 
years ~ expected number of years of survival x utility). By using a method of health 
scale ranking with mutually exclusive categories, Olsson et al. demonstrated that 
measures could be derived from clinical trials that allow direct adjustment of life 
expectancy for quality of life (27). The use of such measures may contribute to a 
clearer understanding of the actual effects on health status of the treatment stud-
ied. In addition, the number of hospitalisations for worsening congestive heart fail-
ure might also indirectly reflect aspects of both quality of life and life expectancy. 
Despite the methodological limitations of measuring quality of life in terms of reli-
ability and validity, the concept of quality-adjusted life years may offer additional 
support to a quantitative approach to issues of life expectancy and quality of life 
in heart failure treatment. Obviously, these considerations will be particularly rel-
evant in patients with severe CHF and debilitating symptoms. In patients with less 
severe CHF, prolongation of life expectancy should be the predominating aim of 
treatment. 
In the absence of an established hierarchy between quality of life and prolonga-
tion of life expectancy in the treatment of patients with severe CHF, priority may 
shift from improvement of survival towards improvement of symptoms. Patients 
with invalidating CHF may choose to use drugs that may improve their symptoms 
even if that leads to an increased risk of death. In our opinion, this is acceptable pro-
vided that the patient is adequately informed of the risk-benefit profile of the drug 
involved. The patient should be regarded as the right person to judge whether the 
severity of symptoms is such that emphasis should be given to improvement of 
quality of life instead of prolongation of life expectancy. This does not mean that 
the patient's judgement is always well founded and that the clinician should agree 
with this judgement without any further comment. In most instances, however, 
patients and their physiCians will agree on this. Based on this judgement and the 
characteristics of the individual patient, the clinician should choose the most appro-
priate therapeutic strategy, bearing in mind these issues of safety and quality of 
life. 
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CONCLUSION 
Improvement of life expectancy and quality of life are botll mainstays of CHF treat-
ment. In severe CHF, Ilowever, tile patient's wisll for improving symptoms may 
prevail over any need for expanding life expectancy. Tllerefore, drugs tllat improve 
quality of life at tile expense of an increased risk of mortality can be of value in tile 
treatment of patients witll severe CHF, provided tllat tile probability of improve-
ment of quality of life and prolongation of life expectancy for tllose using tile drug 
exceeds tile probability of improvement of quality of life and prolongation of life 
expectancy for tllose not using tile drug. Appropriate treatment in tllese patients 
may imply tllat relief of symptoms becomes tile primary aim instead of prolonga-
tion of life expectancy. 
Tile seriousness of CHF, botll at tile level of tile individual patient as well as in 
epidemiological terms, justifies continuous researcll on new tllerapeutical strate-
gies. Aspects of quality of life deserve major attention in tile evaluation of new 
drugs, attention tllat is increasingly obtained in clinical trials. However, most clini-
cal trials in wllicll botll survival and quality of life are evaluated fail to provide 
a risl! assessment in wllicll botll aspects are properly included. Assessment of a 
balanced risk-benefit profile of new drugs implies careful consideration of aspects 
of safety and quality of life, because survival alone sllould not considered to be 
synonymous to overall clinical effect. Only wilen botll aspects are evaluated tllor-
ougllJy, a balanced assessment of tile risk-benefit profile can be made. Based on 
tllis risk-benefit profile, clinicians will be able, in dialogue witll tlleir patients, to 
clloose tile most appropriate treatment available. 
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INTRODUCTION 
Congestive heart failure (CHF) is generally recognised as a major health problem. 
Aging of the population and improved survival after acute myocardial infarction 
are among the most important contributors to its increasing prevalence and inci-
dence (1, 2). In particular severe CHF has to be regarded as an invalidating con-
dition with a poor prognosis. The substantial morbidity which results from CHF 
leads to a significant increase in health care demands (3). 
Although lifestyle modifications, such as sodium restriction, cease smoking advice, 
only modest amounts of alcohol, and promotion of physical activity, may playa role 
in CHF treatment, pharmacotherapy is the mainstay of its treatment (4). Distinction 
has to be made between the treatment of acute and chronic heart failure. There 
are substantial differences between acute and chronic heart failure in both clinical 
characteristics and pharmacotherapeutic treatment. We will restrict our discussion 
to the pharmacotherapeutic treatment of chronic heart failure. 
To reduce the burden of morbidity and health care expenditures caused by CHF, 
and to improve life expectancy of heart failure patients, several new drugs for the 
treatment of CHF have been introduced over the years, such as milrinone, vesna-
rinone, flosequinan, pimobendan and ibopamine (5-9). Although it was assumed 
that these drugs would have favorable effects on mortality, clinical trials demon-
strated a negative effect on survival in patients with CHF. More recently, results 
from clinical trials have shown that beta-blocl{ers, formerly considered to be contra-
indicated in CHF, may improve survival (10-12). 
Both disappointing as well as encouraging results from randomised clinical trials 
(RCT) on heart failure treatments may provide valuable clues to future research. 
Results from recently published RCTs on positive inotropic agents demonstrate 
substantial differences between the intuitive appropriateness of a phannacologi-
cal agent and its actual effects on morbidity and mortality. After summarizing 
some main findings of clinical trials on heart failure drugs, particularly with respect 
to morbidity and mortality, we discuss which implications these findings may have 
on current and future developments of heart failure treatment. 
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MAIN FINDINGS FROM RANDOMISED CLINICAL TRIALS ON HEART 
FAILURE TREATMENT 
Diuretics 
Fluid retention, the main clinical feature of most patients with CHF, can only be 
controlled adequately with diuretics. Although diuretics are generally regarded 
as the cornerstone of the pharmacotherapeutic treatment of CHF, long-term ran-
domised clinical trials on their effects on mortality and morbidity are not available 
(13). Only a few short-term studies have demonstrated that diuretics improve car-
diac function, symptoms and exercise tolerance in patients with CHF (14). Despite 
the lack of solid evidence for their long-term effects on mortality and morbidity, the 
favorable effects of diuretics in patients with CHF are not seriously questioned. 
However, monotherapy with diuretics is unable to obtain long-term clinical stabil-
ity in patients with CHF (15). Therefore, diuretic therapy in heart failure patients 
should preferably be combined with ACE-inhibitors. 
Angiotensin-converting enzyme inhibitors (ACE-inhibitors) 
ACE-inhibitors interfere with the renin-angiotensin system by inhibiting angioten-
sin converting enzyme (ACE) responsible for the conversion of angiotensin I to 
angiotensin II. 
In addition, ACE-inhibition interferes with degradation of kinins, because ACE is 
identical to ldninase II that is responsible for the degradation of kinins. Table I 
presents the results of some major trials on the effects of ACE-inhibitors in patients 
with CHF due to systolic dysfunction. Findings from these trials and other clinical 
trials clearly demonstrate that ACE-inhibitors are able to decelerate the progres-
sion of CHF, and improve clinical status and survival in patients with mild, moder-
ate and severe CHF. Therefore, all patients with CHF due to systolic dysfunction 
should receive an ACE-inhibitor, unless they can not tolerate this drug. 
Digitalis 
The digitalis glycosides inhibit the enzyme Na'K' -ATPase, which results in an 
increase in myocardial contractility. However, inhibition of Na'K' -ATPase in non-
cardiac tissues also seems to contribute to the beneficial effects of digoxin in heart 
failure patients, particularly by attenuating the activation of neurohormonal sys-
tems. Several short-term placebo-controlled studies have shown that digoxin may 
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Table I 
Randomised controlled clinical trials on the effects of ACE-inhibitors in heart failure patients. 
Name 
CONSENSUS 
SOlVD 
V-HeFT-1i 
Year Patients Severity of CH F Drug I daily dosage 
1987 253 NYHA IV enalapril 40mg vs placebo 
1991 2,569 mainly NYHA II-III enalapril 20 mg vs placebo 
1991 804 mainly NYHA II-III enalapril 20 mg vs hydrala-
zine 300 mg + isosorbide 
dinitrate 160 mg 
: Cooperative North Scandinavian Enalapril Survival Study 
: Studies on Left Ventricular Dysfunction 
Main findings 
31 % reduction of mortality one 
year after randomisation (p=O.OO1; 
95% CI not published) 
16% risk reduction (95% CI: 5%-
26%) of mortality at the end of 
scheduled follow-up 
28% reduction of mortality two 
years after randomisation 
(p~0.016; 95% CI not published) 
CONSENSUS-trial (36) 
SOlVO-trial (37) 
V·HeFT-II-trial (22) : Second Veterans Administration Cooperative Vasodilator-Heart Failure Trial 
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have beneficial effects on ejection fraction, exercise tolerance and functional capac-
ity in heart failure patients (16,17). Results from the Digitalis Investigation Group 
(DIG) trial indicate that digoxin has no beneficial effect on mortality in CHF patient 
with normal sinus rythm. Although the risk of being hospitalised for any reason 
decreased with only 6 %, fewer patients randomised to digoxin were hospitalised 
for worsening CHF (Table II). Hence, digoxin may provide clinically relevant symp-
tomatic relief to patients with CHF, and may reduce the risk of hospitalisation 
for worsening CHF. However, digoxin does not improve survival in patients with 
CHF. 
Beta-adrenergic receptor blockers 
In recent years, there has been a growing interest in the use of beta-adrenergic 
receptor blockers for the treatment of CHF. Activation of the sympathetic nervous 
system plays a major role in the pathophysiology of CHF. Norepinephrine has sev-
eral effects on the cardiovascular system which are considered to be harmful to 
heart failure patients, such as peripheral vasoconstriction, impairing renal sodium 
excretion, and inducing myocardial hypertrophy (18-20). In addition, norepineph-
rine may stimulate apopthosis of cardiac myocytes. Results from RCTs have dem-
onstrated that beta-blockers improve survival and reduce morbidity in patient 
with mild to moderate CHF due to systolic dysfunction (Table III). These benefi-
cial effects of beta-blockers were observed in patients who were already on main-
tenance therapy with digoxin, ACE-inhibitor and diuretics. Until now, only few 
patients with severe CHF (NYHA class IV) have been treated with beta-blocl(ers. 
Ongoing research such as the COPERNICUS-trial has to clarify their potential role 
in the management of patients with severe heart failure. Therefore, beta-blockers 
are currently recommended for all patients with stable mild to moderate CHF due 
to left ventricular systoliC dysfunction unless these patients have a contraindica-
tion for their use or have shown to be unable to tolerate beta-blockers. 
Angiotensin-II receptor bloclwrs 
Angiotensin receptor blockers are a new class of drugs which interfere with the 
effects of angiotensin II by means of blockade of the angiotensin II receptor (AT 1-
receptor). Formerly, the benefits of ACE-inhibitors were mainly attributed to the 
suppression of angiotensin II formation, whereas their adverse effects were related 
to the accumulation of kinins. Currently, accumulation of kinins is increasingly 
regarded as essential to the beneficial effects of ACE-inhibitors. Only few studies 
have compared the effects of ACE-inhibitors and AT-II antagonists on mortality 
and morbidity (table II). Based on currently available information, there is no evi-
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Table II 
Randomised controlled clinical trials on the effects of digoxin and losartan in heart failure patients. 
Name 
DIG 
ELITE 
ELITE-II 
DIG-trial (38) 
ELITE (39) 
ELITE-II (47) 
Year Patients Severity of CHF 
1997 6,800 mainly NYHA II-III 
1997 722 mainly NYHA II-III 
2000 3,152 NYHA-II-IV 
: Digitalis Investigation Group 
: Evaluation of Losartan in the Elderly Study 
: Losartan Heart Failure $U1vival Study 
Drug / daily dosage 
digoxin 0.25mg vs placebo 
captopril 150 mg vs 
losartan 50 mg 
Captopril 150 mg vs 
losartan 50 mg 
Main findings 
digoxin did not affect mortality 
digoxin reduced number of 
hospitalisations for worsening CHF 
(RR 0.72; 95% CI:0.66-0.79) 
46% reduced risk of mortality (95% 
CI: 5-69%) 
no statistically significant reduction 
of risk of hospitalisation or com-
bined risk of death and hospital-
isation 
No significant differences in all-
cause mortality or sudden death or 
resuscitated arrests between both 
treatments 
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Table III l> 
Randomised controlled clinical trials on the effects of beta-adrenergic receptor blockers in heart failure patients. ." .., 
en 
'" Name Year Patients Severity of CH F Drug / max. daily dosage Main findings 
'" 
MDC 1993 383 mainly NYHA II-III metoprolol 150 mg vs no reduction of hospitalisations or 
placebo mortality due to CHF 
ClBIS I 1994 641 NYHA III-IV bisoprolo1 5 mg vs placebo 20% reduction of mortality 
(statistically non-significant) 
34% reduced risk of hospitalisation 
for CHF (p<0.01) 
ClBIS II 1999 2,647 NYHA III-IV bisoprolol 10 mg vs 34% reduction in mortality 
placebo (p<0.0001 ) 
20% reduced risk of hospitalisation 
(p=0.0006) 
32% reduced risk of hospitalisation 
for CHF (p<0.0001) 
MERIT-HF 1999 3,991 mainly NYHA II-III metoprolol 200 mg vs 35% reduced risk of mortality 
placebo (p=0.00015) 
t 1996 366 NYHA II-III carvedilol 100 mg vs 48% reduced risk of clinical 
placebo progression (p=0.008) 
77% reduction in mortality 
(p=0.048) 
:j: 1997 415 NYHA II-III carvedilol 50 mg vs 26% reduction in clinical 
placebo progression of CHF (p=0.02) 
23% reduction in risk of 
hospitalisation (p=0.05) 
PRECISE 1996 278 mainly NYHA class carvedilol 100 mg vs no effect on exercise tolerance 
II-III placebo 39% reduction in combined risk of 
death or hospitalisation (p=0.019) 
'" 
'" 
MOCHA 
CIBIS-1(11) 
ClBIS-1i (41) 
MERIT-HF (28) 
t (42) 
:j: (12) 
PRECISE (43) 
MOCHA (10) 
1996 345 mainly NYHA class 
II-III 
: First Cardiac Insufficiency Bisopro!o! Study 
: Second Cardiac Insufficiency Bisoprolol Study 
carvedilol 50 mg vs 
placebo 
: Metopro!ol CRlXL Randomised Intervention Trial in Heart Failure 
: US Carvedilol Heart Failure Study Group 
: Australia / New Zealand Heart Failure Collaborative Group 
: Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise 
: Multicenter Oral Carvedilol Heart Failure Assessment 
no effect on exercise tolerance 
49% reduction in combined risk of 
death or hospitalisation (p=0.002) 
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dence supporting a superior efficacy of AT-II-antagonists in comparison with ACE-
inhibitors in heart failure patients, as shown by the recently published results from 
the ELITE-II trial. 
Phosphodiesterase inhibitors 
Cyclic adenosine monophosphate phosphodiesterase inhibitors (cAMP-PDE-inhibi-
tors) prevent the breal<down of intracellular cAMP by their binding to cAMP-PDE. 
The rise in intracellular cAMP level was thought to have, at least theoretically, 
beneficial effects in patients with CHF as cAMP leads to an increase in myocar-
dial contractility and relaxation of vascular smooth muscle. Results from several 
randomised clinical trials (table IV), however, clearly indicate that cAMP-PDE-
inhibitors reduce survival in heart failure patients. Although favorable effects on 
parameters of quality of life have been reported, the consistent finding in several 
randomised clinical trials that cAMP-PDE-inhibitors reduce survival has substan-
tially minimized their applicability in clinical practice. 
Other agents in the treatment of CHF 
Results from the V-HeFT I-trial (21) demonstrated that compared to placebo, the 
combination of the vasodilators hydralazine (predominantly arterial dilation) and 
isosorbide dinitrate (predominantly venous dilation) reduced mortality in patient 
with mild to moderate CHF who were already treated with digoxin and diuretics. 
ACE-inhibitors have shown to provide further improvement of mortality in the 
V-HeFT II-trial as compared to the combination of hydralazine and isosorbide dini-
trate (22). 
Calcium antagonists dilate arterial resistance vessels in the coronary and systemic 
circulation. Despite these vasodilatory properties, most clinical trials have not 
revealed any benefit from calcium antagonists in heart failure patients. On the 
contrary, several calcium antagonists were associated with an increased risk of 
worsening CHF and death in patients with decreased left ventricular function 
(23-25). Amlodipine, however, a relatively new calcium antagonist, appeared to 
have no adverse effect on survival. This agent was even associated with a trend 
towards decreased all-cause mortality, a finding which needs confirmation in ongo-
ing research (26). 
Inhibiting the effects of aldosterone may exert favourable effects in heart failure 
patients. In patients with severe CHF, treatment with spironolactone was associ-
ated with both a 35 % decrease in hospitalisation rate as well as a 30% decrease 
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Table IV 
Randomised controlled clinical trials on the effects of phosphodiesterase~inhibitors in heart failure patients. 
Name 
VEST-1 
PROMISE 
ENOXIMONE 
VEST-2 
PROMISE (7) 
VEST-1 (6) 
VEST-2 (44) 
ENOXIMONE (S) 
Year Patients Severity of CH F 
1993 477 NYHA class I-IV 
1991 1088 NYHA class III-IV 
1994 151 NYHA class III-IV 
1998 3833 NYHA class III-IV 
Drug I daily dosage 
vesnarinone 120 mg or 60 
mg vs placebo 
milrinone 40 mg vs 
placebo 
enoximone 300 mg vs 
placebo 
vesnarinone 60 mg or 30 
mg vs placebo 
: Prospective Randomized Milrinone Survival Evaluation 
: First Vesnarinone Evaluation of Survival Trial 
: Second Vesnarinone Evaluation of Survival Trial 
Main findings 
120 mg vesnarinone increased the 
risk of mortality 
60 mg vesnarinone 50% risk 
reduction for death or worsening 
heart failure (95% CI:20-69"1o) 
28 % increase in mortality (95% CI: 
1-61%) 
increase in hospitalisations 
(p=0.041) 
increased risk of mortality (p<0.05) 
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Randomised controlled clinical trials on miscellaneous pharmacological agents in heart failure patients. 
Name 
FIRST 
PRIME-II 
PICO 
PROFILE 
XAMOTEROL 
Xamoterol (45) 
FIRST (46) 
PI CO (9) 
PROFILE 
PRIME-II (8) 
Year Patients Severity of CHF Drug / daily dosage 
1997 471 NYHAIII-IV epoprostenol i.v. vs 
conventional treatment 
1997 1,906 NYHA III-IV ibopamine 300 mg vs 
placebo 
1996 317 NYHA II-III pimobendan 2,5 - 5 mg vs 
placebo 
1993 2,304 NYHAIII-IV flosequinan 100 mg vs 
placebo 
1990 516 NYHA III-IV xamoterol 400 mg vs 
placebo 
: The Xamoterol in Severe Heart Failure Study Group 
: Flonan International Randomised Survival Trial 
: Pimobendan in Congestive Heart Failure Trial 
: ReT on the effects of flosequinan on survival in heart failure patients 
: Second Prospective Randomised Study of lbopamine on Mortality and Efficacy 
Main findings 
increased risk of mortality 
26% increased risk of mortality 
(95% CI: 4%-53%) 
hazard ratio for death 1.8 (95% CI: 
0.9-3.5) 
43% increased risk of mortality 
(p<0.05) 
increased risk of mortality (p=0.02) 
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in mortality during 2 years of follow-up (27). Therefore, the use of spironolacone 
may be considered in patients with severe CHF, although its safety and efficacy 
in patients with less severe CHF remains unknown. Patients with CHF tend to 
have frequent and complex ventricular arrhythmias and are at an increased risk of 
sudden death. However, due to their negative inotropic and pro-arrhythmogenic 
properties, anti-arrhythmisc are not recommended for heart failure patients with 
only asymptomatic or non sustained ventricular arrhythmias. If indicated, class III 
anti-arrhytllmics seem to be the most suitable class of anti-arrhthmics for patients 
with CHF. 
Table V shows a number of drugs with various pharmacological effects applied in 
the treatment of CHF. Despite their theoretical benefits, these agents have shown 
to reduce survival in patients with CHF. 
WHAT SHOULD BE STATE OF THE ART HEART FAILURE 
TREATMENT 
For a long period of time, conventional treatment of CHF consisted of diuretics and 
digoxin. During the seventies, vasodilatory therapy was gradually included in most 
pharmacotherapeutic regimens of CHF. Results from the V-Heft I-trial and the CON-
SENSUS-trial demonstrated that both the combination hydralazine-isosorbide dini-
trate as well as ACE-inhibitors improved survival in heart failure patients. Then, 
results from the V-HeFT II-trial revealed that reduction in mortality with enalapril 
was Significantly greater in comparison to hydralazine-isosorbide dinitrate. The 
beneficial effects of ACE-inhibitors were confirmed in the SOLVD-trial on preven-
tion and treatment of CHF, which convincingly showed favorable effects of ACE-
inhibitors on both mortality as well as on the progression of the disease. Triple 
drug therapy (diuretic, digoxin and ACE-inhibitor) appeared to be the most appro-
priate treatment for patients with CHF due to left ventricular dysfunction. 
Over the last few years, beta-blockade has gained growing interest as an option of 
treatment in CHF patients. Result from a number of clinical trials carried out over 
the last few years indicate that beta blockade may lessen symptoms and improve 
survival in heart failure patients. However, several questions with regard to beta-
blockade in CHF are still under investigation in ongoing trials, such as the effects 
on efficacy resulting from pharmacological differences among beta-blockers, and 
the role of beta-blockade in patients with severe CHF. 
A recently published consensus report on the treatment of CHF recommends the 
prescription of beta-blockers to patients with stable NYHA II / III heart failure due 
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to left ventricular systolic dysfunction (28). Hence, a four-drug regimen (diuretiC, 
digoxin and ACE-inhibitor and beta-blocker) may now be regarded as the state-of-
the-art treatment of most patients with NYHA II / III CHF. Recent results from the 
RALES-trial indicate that spironolactone substantially reduces the risl{ of both mor-
bidity and mortality among patients with severe heart failure (47). Future research 
has to show whether spironolactone is also effective in less severe heart failure. 
In addition, more need to be learned about the combined use of beta-blockers and 
spironolactone in severe heart failure. 
With respect to current treatment of CHF treatment, some issues seem to be of par-
ticular interest. Despite the unarguable benefits of ACE-inhibitors, several studies 
have shown that ACE-inhibitors are considerably underutilised in the treatment 
of CHF. Overall treatment rate remains far too low at approximately 50-60% (29). 
Underutilisation of ACE-inhibitors should be regarded as a major impediment to 
a state-of-the-art treatment of CHF. One may wonder why poor application of con-
vincing results from well-designed clinical trials seems to be so prevalent in view 
of the attention currently paid to evidence-based medicine. Presuming that physi-
cians do not deliberately deny a well-proven beneficial treatment to their patients, 
lack of education seems to be at least partially responsible for the underutilisation 
of ACE-inhibitors. Education by means of courses and up to date treatment guide-
lines may be of great value in the effort to reduce underutilisation of ACE-inhib-
itors. In several countries, physiCians are obliged to participate in educational 
programmes. Whether or not such educational programmes are mandatory, physi-
cians involved in the treatment of CHF patients, either general practitioners or 
specialists, should consider it their professional duty to prescribe state-of-the-art 
treatment to their patients. Deviating from well-considered recommendations and 
guidelines on CHF treatment is only legitimate if this results from a careful deci-
sion of the physician, and not from his or her ignorance of state-of-the-art CHF 
treatment. 
Although placebo-controlled double-blinded randomised clinical trials are gener-
ally regarded as the most appropriate design to study treatment effects, their 
results can not always be applied uncritically to each individual patient with CHF. 
Old patients and patients with substantial comorbidity are usually excluded from 
these trials. However, it may seem reasonable to assume that results from RCT 
may also be, at least to some extent, applicable to many patients different from 
the study population. Although this may be true, elderly patients with CHF and 
substantial comorbidity are usually taking drugs for a number of other disorders, 
such as diabetes mellitus, chronic obstructive pulmonary disease or locomotor dis-
orders. When state-of-the-art treatment of CHF implies a four-drug regimen, as 
proposed recently, patients with substantial comorbidity have to be prescribed a 
large number of different drugs which may lead to undesired drug interactions and 
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poor medication compliance. Poor medication compliance is an important problem 
in the treatment of chronic diseases under everyday circumstances, and a major 
impediment to optimal CHF treatment Hence, optimal treatment of CHF should 
always be tailored to individual patients. Physicians have to take into account 
both merits and limitations of RCT, and their treatment should be a synthesis of 
evidence-based medicine and tile individual characteristics of their patients. 
Over the years, several agents considered to be beneficial to patients with CHF 
have shown to reduce survival despite short-term favorable haemodynamic effects. 
In particular phosphodiesterase inhibitors (e.g. milrinone, vesnarinone, enoxim-
one) were associated with increased mortality. In addition, ibopamine (dopami-
nergic agent), pimobendan (phosphodiesterase inhibitor with calcium sensitising 
activity), fiosequinan (vasodilator), and xamoterol (beta-blocker with intrinsic sym-
pathicomimetic activity) have all shown to increase mortality risk in placebo-con-
trolled RCT. Nevertheless, several of these agents have been associated with 
improvement of quality of life. It can be questioned whether conventional RCT are 
the most appropriate design to evaluate quality of life aspects. Even if aspects of 
quality of life have been assessed in clinical trials, only few trials provide risk esti-
mates in which effects on mortality and quality of life are evaluated simulaneously. 
The 'trial and error approach' which characterises drug therapy in clinical practice 
might be able to select those patients who may benefit most from these treatments, 
perhaps even without substantial negative effects on survival. In daily clinical prac-
tice, treatment may be continued only if the patient has symptomatic relief. Hence, 
there may be place for some selected agents which have convincingly shown to be 
capable of providing symptomatic relief in patients with severe CHF, even if these 
agents are associated with an increased risk of death (30). For example, these 
agents might be of value when used concomitantly with beta-blockers in patients 
with severe CHF who can not tolerate betablockade without additional positive ino-
tropic drugs (31). After a period of stabilisation, treatment with positive inotropics 
may gradually be discontinued in these patients, offering the benefits of betablock-
ade without the long-term risk of positive inotropics. However, additional research 
is needed before this approach can be applied in daily clinical practice. 
Obviously, positive inotropic agents will have only a very restricted indication in 
the treatment of CHF. This raises the question what might be the next step for-
ward in CHF treatment. Now we have learned that inotropic therapy appears to 
be unable to improve long-term survival, and that favorable effects on survival 
have only been obtained with ACE-inhibitors and beta-blockers, the most appropri-
ate approach seems to aim at interference with neurohormonal responses and car-
diac remodelling. The increased knowledge on the pathophysiology of CHF has 
revealed that stimulation of both the renin-angiotensin-aldosterone system and 
the sympathetic nervous system has deleterious effects on long-term cardiovascu-
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lar homeostasis. Norepinephrine and angiotensin II are among the factors which 
may contribute to cardiac remodelling, a process regarded as fundamental to the 
progression of CHF. ACE-inhibitors, spironolactone, and beta-blockers directly 
interfere with respectively the renin-angiotensin-aldosterone system and the sym-
pathetic nervous system. Over the years, several factors have been identified 
which may contribute to the process of cardiac remodelling, such as endothelin, 
inflammatory cytoldnes and oxidative stress (32). Endothelin receptor antagonists, 
anticytokines and antioxidant therapy might be of value for patients with CHF. 
Similarly, endopeptidase inhibitors which elevate the level of circulating atrial 
natriuretic peptide may be a valuable new approach in the therapy of CHF (33). 
However, much research and many future trials have to be carried out before any 
reliable estimation can be made on the clinical applicability of these agents in 
the treatment of heart failure patients. There is also insufficient information to 
assess whether calcium sensitisers (e.g. levosimendan), a relatively new class of 
drugs with positive inotropic activity, might be of value to patients with CHF (34). 
Prior experience with pimobendan, which had some calcium-sensitising properties 
gives no reason for optimism despite pharmacological differences between levosi-
mendan and pimobendan. 
There is little reason to suppose that the start of the third millenium will coincide 
with a major breakthrough in heart failure treatment. However, this does not imply 
that no further improvements can be achieved. It seems likely that in the short 
term the most important improvement can be obtained when available knowledge 
on optimal treatment, particularly the prescription of ACE-inhibitors, beta-blockers, 
and spironolactone is actually applied to all patients who may have the benefits 
from it. Apart from this, primary prevention of CHF, based on optimal treatment 
of its most important etiological factors, ischaemic heart disease and hypertension, 
should be one of the main objectives of physicians inVOlved in the management of 
patients with cardiovascular disease (35). 
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INTRODUCTION 
Heart failure is an incapacitating disorder with a poor prognosis, despite recent 
advancements in treatment. Patients are usually prescribed several cardiovascu-
lar drugs, such as diuretics, digoxin, and angiotensin converting enzyme inhibi-
tors (AGE-inhibitors). In addition, other classes of drugs are frequently prescribed 
because of comorbidity. In this thesis, two issues have been studied concerning 
medication use in heart failure patients. 
First, we studied the potentially negative effect of NSAIDs in patients with a first 
occurrence of heart failure (incident heart failure) and in patients with prevalent 
heart failure. According to our findings, and in line with pathophysiologic plausi-
bility, NSAIDs did not induce a first occurrence of heart failure, but appeared to 
be associated with relapses in patients with prevalent heart failure. The cohort 
study described in chapter 3.5 demonstrated an increased risk during current use 
of NSAID in patients with prevalent heart failure. Among patients with a first occur-
rence of heart failure (chapter 3.4), no association between the occurrence of heart 
failure and NSAIDs could be observed. 
Second, we assessed in a nationwide cohort study mortality risk in heart failure 
patients who had been prescribed the dopaminergic agent ibopamine (1). We 
hypothesized that an increased mortality risk may not only be present in the severe 
stages of heart failure, as demonstrated in the PRIME-II trial, but also in patients 
with mild heart failure who were excluded from the trial (2). Our finding that ibo-
pamine was not only associated with an increased mortality risk in patients with 
moderate to severe heart failure, but also in patients with mild heart failure, led 
to the conclusion that the mortality risk of ibopamine should be evaluated first in 
a randomised clinical trial with mild heart failure before a final judgement can be 
made on the safety of this agent in these patients. 
This final chapter will discuss these findings against the background of aspects of 
drug safety, the limitations of clinical trials in heart failure, and the emerging heart 
failure epidemic in western countries. 
DRUG SAFETY 
Monitoring safety aspects of drugs is a major and continuous concern for registra-
tion authorities, for organisations such as the Drug Safety Unit of the Inspectorate 
for Health Gare and the LAREB Pharmacovigilance Foundation in The Netherlands, 
and for pharmaceutical companies. It is well-recognised that pre-marketing safety 
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studies are unable to provide a definite benefitlrisl(-profile of drugs newly intro-
duced on the market (3). Pre-marketing studies are usually not large enough to 
detect rare adverse drug reactions. Nevertheless, relatively rare adverse drug reac-
tions may have a considerable impact on the benefit/risk-profile of drugs. In most 
pre-marketing studies, follow-up is too short to detect adverse drug reactions asso-
ciated with long-term drug use or adverse drug reactions which occur after a 
long delay, such as vaginal carcinoma in the daughters of mothers who had been 
treated with diethylstilboestrol (DES) during pregnancy (4). In addition, pre-mar-
keting studies usually exclude potential users that might be more at risk for an 
increased frequency of adverse drug reactions such as children and aged patients. 
Moreover, multiple drug use, which may be a source of potentially life-threatening 
interactions, is common under everyday circumstances but is much less likely to 
occur in clinical trials. 
The limitations of pre-marketing studies clearly underscore the need for post-mar-
keting surveillance. Pharmacovigilance and pharmacoepidemiological studies are 
the two main forms of postmarketing surveillance. Pharmacovigilance refers to the 
obligations of the marketing authorisation holder and the regulatory authorities to 
set up and maintain a system in order to collect, evaluate and collate information 
about suspected drug reactions. In The Netherlands, there is a spontaneous report-
ing system of suspected adverse drug reactions, and the obligation to marketing 
authorisation holders to report all suspected serious adverse events within 15 days 
to the regulatory authorities. Pharmacoepidemiological studies refer to research 
on drug safety aspects as well as on the effectiveness of drugs under everyday 
circumstances in the post-registration phase. 
Published case reports, spontaneous reporting systems, non-experimental studies 
(commonly referred to as observational studies), and phase IV clinical trials reflect 
different approaches to postmarl(eting surveillance, and may all contribute to 
knowledge on the benefit/risk-profile of drugs. Published case reports are par-
ticularly valuable to distribute knowledge on previously unknown serious ADRs. 
However, depending on the characteristics of the ADR, case reports can usually 
not be regarded as a definite evidence of causality. Similar to published case 
reports, spontaneous reporting systems may be effective in revealing unusual or 
rare adverse drug reactions such as Steven-Johnson syndrome, hepatic necrosis or 
anaphylactic shock although details of such reports are not always generally avail-
able. Causality assessment may be straightforward when there is a clear temporal 
association and a characteristic clinicopathological pattern of these events. How-
ever, when symptoms occur several years after initial drug exposure, an associa-
tion may be more difficult to recognize. Moreover, underreporting (false-negative) 
and false-positive reporting of suspected adverse reactions can make it impossi-
ble to calculate the incidence of ADR. Therefore, post-marketing clinical trials or 
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observational pllarmacoepidemiological studies Ilave to be performed to assess 
tile actual risks of ADRs associated witll drug exposure. Post-marketing clinical 
trials, Ilowever, are usually unable to detect rare ADRs. Moreover, inclusion- and 
exclusion criteria may Ilave as a consequence tllat tile potential ADRs are only 
studied in eligible patients wllicll may limit tile generalizability of tile results. From 
a Ilealtll care point of view, Ilowever, it is of major importance to assess tile risks 
associated witll drug exposure under everyday circumstances, as clinical trials are 
usually unable to provide tllis information. 
Randomised clinical trials are generally regarded as the gold standard in tile eval-
uation of treatment effects. Tile design of randomised clinical trials inllerently 
minimises bias and confounding. Drug safety aspects, Ilowever, can often only 
be adequately evaluated witll an observational (~non-experimental) study design. 
Over tile years, several observational studies Ilave been publislled on potential 
adverse drug reactions. Observational studies provide an important contribution 
to the evaluation of a balanced benefit/risk-profile of drugs, but their validity is 
frequently being cllallenged because of potential bias and / or confounding. A care-
ful design, Ilowever, may reduce or even prevent bias and confounding in observa-
tional studies (5). 
Most registration autllorities are particularly focussed on results obtained from ran-
domised clinical trials. However, extrapolation of results from randomised clinical 
trials to community patients sllould be done cautiously. Witll respect to heart fail-
ure trials, the average clinical trial patient differs substantially from the average 
community patient witll respect to age, gender, and comorbidity (6); aspects gener-
ally regarded as major determinants of .clinical outcome. Registration autllorities 
will increasingly be confronted witll tile results from observational pharmacoepide-
miological studies. Altllougll the interpretation of results from observational stud-
ies may appear less straiglltforward tllan from clinical trials, careful evaluation of 
tlleir results, in view of their strengths and limitations, will provide valuable addi-
tional information on the risk - benefit profile of individual drugs. 
HEART FAILURE 
(Congestive) Ileart failure (CHF) is a rapidly growing public Ilealth problem. Cur-
rently, heart failure is one of the most common cardiovascular disorders among 
elderly in western societies (7-9). Despite improved treatment, the prognosis of 
Ileart failure witll respect to survival remains poor (10, 11). Signs and symptoms 
of moderate to severe CHF may Ilave a significant impact on quality of life. Poor 
prognosis and tile impact on quality of life, next to the economic consequences of 
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increasing health care expenditures, justify the numerous efforts to improve pros-
pects of patients with CHF. The morbidity, mortality and health care costs asso-
ciated with CHF make prevention a more attractive and effective public health 
strategy than treatment. Adequate treatment of the major etiologic factors, isch-
aemic heart disease, hypertension, and valvular disease may postpone or prevent 
the onset of heart failure (12). Unfortunately, for patients attending their general 
practitioner or cardiologist with signs and symptoms of heart failure, prevention is 
no longer an option. 
Over the years, several new drugs have been developed in an attempt to prolong 
survival and preserve quality of life of heart failure patients. Positive inotropic 
agents were thought to improve left ventricular performance, but most of them 
turned out to be associated with increased mortality risk as compared to placebo 
(13-16). Currently, ACE-inhibitors and loop diuretics are the mainstays of heart 
failure treatment. Recent trials have shown additional beneficial effects of beta-
blockers and spironolactone (17-21). Optimising heart failure treatment does not 
only imply ongoing research on new treatment strategies, but also the implementa-
tion of these results from clinical trials in clinical practice. 
IBOPAMINE AND HEART FAILURE 
The limitations of clinical trials as discussed before regarding the benefitlrisk- pro-
file of drugs under everyday circumstances have motivated us to initiate the nation-
wide cohort study among heart failure patients who used the dopaminergic agent 
ibopamine. Results from an interim-analysis of the placebo-controlled PRIME-II 
trial indicated an increased mortality risk associated with ibopamine (2). How-
ever, only patients with NYHA III and IV heart failure were included in this trial, 
whereas ibopamine was also registered in The Netherlands for the treatment of 
NYHA II heart failure. Therefore, the results of this trial did not provide an answer 
to the question whether ibopamine was safe in patients with NYHA II heart fail-
ure. 
The results of the nationwide cohort study described in chapter 4.1 were consis-
tent with the PRIME-II-trial, indicating an increased mortality risk in patients with 
moderate and severe heart failure (1). Interestingly, we also found an increased 
mortality risk in NYHA class II heart failure patients. These patients were excluded 
from the PRIME-II trial. Based on the findings of the PRIME-II-trial, the indication 
of ibopamine in The Netherlands was restricted to mild congestive heart failure 
(NYHA II) only. The Dutch Medicines Evaluation Board decided to maintain NYHA 
class II as an indication for ibopamine, mainly because the increased mortality risl' 
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in NYHA class II that was demonstrated in the nationwide cohort study would in 
their view have to be confirmed by results of a randomised double-blinded clinical 
trial (22), In addition, the observational design was regarded to be subject to poten-
tial biases and confounding, although others did not share this opinion (23), This 
decision of the Dutch Medicines Evaluation Board can be questioned, First, NYHA 
class II is still a registered indication for ibopamine despite the lack of mortality 
data from randomized clinical trials that convincingly demonstrate that ibopamine 
is safe in patients with NYHA II CHF, The Dutch Medicines Evaluation Board, how-
ever, is fully aware of the fact that it is unlikely that there will ever be reliable 
mortality data on ibopamine in NYHA II heart failure patients (22), and that the fol-
low-up in available studies on ibopamine in NYHA II CHF was far too short to pro-
vide useful information regarding mortality, Second, European guidelines clearly 
state that there is no place for ibopamine in the treatment of CHF (24), and ibopa-
mine is not even mentioned in recent American guidelines on heart failure treat-
ment (25), Third, everyday clinical practice has learned that since the publication of 
the PRIME-II trial in 1995, ibopamine has gradually disappeared from the pharma-
cotherapeutical repertory without leaving behind the impression that a valuable 
drug was lost. Finally, it is remarkable that a former indication of a drug becomes 
a strict contraindication to the moderate and severe stages of a disease, while its 
use in the mild stages is not contraindicated, As clinical practice learns that drugs 
which are once prescribed are likely to be continued, maintaining NYHA class II as 
an indication for ibopamine can easily lead to continuing use in the more severe 
stages of this progressive disease, 
NSAIDS AND HEART FAILURE 
A substantial part of this thesis concerns the potential negative effects of NSAIDs 
on cardiovascular homeostasis in heart failure patients, Case-reports describing 
the onset of CHF associated with NSAIDs and an earlier study indicating a two-
foldly increased risll of first hospitalisation for CHF during concomitant use of 
diuretics and NSAIDs suggested a negative effect of NSAIDs on cardiovascular 
homeostasis (26-30), Recently, a case-control study also demonstrated an increased 
risll of first hospitalisation for CHF in patients who were using NSAIDs in the 
period preceding hospital admission (31), Our cohort study in patients with a his-
tory of one hospitalisation for CHF (chapter 3,5) also revealed an increased rislc 
of hospitalisation for relapsing CHF during NSAID use, This study suggested that 
the so-called process of 'depletion of susceptibles' may playa role, indicating a 
decreasing risk with prolonged exposure to NSAIDs, This finding implies that 
patients who are particularly susceptible to the cardiovascular effects of NSAIDs 
are more likely to have relapsing CHF after a first prescription, As this study was 
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carried out in a record linkage database, no clinical information was available on 
the severity of CHF, This phenomenon of 'depletion of susceptibles' might reflect a 
group of patients with severe left ventricular dysfunction that is particularly prone 
to develop relapsing CHF in response to NSAID exposure, 
In view of the pathophysiology of CHF, it seems plausible that NSAlDs may in par-
ticular induce relapses in patients with prevalent heart failure, However, NSAlDs 
have also been associated with first hospitalisations for heart failure, suggesting 
that NSAIDs may cause a first occurrence of heart failure, In these studies, ris]{ 
of hospitalisation was more pronounced in patients with a history of cardiovascu-
lar disease (30, 31), This may indicate that these patients may have already had 
impaired left ventricular function before their hospitalisation for CHF, As described 
in chapter 3.4, we used data from the Rotterdam Study, a prospective population-
based cohort study characterised by a stringent individual follow-up procedure 
of all cohort members (32), The intensive follow-up procedures of the Rotterdam 
Study provided the possibility to include in the study population only participants 
with a certain diagnosis of heart failure and participants without any known suspi-
cion heart failure, This study showed no association between NSAlDs and a first 
occurrence of heart failure, In an additional analysis in which participants were 
followed from the date of diagnosis of the first occurrence of heart failure until a 
first relapse or end of the study period, an association between NSAIDs and relaps-
ing CHF was demonstrated that was compatible with the increased risk found in 
the study among patients with prevalent heart failure (chapter 3,5), These findings 
are clinically relevant, as NSAIDs are agents with potent anti-inflammatory and 
analgesic properties which are often used in the relief of pain from common mus-
culoskeletal disorders in elderly patients, Any finding that NSAIDs might cause a 
first occurrence of heart failure would have far-reaching consequences, However, 
their use in patients with prevalent heart failure should be discouraged, as their 
liability to cause a relapse is substantial. 
FUTURE MANAGEMENT OF CHF 
Optimal heart failure management pertains to both pharmacological and non-phar-
macological treatment of the disease, There can be no doubt that pharmacotherapy 
remains the mainstay of heart failure treatment, Although several new approaches 
are currently under study, they will probably not be introduced in the next few 
years and will not be discussed here (33), In the meantime, much can be gained by 
treating heart failure patients in accordance with present knowledge, Underutilisa-
tion of ACE-inhibitors is a well-recognised problem, indicating suboptimal heart 
failure treatment (34, 35), Another challenge is to put the results into clinical prac-
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tice from recent trials on beta-blocker and spirolactone. 
There is a growing interest in multidisciplinary interventions aiming at the pre-
vention of hospital readmissions and improvement of the quality of life (3, 36-40). 
Studies with these interventions have shown favorable effects on these clinically 
relevant outcomes. In addition, positive effects have been demonstrated on cost-
effectiveness. Until now, only few patients have the opportunity to participate 
in multidisciplinary heart failure management programs. Despite the beneficial 
effects of these programs, several important aspects still need to be addressed. 
The diversity of the studied multidisciplinary interventions complicates a critical 
evaluation of the individual contribution of the various components. Hence, it 
remains unclear what multidisciplinary approach is the most appropriate in terms 
of patient's benefits and cost-effectiveness. A second issue is that it remains to 
be discovered which patients with heart failure are most likely to benefit from a 
multidisciplinary intervention. It can be questioned whether these interventions 
are able to improve clinical outcome in patients with end-stage heart failure. On 
the other hand, patients with mild heart failure may be adequately treated with 
standard care. Psychosocial factors and living circumstances may also affect clini-
cal outcome in heart failure patients (41). Providing optimal care, both pharmaco-
logically as well as non-pharmacologically, is lil(ely to improve prospects of many 
patients with heart failure. 
CONCLUSION 
The prevention, postponement and optimal treatment of heart failure will be one of 
the most important challenges of cardiovascular medicine in the next future. Con-
tributions from both clinical trials as well as observational studies are needed to 
define optimal care. Despite disappointing results in the past regarding several 
promising cardiovascular drugs for the treatment of heart failure, pharmacological 
treatment remains to be the mainstay of therapy. Future research should dem-
onstrate which combinations of pharmacological and non-pharmacological inter-
ventions yield the best results with respect to survival, quality of life, and 
cost-effectiveness. Prevention of relapses of heart failure in patients with preva-
lent heart failure may substantially contribute to quality of life and costs-effective-
ness. Awareness of potentially preventable causes of relapsing heart failure such 
as use of NSAIDs will play an important role in optimal heart failure management. 
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Summary 

Summary 
The general objective of the work presented in this thesis was to study adverse cardiovascular effects of drug use in patients with heart faUure. After a litera-
ture review on precipitating factors for either first or relapsing heart failure and the 
effects of medication, two safety aspects of drug use in heart failure patients were 
evaluated in further detail. First, we evaluated the potential adverse cardiovascu-
lar effects of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with heart 
failure. Second, we studied risk factors for mortality in patients with heart failure 
who had been prescribed the dopaminergic agent ibopamine. 
A number of factors that may precipitate relapses of heart failure are discussed 
in chapter 2.1. Although relapses of heart failure oCCur frequently and have seri-
ous consequences in terms of mortality, morbidity and health care expenditures, 
only limited data are available on the role of precipitating factors that may trigger 
relapses. Alcohol, smoking, psychological stress, uncontrolled hypertension, car-
diac arrhythmias, myocardial ischaemia, poor treatment compliance, and inappro-
priate medical treatment are among the factors that may precipitate heart failure. 
Poor treatment compliance is frequently encountered in patients with relapsing 
heart failure. However, iatrogenic causes of relapsing heart failure such as inap· 
propriate medication and excessive intravenous fluid administration may also pre-
cipitate heart failure. 
The identification of precipitating factors may contribute to optimal treatment of 
patients with heart failure, and may reduce the number of relapses. 
Although heart failure is predominantly caused by cardiovascular disorders such 
as ischaemic heart disease, valvular disease and hypertension, several classes 
of drugs have the potential to induce heart failure in patients with previously 
normal myocardial function or to precipitate relapses in patients with compen-
sated heart failure. Cytostatics, immnnomodulating drugs, antidepressants, cal-
cium entry blockers, NSAIDs, anti-arrhythmics, beta-blockers and anesthetics are 
among the agents discussed in chapter 2.2 that are associated with the onset of 
drug-induced heart failure. Drug-induced heart failure should be regarded as a 
potentially preventable cause of heart faUure. However, sometimes other priori· 
ties offer no therapeutic alternatives (e.g., anthracycline-induced cardiomyopathy). 
Awareness of clinicians of potential adverse effects on cardiac performance by 
several classes of drugs, particularly in patients with pre· existing ventricular dys-
function, may contribnte to timely diagnosis and treatment or prevention of drug-
induced heart failure. 
Knowledge on potentially precipitating factors may improve treatment and care of 
patients with heart failure. Chapter 2.3 describes a study which evaluates the pres-
ence of precipitating factors in patients hospitalised for heart failure, particularly 
with respect to medication compliance. We analysed 318 hospital discharge letters 
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of participants of the Rotterdam Study admitted to hospital for heart failure. Medi-
cation compliance was assessed in patients with more than one hospitalisation by 
comparing dispensed medication after the first hospitalisation with the dispensed 
medication in the period preceding the first readmission for heart failure. 
Potentially precipitating factors were described in 60% of the first hospitalisa-
tions for heart failure as compared to 43% of the readmissions. Among the most 
frequently encountered preCipitating factors were atrial fibrillation I fiutter, myo-
cardial infarction or ischaemia, and pulmonary disease. Lack of medication compli-
ance was notified in only 3 % of the discharge letters of patients rehospitalised for 
heart failure. Based on dispensed medication according to computerised pharmacy 
records, however, non-compliance to either digoxin, diuretics or ACE-inhibitors 
was observed in 46% of rehospitalised patients. 
Little attention is paid in hospital discharge letters to potentially preCipitating fac-
tors for heart failure. In particular, lack of medication compliance seems to be sig-
nificantly more common than may be expected on the basis of the information 
provided by hospital discharge letters. As lack of medication compliance should be 
regarded as a major impediment of optimal heart failure treatment, information on 
this aspect should be notified in hospital discharge letters. 
In chapter 3.1, the cardiovascular effects of NSAIDs in patients with heart failure 
are discussed. NSAIDs inhibit the function of cyclo-oxygenase, an enzyme essen-
tial for the transformation of arachidonic acid into prostaglandins. The inhibition 
of the production of prostaglandins does not only explain the beneficial effects of 
NSAIDs to a large extent, but also many of their adverse reactions. 
In patients with heart failure, particularly the advanced stages, renal function is at 
risk because of a decrease in renal blood flow. Until the terminal stages of heart 
failure, glomerular filtration rate is usually preserved within acceptable limits. Pros-
taglandins have an important role in the maintenance of adequate renal function. 
The kidney releases 2 types of prostaglandins that are particularly important in the 
regulation of renal function, prostaglandin-I, and prostaglandin-E,. These prosta-
glandins have vasodilatating activity in patients with heart failure, and inhibition 
of their synthesis may adversely affect cardiovascular homeostasis. In addition, 
prostaglandins reduce renal sodium and water reabsorption, which is considered 
to be beneficial to patients with heart failure. 
During the period 1985 - 1995, the Drug Safety Unit of the Inspectorate for Health 
Care in the Netherlands received a number of reports of patients who developed 
heart failure which was attributed to the use of NSAIDs. A description of these 
cases is given in chapter 3.2. This case series pertains to patients who developed 
definite heart failure as well as to patients who developed fluid retention without 
overt heart failure. In all patients, a causal relation with the use of NSAIDs was 
considered to be at least probable. Most reports concerned elderly women who 
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were prescribed NSAIDs for locomotor disease. All patients with definite heart fail-
ure had a history of cardiovascular disease, such as atrial fibrillation and coronary 
artery disease. Although the dosage of NSAIDs influences their pharmacological 
effects, the onset of significant fluid retention or symptomatic heart failure seems 
to depend predominantly on patient characteristics such as concomitant cardiovas-
cular disease. 
In particular patients with left ventricular (LV) dysfunction seem to be suscepti-
ble to the adverse cardiovascular effects of NSAIDs. Chapter 3.3 presents a study 
which evaluates the effects of NSAIDs on fractional shortening (FS) of the left ven-
tricle. 
Data for this study were obtained from the Rotterdam Study, a population-based 
prospective cohort study among 7,983 participants aged 55 years and older. Echo-
cardiographic measurements were carried out in a random sample of 1919 par-
ticipants. A fractional shortening of 30% was considered to be the lower limit of 
normal LV systoliC function. Exposure to NSAIDs was determined on the basis 
of computerised medication histories. Participants were considered to be current 
users of NSAIDs when the date of echocardiography fell within the legend dura-
tion of a prescription of an NSAID. Multiple linear regression was carried out to 
assess the effect of NSAIDs on FS. In an overall analysis, current use of NSAIDs 
was associated with a small and statistically non-significant absolute decrease in 
FS with 1.6% (95% CI: -4.9%,1.7%). In participants with a FS < 30%, current use of 
NSAIDs was associated with an absolute decrease in FS of 11.8% (95% CI: -22.3%, 
-1.3%) whereas in participants with FS;:' 30% a decrease in FS of 1.7% (95% CI: 
-4.4 %, 1.1 %) was demonstrated. Current users of NSAIDs with a FS < 30% were 
using a mean daily dosage of 1.63 DDDs/day as compared to 0.98 DDDs/day in cur-
rent users with a FS;:' 30%. In patients with FS < 30%, current use of NSAIDs had a 
substantial negative effect on FS. In patients with normal LV function, current use 
of NSAIDs was associated with a negligible effect on FS. 
The association between the use of NSAIDs and incident heart failure was evalu-
ated in a study presented in chapter 3.4. Data were obtained from the Rotterdam 
Study. A diagnosis of incident heart failure during follow-up was made in 345 par-
tiCipants. Current use of NSAIDs was associated with a RR of incident heart failure 
of 1.11 (95% CI: 0.74 - 1.68), adjusted for age, gender, and concomitant medica-
tion. To study the effect of NSAIDs in prevaientheart failure, patients with incident 
heart failure were followed from the date of diagnosis until the end of the study. 
In patients with prevalent heart failure who filled at least one NSAID-prescription 
since diagnosis of heart failure, the adjusted risk estimate of NSAIDs-associated 
relapsing heart failure was 9.89 (95% CI: 1.72 - 57.01). 
In chapter 3.5, a cohort study is presented that assesses the risk of relapsing heart 
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failure associated with the use of NSAlDs in a cohort of patients aged 50 years and 
older with a history of one hospitalisation for heart failure. Data were used from the 
PHARMO record linkage system, a database containing drug-dispensing records 
from community pharmacies and linked hospital discharge records of 450,000 resi-
dents of 12 population-defined areas in The Netherlands. For each individual in the 
cohort, exposure to NSAlDs and concomitant cardiovascular and pulmonary medi-
cation was assessed during the follow-up period. The cohort was followed from 
the date of discharge of the first hospital admission until the second hospitalisation 
because of relapsing heart failure or end of the study period. The outcome of the 
study was defined as a readmission with a primary diagnosis of heart failure of a 
member of the cohort during the study period. 
In the cohort of 1,405 patients with heart failure, the overall risk of hospitalisation 
a relapse of heart failure associated with NSAID use was 1.41 (95% CI: 0.97 -
2.06), adjusted for age, gender and concomitant medication. Among patients who 
had received at least one NSAID prescription during the follow-up period, use of 
NSAlDs was associated with an overall twofolclly increased risk for rehospitalisa-
tion for heart failure (RR 2.20; 95% CI: 1.44 - 3.36). A first NSAID prescription was 
associated with an adjusted RR of 3.30 (95% CI: 1.63 - 6.71), a second to fourth 
prescription with an adjusted RR of 1.85 (95% CI: 1.00 - 3.45), and a fifth or more 
prescription with an adjusted RR of 2.18 (95% CI: 1.07 - 4.46). The calculated attrib-
utable fraction was 22.8%. 
The results of this study indicate that the use of NSAIDs in patients with a previ-
ous hospitalisation for heart failure was associated with an increased overall risll 
of rehospitalisation for heart failure. Among users, a first prescription is associated 
with a threefolclly increased risk, whereas more regular use is associated with a 
lower risk estimate. This observation may be explained by 'depletion of suscep-
tibles'. The calculated attributable fraction indicates that in the users of NSAlDs in 
our study population approximately 23 % of the rehospitalisations because of heart 
failure may be attributable to the use of NSAIDs. 
In September 1995, the indication for the oral dopamine agonist ibopamine was 
restricted in the Netherlands and in several other European countries to patients 
with NYHA-class II heart failure as a result of an interim analysis of the PRIME-II 
trial. This trial demonstrated an increased mortality risk in patients with NYHA-
class III / IV heart failure randomised to ibopamine. In chapter 4.1, a nationwide 
retrospective cohort study is presented to assess the effects of ibopamine under 
everyday circumstances in a cohort of users of ibopamine in all NYHA-classes in 
The Netherlands. All 2147 community pharmacies and drug dispensing general 
practitioners received a request to list all patients to whom they had dispensed 
ibopamine in the preceding years. All responding drug dispensing outlets (DDO) 
received a questionnaire on cardiovascular risk factors and mortality for the gen-
eral practitioner of a random sample of these patients. DDO were also requested to 
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send an anonymised printout of the complete medication record. 
In patients with NYHA·class III / IV heart failure, mUltivariate analysis Indicated 
that current use of ibopamine was significantly associated with an increased risk 
of mortality (RR 1.37; 95% CI: 1.15 - 1.64). In patients with NYHA-class IIII heart 
failure, however, multivariate analysis showed a twofoldly increased risk of mortal· 
ity in current users of ibopamine (RR 2.03; 95% CI: 1.10 - 3.72). Apart from current 
use of ibopamine, male gender and increased serum creatinine were also indepen-
dent risk factors for mortality in all NYHA-classes. These results indicate that ibo-
pamine seems to be associated with an increased risl{ of mortality not only in 
patients with moderate to severe heart failure, but also in patients with mild heart 
failure. 
Confounding by contraindication pertains to differences in outcome between 
treated and untreated patients which may be attributed to the presence of a con-
traindication for treatment in untreated patients. In chapter 4.2, we evaluated in 
detail the effects of confounding by contraindication in the analysis of the nation-
wide retrospective cohort study on risk factors for mortality in users of ibopamine. 
On september 8'" 1995, the former indication for ibopamine NYHA class III and IV 
heart failure became a strict contraindication. In patients with an index date before 
September 8'" 1995, current use of ibopamine was univariately associated with a 
relative risk of mortality of 3.02 (95% CI: 2.12 - 4.30), whereas in patients with an 
index date after September 8th 1995, the relative risk of mortality during current 
use of ibopamine was 0.71 (95% CI: 0.53 - 0.96). In the multivariate analysis, these 
associations were 2.62 (95% CI: 1.76 - 3.90) and 0.93 (95% CI: 0.84 - 1.02), respec-
tively. These differences were statistically significant. In the absence of any other 
likely alternative explanation, the marked inversion of the relative risk estimate 
can be regarded as a practical example of confounding by contraindication in an 
epidemiological study. 
In chapter 4.3, the aspects of safety and quality of life of heart failure treatment are 
discussed. Heart failure has a profound impact on life expectancy and quality of 
life. This has been a continuous stimulus for the development of new drugs for the 
treatment of heart failure. Despite favourable effects on quality of life parameters, 
several of these new agents have been associated with reduced survival in large-
scale mortality trials. However, patients with severe heart failure may experience 
such incapaCitating symptoms that the question may rise whether an improve-
ment of quality of life mal{es an increased risk of mortality associated with some 
heart failure drugs acceptable. Drugs which improve quality of life at the expense 
of an increased risk of mortality may be of value, provided that the composite prob· 
ability of improvement of quality of life and prolongation of life expectancy for 
those using the drug exceeds the probability of improvement of quality of life and 
prolongation of life expectancy for those not using the drug. Most clinical trials, 
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however, fail to evaluate this composite probability. 
Chapter 5 discusses some current and future aspects of the treatment of heart 
failure. Heart failure is generally recognised as a major health problem. Over the 
years, several new drugs have been introduced for the treatment of heart failure. 
However, a numher of these agents (e.g. phosphodiesterase-inhibitors, ibopamine, 
flosequinan) appeared to be associated with an increased mortality risk. On the 
other hand, encouraging results have been obtained from clinical trials with ACE-
inhibitors and beta-blockers. Recently, spironolactone showed to have a benefi-
cial effect on survival in patients with heart failure. The role of new drugs such 
as calcium sensitizers in the treatment of heart failure has to be established in 
future research. It seems likely that in the short term the most important improve-
ment can be obtained when available knowledge on optimal treatment is actually 
applied to all patients who may benefit from this. 
In the general discussion (chapter 6), the findings of the studies in this thesis are 
discussed against the background of aspects of drug safety, strengths and limita-
tions of clinical trials in heart failure, and the emerging heart failure epidemic in 
western countries. 
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Het onderwerp van dit proefschrift betreft de bestudering van cardiovasculaire bijwerkingen van niet-steroidale anti-inflammatoire geneesmiddelen (NSAlDs) 
en ibopamine bij patiiinten met hartfalen, Na enkele inleidende hoofdstukken 
over luxerende factoren voor het ontstaan van (recidief) hartfalen en de rol die 
medicatie-gebruik hierbij vervult, wordt een tweetal onderwerpen aangaande car-
diovasculaire bijwerkingen van bovengenoemde medicatie bij patiiinten met hart-
falen nader bestudeerd, Ten eerste werd het verband tussen het gebruik van 
non-sterojdale anti-infiammatoire geneesmiddelen (NSAlDs) en het ontstaan van 
(recidief) hartfalen onderzocht, Ten tweede werd onderzoek gedaan naar risicofac-
toren voor sterfte bij patiiinten met hartfalen die de orale dopamine-agonist ibopa-
mine voorgeschreven hadden gekregen, 
Een aantal factoren die recidief hartfalen kunnen luxeren wordt beschreven in 
hoofdstuk 2,1, Hoewel recidief hartfalen frequent optreedt en belangrijke gevol-
gen heeft met betrekking tot mortaliteit, morbiditeit en kosten van de gezond-
heidszorg, zijn er relatief weinig gegevens bekend aangaande factoren die een 
recidief hartfalen kunnen luxeren, Alcoholgebruik, roken, psychische spanning, 
ongecontroleerde hypertensie, cardiale arrhythmieiin, myocard-ischaemie, onvol-
doende medicatietrouw en onjuiste medische behandeling behoren tot de factoren 
die een recidief hartfalen kunnen luxeren, Onderkenning van luxerende factoren 
kan belangrijk bijdragen aan een zo optimaal mogelijke behandeling van patiiinten 
met hartfalen, en biedt aan behandelende artsen de mogelijkheid om de kans op 
recidief hartfalen te vermin deren, 
Hoewel hartfalen in hoofdzaak wordt veroorzaakt door cardiovasculaire aandoenin-
gen zoals coronairlijden, hypertensie en kleplijden, zijn er een aantal geneesmidde-
len die hartfalen kunnen veroorzaken bij patiiinten die tevoren een normale linker 
ventrikelfunctie hadden of die recidief hartfalen kunnen luxeren bij patiiinten 
met gecompenseerd hartfalen, Cytostatica, immuno-modulerende geneesmiddelen, 
antidepressiva, calcium-antagonisten, NSAlDs, anti-arrhythmica, beta-blokkers en 
anaesthetica behoren tot de geneesmiddelen die besproken worden in hoofdstuk 
2,2, Het gebruik van deze geneesmiddelen wordt in de literatuur geassocieerd met 
hartfalen, Hartfalen door geneesmiddelen moet worden beschouwd als een poten-
tieel vermijdbare oorzaak, In een aantal gevallen bieden andere prioriteiten even-
weI nauwelijks een alternatief (bv, anthracycline-ge'induceerd hartfalen), Kennis 
van mogelijl{8 bijwerkingen van geneesmiddelen op de cardiale pompfunctie, in 
het bijzonder bij patienten met reeds verminderde linker ventrikelfunctie, kan bij-
dragen aan preventie en tijdige diagnose en behandeling van geneesmiddelen-
gejnduceerd hartfalen, 
Kennis betreffende mogelijk luxerende factoren kan bijdragen aan de zorg en 
behandeling van patiiinten met hartfalen, Hoofdstuk 2,3 beschrijft een studie 
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waarin wordt onderzocht in welke mate mogelijk luxerende factoren worden ver-
meld in ontslagbrieven, met name wat betreft medicatie-trouw. Hiertoe werden 
318 ziekenhuis-ontslagbrieven bestudeerd van deelnemers aan het ERGO-onder-
zoek die waren opgenomen wegens hartfalen. Medicatie-trouw werd beoordeeld 
bij patienten met meerdere ziekenhuisopnames wegens hartfalen door de ver-
strekte medicatie direct na de eerste opname te vergelijken met de verstrekte 
medicatie in de peri ode voorafgaande aan de tweede opname. Potentieel luxe-
rende factoren werden beschreven bij 60% van de eerste ziekenhuisopnames 
we gens hartfalen in vergelijking met 43 % van de recidief opnames. De me est 
vermelde luxerende factoren waren atriumfibrillereniatriumflutter, myocardinfarctl 
ischaemie en longlijden. Gebrekkige medicatie-trouw werd slechts vermeld in 3% 
van de ontslagbrieven van patiiinten die opnieuw werden opgenomen wegens reci-
dief hartfalen. Op basis van de geautomatiseerde medicatiegegevens werd het ver-
moeden van medicatie-ontrouw echter geconstateerd bij 46% van de patiiinten die 
werden opgenomen vanwege een eerste recidief hartfalen. 
In het algemeen wordt weinig aandacht besteed aan mogelijk luxerende factoren 
voor hartfalen in ziekenhuisontslagbrieven. Vooral medicatie-ontrouw blijkt veel 
vaker voor te komen dan verwacht Iran worden op basis van de ontslagbrief uit 
het ziekenhuis. Aangezien medicatie-ontrouw moet worden beschouwd als een 
belangrijke belemmering voor een optimale behandeling van hartfalen, dient deze 
informatie zo veel mogelijk te worden vermeld in de ontslagbrieven, zodat dit 
onder de aandacht van de huisarts wordt gebracht. 
Hoofdstuk 3.1 beschrijft de cardiovasculaire effecten van NSAIDs bij pati8nten met 
hartfalen. NSAIDs hebben een remmende werking op het enzym cyclo-oxygenase, 
een enzym dat essentiiiel is voor de omzetting van arachidonzuur in prostaglandi-
nes. De remming van de aanmaak van prostaglandines verklaart niet aileen voor 
een groot deel de gunstige effecten van NSAIDs, maar ook veel van de bijwerkin-
gen. 
Bij patienten met hartfalen, in het bijzonder ernstig hartfalen, kan een adequate 
nierfunctie in gevaar komen ten gevolge van een verminderde renale perfusie. Tot 
in het eindstadium van hartfalen blijft de glomerulaire filtratie veelal op een accep-
tabel niveau. Prostaglandines leveren een belangrijke bijdrage aan de handhaving 
van een voldoende nierfunctie. In de nieren komen prostaglandine-12 en prostaglan-
dine-E2 vrij die een belangrijke rol spelen bij het reguleren van de nierfunctie. Deze 
prostaglandines hebben vaatverwijdende eigenschappen en remming van hun 
synthese kan het cardiovasculaire evenwicht bij patienten met hartfalen ongun-
stig belnvloeden. Bovendien remmen deze prostaglandines de renale natrium- en 
water-reabsorptie hetgeen als gunstig beschouwd dient te worden bij patiiinten 
met hartfalen. 
Gedurende de periode 1985 - 1995 ontving de afdeling Geneesmiddelenbewaking 
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van de Inspectie voor de Gezondheidszorg een aantal meldingen betreffende 
patienten die tekenen van hartfalen hadden ontwikkeld die werden toegeschreven 
aan het gebruik van NSAIDs. Een beschrijving van deze patiiinten wordt weerge-
geven in hoofdstuk 3.2. Ret betreft zowel patiiinten die evident het klinische syn-
droom van hartfalen had den ontwikkeld als patienten die vochtretentie hadden 
zonder verdere verschijnselen van hartfalen. Bij aile patiiinten werd de causaliteit 
met betrekking tot het voorafgaande gebruik van NSAIDs als ten minste waar-
schijnlijk beoordeeld. De meeste meldingen hadden betrekking op oudere vrouwen 
waaraan NSAIDs waren voorgeschreven vanwege klachten van het bewegings-
apparaat. Alle patienten met een zekere diagnose hartfalen hadden een voorge-
schiedenis van cardiovasculaire ziekte zoals atriumfibrilleren en coronarialijden. 
Roewel de dosering van NSAIDs invloed heeft op het farmacologische effect lijkt 
het risico op vochtretentie of hartfalen met name afhankelijk te zijn van cardiovas-
culaire comorbiditeit. 
In het bijzonder patient en met linker ventrikel dysfunctie lijken gevoelig te zijn 
voor de ongunstige cardiovasculaire effecten van NSAIDs. Roofdstuk 3.3 beschrijft 
een studie waarin het effect van NSAIDs op de fractionele verkorting van de linker 
ventrikel is onderzocht. De gegevens van de studie zijn af]mmstig van het ERGO-
onderzoek, een prospectief cohort-onderzoek onder 7983 deelnemers van 55 jaar 
en ouder in de wijk Ommoord te Rotterdam. Echocardiografische gegevens van 
1919 deelnemers werden geanalyseerd, waarbij een fractionele verkorting van 
30% als ondergrens van een nonnale systolische ventrikelfunctie werd beschouwd. 
Gebruil< van NSAIDs werd vastgesteld op basis van geautomatiseerde prescriptie-
gegevens afkomstig van de apotheek. Deelnemers werden geacht actueel gebrui-
ker van een NSAID te zijn wanneer de datum van echocardiografie lag binnen de 
prescriptieduUI van het NSAID-recept. Multiple lineaire regressie analyse werd 
verricht om het effect van NSAID-gebruik op de fractionele verkorting te onderzoe-
ken. Bij deelnemers met een fractionele verkorting van < 30% was actueel gebruik 
van NSAIDs geassocieerd met een absolute vermindering van de fractionele ver-
korting met 11.8% (95% BJ: -22.3%, -1.3%), terwijl bij deelnemers met een fractio-
nele verkorting ;> 30% een vermindering van de fractionele verkorting met 1.7 % 
(95% BJ: -4.4%, 1.1 %) werd vastgesteld. Actuele gebruikers van NSAIDs met een 
fractionele verkorting van < 30% gebruikten een gemiddelde dagelijkse dosering 
van 1.63 DDDs/dag in vergelijking met 0.98 DDDs/dag bij actuele gebruikers met 
een fractionele verkorting;> 30%, een statistisch significant verschil. Bij patienten 
met een fractionele verkorting kleiner dan 30% lijkt actueel gebruik van NSAIDs 
een negatief effect te hebben op de fractionele verlmrting. Bij patienten met een 
normale systolische linker ventrikelfunctie is het gebruik van NSAIDs niet geasso-
cieerd met een belangrijk negatief effect op de fractionele verkorting. 
Ret verband tussen NSAID-gebruik en een eerste optreden van hartfalen Unci-
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dent hartfalen) wordt beschreven in hoofdstuk 3.4. De gegevens van deze studie 
zijn afimmstig van het ERGO·onderzoek. Om het effect van NSAIDs separaat te 
bestuderen bij patienten met prevalent hartfalen werden in deze stu die tevens 
patienten na de diagnose hartfalen gevolgd tot het optreden van recidief hartfa-
len of eind van de follow-up. Actueel gebruik van NSAIDs was geassocieerd met 
een relatief risico op incident hartfalen van 1.11 (95% BI: 0.74·1.68), gecorrigeerd 
voor leeftijd, geslacht en comedicatie. Bij patienten met prevalent hartfalen die ten 
minste sen prescriptie voor een NSAID ontvingen was het risico op NSAID-geasso-
cieerd recidief hartfalen in de gecorrigeerde analyse 9.89 (95% BI: 1. 72 - 57.01), een 
statistisch significante toename. 
Hoofdstul{ 3.5 beschrijft een cohort-onderzoek waarin het risico op recidief hart-
falen tijdens gebruik van NSAIDs werd bestudeerd in een cohort patienten van 
50 jaar en ouder met een voorgeschiedenis van een ziekenhuisopname we gens 
hartfalen. Gegevens van deze studie zijn afkomstig van de PHARMO-database, 
die medicatiegegevens bevat van openbare apotheken met daaraan gekoppeld 
ziekenhuisontslagdiagnoses betreffende 450.000 inwoners uit 12 verschillende 
bevolkingsgebieden in Nederland. V~~r ieder individu in het cohort werd het 
gebruik van NSAIDs en cardiovasculaire en pulmonale comedicatie vastgesteld 
gedurende de follow-up periode. Het cohort werd gevolgd vanaf de ontslagdatum 
van de eerste opname wegens hartfalen tot aan de datum van een tweede opname 
wegens recidief hartfalen of eind van de studie periode. De uitkomst van de studie 
was gedefinieerd als een heropname met als hoofddiagnose hartfalen. 
In het totale cohort van 1405 patienten bedroeg het risico op heropname we gens 
recidief hartfalen geassocieerd met NSAID gebruik 1.41 (95% B1: 0.97-2.06), gecor-
rigeerd voor leeftijd, geslacht en comedicatie. Bij patienten aan wie tenminste een-
maal een NSAID was verstrekt gedurende de follow-up periode (n~559) was het 
actuele gebruik van een NSAID geassocieerd met een ruim tweemaal verhoogde 
kans op een heropname we gens recidiefhartfalen (RR 2.20; 95% B1: 1.44-3.36). Een 
eerste NSAID prescriptie was geassocieerd met een gecorrigeerd RR van 3.30 (95% 
B1: 1.63·6.71), twee tot vier prescripties met een gecorrigeerd RR van 1.85 (95% 
BI: 1.00·3.45), vijf of meer prescripties met een gecorrigeerd RR van 2.18 (95% BI: 
1.07-4.46). De berekende attributieve fractie bedroeg 22.8%. 
Het resultaat van deze studie geeft aan dat het gebruik van NSAIDs bij patienten 
met bestaand hartfalen geassocieerd is met een verhoogd risico op het ontstaan 
van recidief hartfalen. Een eerste prescriptie was geassocieerd met een drievoudig 
verhoogd risico, terwijl regelmatig gebruik geassocieerd is met een verdubbeling 
van het risico. Deze bevinding kan worden verklaard door 'depletion of suscepti-
bles'. Bovendien wijst de berekende attributieve fractie uit dat een substantieel 
deel van het aantal heropnames we gens hartfalen mogelijk is toe te schrijven aan 
het gebruik van NSAIDs. 
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In september 1995 werd de indicatie voor de orale dopamine agonist ibopamine 
in Nederland en een aantal andere Europese landen beperkt tot patienten met 
NYHA-II hartfalen als gevolg van de resultaten van een interim-analyse van het 
PRIME-II-onderzoek. Dit onderzoek toonde een verhoogd sterfte-risico aan ten 
opzichte van placebo bij patienten met NYHA III / IV hartfalen die ibopamine 
gebruikten. In hoofdstuk 4.1 wordt een landeJijk cohort-onderzoek besclueven 
naar de effecten van ibopamine bij gebruik onder alledaagse omstandigheden in 
een cohort van gebruikers van ibopamine afkomstig uit alle NYHA-klassen. Alle 
2147 openbare apotheken en apotheekhoudende huisartsen ontvingen het verzoek 
een uitdraai te maken van alle patiiinten aan wie zij ibopamine hadden verstrekt. 
Alle responderende apotheekhoudenden ontvingen vervolgens een vragenlijst aan-
gaande cardiovasculaire risicofactoren en mortaliteit voor een aselecte steekproef 
van de patient en. Verzocht werd deze door de huisarts te laten invullen. Apotheek-
houdenden werden bovendien verzocht een uitdraai op te sturen van de medicatie-
historie van deze patienten. 
Bij patiiinten met NYHA IIIIIV hartfalen bleel( actueel gebruik van ibopamine 
significant geassocieerd te zijn met een 37% verhoogd sterfte-risico (RR 1.37; 
95% 81: 1.15 - 1.64). Patiiinten met NYHA II hartfalen bleken bij multivariaat ana-
lyse een verdubbeld sterfte-risico te hebben tijdens gebruil( van ibopamine (RR 
2.03; 95% 81: 1.10-3.72). Naast actueel gebruik van ibopamine vormden het man-
nelijk geslacht en een verminderde nierfunctie risicofactoren voor een toegenomen 
sterfte-risico. Dit onderzoek geeft aan dat ibopamine niet alleen een toegenomen 
risico op sterfte geeft bij patienten met matig- tot ernstig hartfalen, maar ook geas-
socieerd is met een toegenomen sterfte-risico bij patienten met mild hartfalen. 
Confounding by contraindication is een epidemiologisch begrip dat aangeeft dat 
verschillen in studie-uitkomst tussen behandelde en niet-behandelde patienten 
zouden kunnen worclen toegeschreven aan de aanwezigheicl van een contra-incli-
catie voor behandeling bij de niet-behanclelcle patiiinten. In hoofdstuk 4.2 worclt 
het effect beschreven van confouncling by contraindication in de analyse van de 
landelijl(8 cohort-studie naar risicofactoren voor sterfte bij gebruikers van ibopa-
mine. Bij patienten met een index clatum voor 8 september 1995 was actueel 
gebruik van ibopamine geassocieerd met een relatief risico op sterfte van 3.02 
(95% BI: 2.12-4.30), terwijl patienten die een index datum hadclen na 8 septem-
ber 1995 dit relatief risico 0.71 (95% BI: 0.53-0.96) was. In de multivariate analyse 
waren deze relatieve risico's respectievelijk 2.62 (95% BI: 1.76-3.90) en 0.93 (95% 
BI: 0.84-1.02), een statistisch significant verschil. Bij afwezigheicl van een andere 
plausibele verklaring kan cleze opvallencle omslag van het relatieve risico worclen 
beschouwd als een praktisch voorbeelcl van confouding by contraindication in een 
epiclemiologische studie. 
In hoofdstuk 4.3 worden overwegingen besproken die betrekking hebben op de 
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veiligheid van geneesmiddelen voor de behandeling van hartfalen in het licht van 
de kwaliteit van leven. Hartfalen geeft in zijn algemeenheid een belangrijke verkor-
ting van de levensverwachting en een vermindering van de kwaliteit van leven. Dit 
gegeven is altijd een belangrijke stimulans geweest om nieuwe geneesmiddelen 
te ontwikkelen ter behandeling van hartfalen. Hoewel een aantal nieuwe genees-
middelen een gunstig effect hadden op parameters van kwaliteit van leven, bleken 
deze geneesmiddelen vaak geassocieerd te zijn met een toegenomen sterfte-risico 
in graotschalige ldinisch onderzoek. Ernstig hartfalen kan echter als dermate inva-
liderend worden ervaren dat de vraag gerechtvaardigd is onder welke omstandig-
heden de kans op verbetering van kwaliteit van leven zou kunnen opwegen tegen 
een toegenomen sterfte-kans. Geneesmiddelen die de kwaliteit van leven verbete-
ren ten koste van een toegenomen sterfte-kans kunnen van waarde zijn, voorap-
gesteld dat de samengestelde kans op verbetering van kwaliteit van leven en 
langere overleving voor diegenen die het geneesmiddel gebruiken groter is dan de 
samengestelde kans op verbetering van l(waliteit van leven en langere overleving 
voor diegenen die het geneesmiddel niet gebruiken. De meeste klinische onderzoe-
ken verstrekken echter niet voldoende informatie om bovengenoemde afweging te 
lmnnen maken. 
Hoofdstuk 5 bespreekt een aantal aspecten aangaande de farmacotherapeutische 
behandeling van hartfalen. Hartfalen wordt algemeen beschouwd als een zeer 
belangrijk gezondheidsprableem. In de afgelopen jaren zijn verschillende nieuwe 
geneesmiddelen geintraduceerd voor de behandeling van hartfalen. Een aantal 
van deze geneesmiddelen bleek echter geassocieerd te zijn met een verhoogd 
sterfte-risico. Anderzijds werden positieve resultaten gemeld uit klinisch onder-
zoek naar de effecten van beta-blokkers. Bovendien werd recentelijk aangetoond 
dat spironolacton een gunstig effect heeft op de overleving bij patienten met hart-
falen. Deze geneesmiddelen zullen een belangrijke ral krijgen als aanvulling op 
de standaard therapie met diuretica, ACE-remmers en veelal digoxine. De ral die 
nieuwe geneesmiddelen zoals de zogenaamde calcium sensitizers kunnen gaan 
vervullen bij de behandeling van hartfalen vereist nog verder onderzoek. Zonder 
twijfel kan op de korte termijn de meeste winst worden verkregen wanneer de 
reeds beschikbare kennis aangaande de me est optimale behandeling van hartfalen 
ook daadwerkelijk wordt toegepast op zoveel mogelijk patienten met hartfalen. 
Hoofdstuk 6 (algemene discussie) bespreekt de resultaten van de studies zoals 
weergegeven in dit proefschrift tegen het licht van diverse aspecten van genees-
middelenbewaking, kracht en beperkingen van gerandomiseerd klinisch onder-
zoek en de voorziene toename van hartfalen in de westerse wereld. 
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Dit proefschrift is tot stand gekomen door de samenwerking tussen de afdeling Epidemiologie & Biostatistiek van de Erasmus Universiteit Rotterdam en de 
Inspectie voor de Gezondheidszorg te Den Haag. Op deze plaats wi! ik graag een 
aantal mens en bedanken die ieder op verschillende wijze een bijdrage hebben 
geleverd aan dit proefschrift. 
Allereerst een woord van dank gericht aan dr. B.H.CH. Stricker, mijn co-promotor. 
Bruno, jouw begeleiding in de afgelopen jaren heb ik bijzonder op prijs gesteld. 
Sinds het najaar van 1995 hebben wij nauw samengewerkt, zodat je al snel op 
de hoogte was van mijn interesses en desinteresses. Door hier adequaat op in te 
spelen heb je in belangrijke mate bijgedragen aan de totstandkoming van dit proef-
schrift (ennog een aantal andere stukjes). Ik waardeer het zeer dat je altijd open 
stond voor discussie, wat overigens niet betekende dat je gemakkelijk bent te over-
tuigen. Het (aanstaande) hoogleraarschap is je van harte gegund. 
Mijn promotor, prof.dr. D.E. Grobbee, dank ik voor zijn heldere commentaar op mijn 
artikelen en zijn bereidheid mij te blijven begeleiden ondanks zijn overgang naar 
Utrecht. Rick, sinds je vertrek naar Utrecht liet ons onderlinge contact zich l<arak-
teriseren door "niet frequent, wei efficient". Dit liep in de praktijk prima. Ik stel 
het op prijs dat ik heb kunnen profiteren van jouw kennis van epidemiologische 
en klinische aspecten van cardiovasculaire ziekten en jouw bedrevenheid in het 
creeren van samenhang tussen de verschillende onderdelen van dit proefschrift. 
Onderzoek op het gebied van de geneesmiddelenbewaking vormt de basis van dit 
proefschrift. Het onderzoel{ in dit proefschrift had niet kunnen worden uitgevoerd 
zonder de steun van de Inspectie voor de Gezondheidszorg. Op deze plaats wi! 
ik de Inspectie voor de Gezondheidszorg, en in het bijzonder drs. P.H. Vree, Hoofd-
inspecteur voor Farmacie en Medische Technologie, danken voor het belang dat 
wordt gehecht aan de uitvoering van dergelijk onderzoek en de financiiile onder-
steuning die hieraan wordt gegeven. Ook dank ik de collega-inspecteurs en ove-
rige medewerl{ers van de Inspectie voor de Gezondheidszorg voor de plezierige 
samenwerking, in het bijzonder de medewerkers van de afdeling geneesmiddelen-
bewaking, Ria Runnenberg en Janny Wieringa. 
Prof. J.H.P. Wilson, prof. dr. H.G.M. Leufkens en prof. dr. PA De Graeff wi! ik 
danken voor hun bereidheid om zitting te nemen in de promotiecommissie. 
Ron Herings en Rob Heerdink hebben voor mij de gegevens aangeleverd die afkom-
stig zijn uit de PHARMO database, waarvoor dank. Arend Mosterd en Arno Hoes 
wi! ik danken voor hun adviezen in de beginfase van mijn onderzoek en hun nut-
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tige commentaar bij een aantal artikelen. 
Ool{ een woord van dank aan alle huisartsen, apothekers, medewerkers en deelne-
mers die betrokken zijn bij het ERGO-onderzoek. 
Het verblijf tussen de betonnen muren van Hoboken werd veraangenaamd door 
de aanwezigheid van vele collega-onderzoekers en medewerkers van de afdeling 
Epidemiologie & Biostatistiek. Op deze plaats in het bijzonder een woord van dank 
gericht aan mijn kamergenoten, Melanie van Riemsdijk, Paul van der Linden en 
Bas in't Veld. 
Melanie, zoals je wellicht was opgevallen heb ik weI even moeten wennen aan 
jouw aanwezigheid twee meter achter mijn rug. Dit is vast wederzijds geweest. In 
de loop van de afgelopen jaren heb ik jouw aanwezigheid evenwelleren waarde-
ren. Ik moest in september vorig jaar bijna wennen aan je afwezigheid twee meter 
achter mijn rug. Ik hoop dat het je goed gaat. 
Paul, jouw enthousiasme v~~r fIuoroquinolon-geassocieerde peesaandoeningen 
heeft een bijna spreekwoordelijk lmrakter gekregen. Tijdens de besprekingen van 
bijwerkingen op het ministerie viel regelmatig de zin "leuk voor Paul om uit te 
zoeken" wanneer weer eens een melding van een aan fIuoroquinolon-gebruik toe-
geschreven peesaandoening ter tafel verscheen. Jouw aanwezigheid droeg altijd 
bij aan een gezellige sfeer op onze kamer, zolang je tenminste maar geen opera-
muziek opzette. lk denk dat je een zeer geschikte ziekenhuisapotheker zult worden 
met oog voor de sterke en minder sterlm kanten van zowel artsen als apothekers. 
Bas, jouw komst in de zomer van 1996 was mij zeer welkom. Dit gaf mij de gelegen-
heid om enigszins te ontkomen aan een activiteit die mij nogal zwaar valt, name-
lijk langdurig vergaderen. Ik heb dan ook stellig de indrul{, en jij ongetwijfeld ook, 
dat je wat dat betreft wat veel op je bordje hebt gekregen. Wellicht ten onrechte 
heb ik dit altijd trachten te rechtvaardigen aan de hand van het gegeven dat ik 
voor slechts 40% en jij voor maar liefst 50% bij het ministerie was aangesteld. Aan-
gezien wij beiden in een huisje-boompje-beestje-situatie verkeren hebben wij het 
nodige gemeen. Ik kijk met plezier terug op onze gedachtenwisselingen hierover 
en wens je veel succes in je nieuwe baan. Eindelijk weer verhoogde adrenaline-
spiegels op de werkvloer. 
Ool{ de andere leden van onze farmaco-epidemiologie groep, Fernie Penning, 
Jeanne Dieleman, Ingo Eland en Miriam Sturkenboom, wi! ik graag bedanken voor 
hun interesse, samenwerking en het constructieve commentaar op artikelen die 
werden besproken op onze woensdagmiddag-vergaderingen. 
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Dankwoord 
Mijn overgang van bureau-dokter naar de kliniek in september 1999 werd verge-
makkelijkt door de plezierige samenwerking met internisten, cardiologen en long-
arts en van het Albert Schweitzer Ziekenhuis lokatie Amstelwijck te Dordrecht. Een 
woord van dank ool{ aan mijn opleider, dr. A,G,M, van Vliet. Adrie, ik stel het zeer 
op prijs dat je na een sollicitatiegesprek bereid bent geweest mijn kandidatuur 
voor een opleidingsplaats interne geneeskunde te ondersteunen, Ik hoop mij nog 
geruime tijd in te kunnen zetten voor de patientenzorg in het Dordrechtse, op 
welke lokatie dan oolc De plezierige samenwerking met mijn collega arts-assisten-
ten heeft er toe bijgedragen dat ik mij al gauw weer op mijn gemak voelde in het 
ziekenhuis, 
Mijn ouders wi! ik danl{en voor al hun goede zorgen, steun en interesse van kinds-
been af. Ook al is de toekomst vol zorgen, toch hoop ik dat jullie nog geruime tijd 
samen mogen zijn, 
Petra, jouw Hefde en zorg zijn voor mij een enorme steun geweest in de afgelopen 
jaren, Jij en onze zoontjes Douwe en Mark, nog geheel onwetend van promotie-
perikelen, maken mij gelukkig, meer dan welke promo tie dan ook. 
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De schrijver van dit proefschrift werd geboren op 10 december 1965 in Ede. Na 
het behalen van het VWO-diploma aan het Christelijk Streeklyceum te Ede in 1984 
ging hij geneeskunde studeren aan de Katholieke Universiteit Nijmegen alwaar hij 
in 1991 het arts-examen behaalde. In de periode 1991-1993 werkte hij a1s arts-assi-
stent chirurgie en gynaecologie/verloskunde in het ziekenhuis de Tjongerschans 
te Heerenveen. Na een korte militaire opleiding bij het Opleiding Centrum Militair 
Geneeskundige Dienst in Hollandsche Rading was hij in de periode 1993-1995 
werkzaam als kapitein-arts binnen het Perifeer Militair Team Heerenveen, onder-
deel van de Krijgsmacht Hospitaal Organisatie. Gedurende deze periode werden 
arts-assistentschappen cardiologie en interne geneeskunde in bovengenoemd zie-
kenhuis te Heerenveen vervuld. In oktober 1995 werd een aanvang gemaakt met 
het in dit proefschrift beschreven onderzoek en werd hij aangesteld als arts-onder-
zoeker bij de afdeling Epidemiologie & Biostatistiek van de Erasmus Universiteit 
Rotterdam. Daarnaast was hij werkzaam bij de Afdeling Geneesmiddelenbewa-
king van de Inspectie voor de Gezondheidszorg, thans gevestigd te Den Haag. In 
de periode 1996-1997 werd de Master of Science-opleiding in klinische epidemi-
ologie gevolgd. Sinds september 1999 is hij werkzaam als arts-assistent interne 
geneeskunde in het Albert Schweitzer Ziekenhuis lokatie Amstelwijclr in Dor-
drecht, alwaar hij in opleiding tot internist is. 
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